BioMedLib Search Engine
[ goto HOMEPAGE ]
Don't miss relevant answers!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adenocarcinoma of colon stage i 2005:2010[pubdate] *count=100
606 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adenocarcinoma of colon stage i
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 606
1.
Ragazzi E, Pucciarelli S, Seraglia R, Molin L, Agostini M, Lise M, Traldi P, Nitti D:
Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer.
J Mass Spectrom
; 2006 Dec;41(12):1546-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Using matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS), the plasma protein profile was determined in nine
stage
IV CRC patients (study group) and nine clean-
colon
healthy subjects (control group).
[MeSH-major]
Adenocarcinoma
/ blood. Biomarkers, Tumor / analysis. Colorectal Neoplasms / blood. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17117375.001).
[ISSN]
1076-5174
[Journal-full-title]
Journal of mass spectrometry : JMS
[ISO-abbreviation]
J Mass Spectrom
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Blood Proteins
2.
Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, Ychou M, Senesse P, Ozsahin M, Pèlegrin A, Dubois JB, Thèzenas S:
Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.
BMC Cancer
; 2005;5:62
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We wished to ascertain whether a correlation exists between the expression of EGFR and treatment outcome in a group of patients with rectal
adenocarcinoma
who had undergone preoperative radiotherapy (RT).
Initial staging showed 75% and 25%
stage
II and III tumors, respectively.
Genetic Alliance.
consumer health - Rectal Cancer
.
MedlinePlus Health Information.
consumer health - Radiation Therapy
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):29-35
[
9588914.001
]
[Cites]
Br J Cancer. 2005 Jun 20;92(12):2114-21
[
15956964.001
]
[Cites]
Radiat Res. 2000 Mar;153(3):245-57
[
10669545.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32
[
10760290.001
]
[Cites]
N Engl J Med. 2001 Aug 30;345(9):638-46
[
11547717.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):410-8
[
11567815.001
]
[Cites]
Eur J Cancer. 2001 Nov;37(17):2169-77
[
11677103.001
]
[Cites]
Lancet. 2001 Oct 20;358(9290):1291-304
[
11684209.001
]
[Cites]
Clin Cancer Res. 2002 Mar;8(3):885-92
[
11895923.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1460-5
[
12459370.001
]
[Cites]
Cancer Res. 2002 Dec 15;62(24):7350-6
[
12499279.001
]
[Cites]
Semin Radiat Oncol. 2003 Jan;13(1):22-30
[
12520461.001
]
[Cites]
Semin Radiat Oncol. 2003 Oct;13(4):403-18
[
14586830.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):11-20
[
15093894.001
]
[Cites]
N Engl J Med. 2004 Jul 22;351(4):337-45
[
15269313.001
]
[Cites]
Proc Natl Acad Sci U S A. 1987 Oct;84(20):7159-63
[
2890160.001
]
[Cites]
Surgery. 1990 Oct;108(4):787-92; discussion 792-3
[
2218892.001
]
[Cites]
Br J Surg. 1990 Dec;77(12):1352-4
[
2276016.001
]
[Cites]
Head Neck. 1991 Mar-Apr;13(2):132-9
[
2022478.001
]
[Cites]
Clin Otolaryngol Allied Sci. 1991 Oct;16(5):466-9
[
1742894.001
]
[Cites]
Surg Gynecol Obstet. 1992 Jan;174(1):27-32
[
1729745.001
]
[Cites]
Hum Pathol. 1992 Sep;23(9):974-9
[
1355464.001
]
[Cites]
Cancer. 1993 Apr 15;71(8):2454-60
[
8095852.001
]
[Cites]
Surg Today. 1993;23(1):21-30
[
8461602.001
]
[Cites]
J Pathol. 1993 Mar;169(3):323-8
[
8492225.001
]
[Cites]
J Clin Oncol. 1993 Oct;11(10):1873-8
[
8410112.001
]
[Cites]
J Cell Biochem Suppl. 1993;17F:188-91
[
8412192.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):91-8
[
8083133.001
]
[Cites]
J Biol Chem. 1996 Apr 19;271(16):9185-8
[
8621573.001
]
[Cites]
Br J Surg. 1996 Mar;83(3):375-9
[
8665198.001
]
[Cites]
Laryngoscope. 1996 Jul;106(7):884-8
[
8667988.001
]
[Cites]
Br J Surg. 1996 Jun;83(6):781-5
[
8696739.001
]
[Cites]
Eur J Surg. 1996 Aug;162(8):643-8
[
8891623.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13704-8
[
8942998.001
]
[Cites]
Biochim Biophys Acta. 1996 Nov 8;1314(1-2):147-56
[
8972728.001
]
[Cites]
Dis Colon Rectum. 1997 Jan;40(1):15-24
[
9102255.001
]
[Cites]
Int J Colorectal Dis. 1997;12(1):19-23
[
9112145.001
]
[Cites]
FEBS Lett. 1997 Jun 23;410(1):83-6
[
9247128.001
]
[Cites]
Pathology. 1997 Aug;29(3):251-4
[
9271009.001
]
[Cites]
Oncogene. 1997 Sep 4;15(10):1191-7
[
9294612.001
]
[Cites]
Radiat Oncol Investig. 1997;5(4):180-6
[
9327497.001
]
[Cites]
Biochim Biophys Acta. 1997 Oct 11;1358(3):289-99
[
9366260.001
]
[Cites]
Radiat Res. 1998 Jun;149(6):579-87
[
9611096.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):585-91
[
9635706.001
]
[Cites]
Oncogene. 1998 May 28;16(21):2787-96
[
9652746.001
]
[Cites]
J Pathol. 1998 Jun;185(2):167-74
[
9713343.001
]
[Cites]
Int J Cancer. 1999 Apr 20;84(2):188-91
[
10096253.001
]
[Cites]
Br J Cancer. 1999 Apr;79(11-12):1864-9
[
10206306.001
]
[Cites]
Mol Biol Cell. 1999 Aug;10(8):2493-506
[
10436007.001
]
[Cites]
Clin Cancer Res. 1999 Oct;5(10):2884-90
[
10537357.001
]
(PMID = 15967033.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
[Other-IDs]
NLM/ PMC1185521
3.
Phang PT, McGahan CE, McGregor G, MacFarlane JK, Brown CJ, Raval MJ, Cheifetz R, Hay JH:
Effects of change in rectal cancer management on outcomes in British Columbia.
Can J Surg
; 2010 Aug;53(4):225-31
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: In a province-wide audit of patients undergoing treatment for rectal cancer in British Columbia in 1996, the 4-year rate of pelvic recurrence for
stage
3 rectal cancer was 27%.
Relative to the 1996 cohort, there was a decreasing trend in 2-year overall pelvic recurrence rates in the 2003/04 cohort (9.6% v. 6.9%) and a significant decrease in recurrence among patients with
stage
3 cancers (18.2% v. 9.2%; p = 0.020).
[MeSH-major]
Adenocarcinoma
/ therapy. Antineoplastic Agents / therapeutic use. Colectomy / methods. Rectal Neoplasms / therapy
Genetic Alliance.
consumer health - Rectal Cancer
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cochrane Database Syst Rev. 2000;(2):CD000125
[
10796491.001
]
[Cites]
Can J Surg. 2010 Aug;53(4):222-4
[
20646394.001
]
[Cites]
Lancet. 2000 Jul 8;356(9224):93-6
[
10963244.001
]
[Cites]
N Engl J Med. 2001 Aug 30;345(9):638-46
[
11547717.001
]
[Cites]
J Clin Oncol. 2002 Apr 1;20(7):1729-34
[
11919228.001
]
[Cites]
Am J Surg. 2002 May;183(5):504-8
[
12034381.001
]
[Cites]
Dis Colon Rectum. 2002 Jul;45(7):857-66
[
12130870.001
]
[Cites]
BMJ. 2003 Jul 5;327(7405):33-5
[
12842955.001
]
[Cites]
N Engl J Med. 2004 Oct 21;351(17):1731-40
[
15496622.001
]
[Cites]
JAMA. 1999 Sep 1;282(9):867-74
[
10478694.001
]
[Cites]
J Clin Oncol. 2005 Dec 20;23(36):9257-64
[
16361623.001
]
[Cites]
Br J Surg. 2006 Oct;93(10):1215-23
[
16983741.001
]
[Cites]
Br J Surg. 2007 Oct;94(10):1285-92
[
17661309.001
]
[Cites]
Ann Surg. 2007 Nov;246(5):693-701
[
17968156.001
]
[CommentIn]
Can J Surg. 2010 Aug;53(4):222-4
[
20646394.001
]
(PMID = 20646395.001).
[ISSN]
1488-2310
[Journal-full-title]
Canadian journal of surgery. Journal canadien de chirurgie
[ISO-abbreviation]
Can J Surg
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Canada
[Chemical-registry-number]
0 / Antineoplastic Agents
[Other-IDs]
NLM/ PMC2912013
Advertisement
4.
Jung SH, Kim HC, Yu CS, Chang HM, Ryu MH, Lee JL, Kim JS, Kim JC:
[Clinicopathologic characteristics of colorectal neuroendocrine tumor].
Korean J Gastroenterol
; 2006 Aug;48(2):97-103
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Nine tumors were located in the rectum, two in the sigmoid, and each one in the transverse
colon
and cecum, respectively.
All patients were advanced at the time of diagnosis, with AJCC TNM staging:
stage
IIIB (n=2),
stage
IIIC (n=3), and
stage
IV (n=8).
Five patients who received chemotherapy showed median survival of 32 months (
stage
III) and 17.5 months (
stage
IV), whereas other five patients without chemotherapy died with a median survival of 6.2 months.
[MeSH-minor]
Adenocarcinoma
/ pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Biopsy. Chromogranin A / analysis. Chromogranin A / immunology. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sigmoid Neoplasms / drug therapy. Sigmoid Neoplasms / mortality. Sigmoid Neoplasms / pathology. Synaptophysin / analysis. Synaptophysin / immunology
Genetic Alliance.
consumer health - Pancreatic islet cell tumors
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16929153.001).
[ISSN]
1598-9992
[Journal-full-title]
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
[ISO-abbreviation]
Korean J Gastroenterol
[Language]
kor
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Korea (South)
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Synaptophysin
5.
Bedaiwy MA, Hussein MR, Biscotti C, Falcone T:
Pelvic endometriosis is rarely associated with ovarian borderline tumours, cytologic and architectural atypia: a clinicopathologic study.
Pathol Oncol Res
; 2009 Mar;15(1):81-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Stage
IV endometriosis with extensive pelvic involvement was found in two patients.
Intraoperatively, the endometriotic lesions involved the ovaries (all cases); Cul
de
sac (four cases); urinary bladder (two cases); sigmoid
colon
, hemidiaphragms, and uterine vessels (one case each).
The endometriotic lesions were associated with uterine leiomyomas (two patients) and
adenocarcinoma of
the vagina (one patient).
One patient had recurred with metastatic
adenocarcinoma of
the vault.
Genetic Alliance.
consumer health - Endometriosis
.
MedlinePlus Health Information.
consumer health - Endometriosis
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
MedlinePlus Health Information.
consumer health - Pelvic Pain
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Eur J Clin Invest. 2002 Mar;32(3):199-206
[
11895472.001
]
[Cites]
Cancer Sci. 2007 Mar;98(3):387-91
[
17270029.001
]
[Cites]
Fertil Steril. 2005 Jul;84(1):12-5
[
16009147.001
]
[Cites]
Mod Pathol. 2006 Dec;19(12):1615-23
[
16980942.001
]
[Cites]
Int J Gynecol Pathol. 2000 Jul;19(3):276-9
[
10907178.001
]
[Cites]
J Reprod Immunol. 2005 Feb;65(1):55-63
[
15694967.001
]
[Cites]
Hum Pathol. 2007 Jul;38(7):1074-80
[
17442376.001
]
[Cites]
Ann N Y Acad Sci. 2002 Mar;955:281-92; discussion 293-5, 396-406
[
11949955.001
]
[Cites]
Dis Markers. 2007;23(5-6):367-76
[
18057520.001
]
[Cites]
Eur J Obstet Gynecol Reprod Biol. 2007 Sep;134(1):83-6
[
16844279.001
]
[Cites]
Arch Pathol Lab Med. 2003 Aug;127(8):1003-6
[
12873175.001
]
[Cites]
Int J Gynecol Cancer. 2003 Jul-Aug;13(4):466-71
[
12911723.001
]
[Cites]
Zhonghua Bing Li Xue Za Zhi. 2001 Jun;30(3):169-72
[
11866970.001
]
[Cites]
Adv Anat Pathol. 2007 Jul;14(4):241-60
[
17592255.001
]
[Cites]
Diagn Cytopathol. 2002 Dec;27(6):379-81
[
12451571.001
]
[Cites]
Hum Reprod. 2001 Dec;16(12):2668-71
[
11726593.001
]
[Cites]
Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):239-42
[
14505256.001
]
[Cites]
Eur J Obstet Gynecol Reprod Biol. 1999 Jan;82(1):85-7
[
10192492.001
]
[Cites]
Gynecol Obstet Invest. 2000;50 Suppl 1:39-43
[
11093060.001
]
[Cites]
Int J Gynecol Pathol. 2003 Jan;22(1):42-51
[
12496697.001
]
[Cites]
Fertil Steril. 2002 Oct;78(4):743-9
[
12372450.001
]
[Cites]
Mod Pathol. 2006 Jan;19(1):83-9
[
16258507.001
]
[Cites]
Zhonghua Fu Chan Ke Za Zhi. 2006 Feb;41(2):111-3
[
16640860.001
]
[Cites]
Am J Clin Pathol. 1999 Feb;111(2):248-51
[
9930148.001
]
[Cites]
Gynecol Obstet Invest. 2000;50 Suppl 1:2-10
[
11093055.001
]
[Cites]
Am J Obstet Gynecol. 2001 Jun;184(7):1407-11; discussion 1411-3
[
11408860.001
]
[Cites]
Arch Pathol Lab Med. 2007 Jan;131(1):138-44
[
17227115.001
]
[Cites]
Int J Gynecol Cancer. 2003 May-Jun;13(3):376-80
[
12801273.001
]
[Cites]
Eur J Obstet Gynecol Reprod Biol. 2003 Jul 1;109(1):97-101
[
12818453.001
]
[Cites]
Pathol Res Pract. 2006;202(6):433-7
[
16513291.001
]
[Cites]
Diagn Cytopathol. 1996 Jun;14(4):331-3
[
8725135.001
]
[Cites]
Int J Gynecol Pathol. 2007 Jul;26(3):345-51
[
17581423.001
]
[Cites]
Ginekol Pol. 2001 May;72(5):268-72
[
11526755.001
]
[Cites]
J Med Genet. 2006 Jan;43(1):84-90
[
15930087.001
]
[Cites]
Int J Gynecol Pathol. 2006 Jul;25(3):223-9
[
16810057.001
]
[Cites]
Reproduction. 2001 Apr;121(4):581-6
[
11277878.001
]
[Cites]
Am J Surg Pathol. 2004 Mar;28(3):285-97
[
15104291.001
]
[Cites]
Gynecol Obstet Invest. 2000;50 Suppl 1:44-50
[
11093061.001
]
[Cites]
Am J Surg Pathol. 2007 Oct;31(10):1490-501
[
17895749.001
]
[Cites]
Int J Gynecol Pathol. 2002 Oct;21(4):401-6
[
12352189.001
]
[Cites]
Med Electron Microsc. 2004 Jun;37(2):97-100
[
15221651.001
]
[Cites]
Zhonghua Fu Chan Ke Za Zhi. 2000 Nov;35(11):667-9
[
11218895.001
]
[Cites]
Am J Obstet Gynecol. 2004 Nov;191(5):1725-7
[
15547552.001
]
(PMID = 18575828.001).
[ISSN]
1219-4956
[Journal-full-title]
Pathology oncology research : POR
[ISO-abbreviation]
Pathol. Oncol. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
6.
Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC:
Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas.
BMC Cancer
; 2006;6:241
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Here, we report on the prevalence and potential clinical significance of fascin expression in relation to the progression of colorectal
adenocarcinoma
and to tumor cell proliferation as measured by Ki67 index.
In the clinically-annotated tumors, fascin immunoreactivity was more common in tumors located in the proximal
colon
(p = 0.009), but was not associated with age, gender, or TNM
stage
.
Patients with
stage
III/IV adenocarcinomas (n = 62) with strong fascin immunoreactivity had a worse prognosis than patients with low or absent fascin, (3-year overall survival of 11% versus 43% for fascin-negative patients; p = 0.023).
Strong and diffuse expression was seen in a subset of advanced colorectal adenocarcinomas that correlated with shorter survival in
stage
III and IV patients.
[MeSH-major]
Adenocarcinoma
/ genetics. Adenoma / genetics. Carrier Proteins / biosynthesis. Colorectal Neoplasms / genetics. Gene Expression Regulation, Neoplastic / physiology. Microfilament Proteins / biosynthesis
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 2000 May 20;355(9217):1745-50
[
10832824.001
]
[Cites]
Cancer Res. 2004 Dec 1;64(23):8585-94
[
15574765.001
]
[Cites]
Br J Cancer. 2000 Oct;83(7):870-3
[
10970687.001
]
[Cites]
Am J Pathol. 2000 Dec;157(6):1947-53
[
11106567.001
]
[Cites]
Curr Opin Oncol. 2001 Jan;13(1):63-9
[
11148689.001
]
[Cites]
Clin Exp Metastasis. 2000;18(1):83-8
[
11206843.001
]
[Cites]
J Cell Biol. 2001 Mar 19;152(6):1169-82
[
11257118.001
]
[Cites]
Nature. 2001 May 17;411(6835):375-9
[
11357145.001
]
[Cites]
Am J Pathol. 2001 Nov;159(5):1613-7
[
11696421.001
]
[Cites]
J Clin Oncol. 2002 Feb 15;20(4):1043-8
[
11844828.001
]
[Cites]
Int J Biochem Cell Biol. 2002 Jun;34(6):685-98
[
11943599.001
]
[Cites]
Bioessays. 2002 Apr;24(4):350-61
[
11948621.001
]
[Cites]
Cancer Cell. 2002 Apr;1(3):233-6
[
12086859.001
]
[Cites]
Am J Clin Pathol. 2002 Jul;118(1):52-9
[
12109856.001
]
[Cites]
Int J Cancer. 2002 Oct 10;101(5):403-8
[
12216066.001
]
[Cites]
Am J Pathol. 2003 Jan;162(1):69-80
[
12507891.001
]
[Cites]
Br J Cancer. 2003 Feb 24;88(4):537-47
[
12592367.001
]
[Cites]
Nat Rev Cancer. 2003 May;3(5):362-74
[
12724734.001
]
[Cites]
Oncogene. 2003 Jun 5;22(23):3616-23
[
12789270.001
]
[Cites]
Mod Pathol. 2003 Sep;16(9):902-12
[
13679454.001
]
[Cites]
N Engl J Med. 2003 Jul 17;349(3):247-57
[
12867608.001
]
[Cites]
Curr Opin Cell Biol. 2004 Feb;16(1):14-23
[
15037300.001
]
[Cites]
J Clin Oncol. 2004 May 1;22(9):1564-71
[
15051756.001
]
[Cites]
Curr Opin Cell Biol. 2004 Oct;16(5):590-6
[
15363811.001
]
[Cites]
Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26
[
15459662.001
]
[Cites]
Gene Expr Patterns. 2004 Oct;4(6):637-43
[
15465486.001
]
[Cites]
Cell. 1996 Feb 9;84(3):345-57
[
8608588.001
]
[Cites]
Science. 1996 May 24;272(5265):1187-90
[
8638166.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13927-31
[
9391129.001
]
[Cites]
Mol Biol Cell. 1998 May;9(5):993-1006
[
9571235.001
]
[Cites]
Semin Cancer Biol. 1999 Aug;9(4):245-54
[
10448112.001
]
[Cites]
Oncology. 2004;67(3-4):262-70
[
15557788.001
]
[Cites]
J Surg Oncol. 2004 Dec 15;88(4):261-6
[
15565587.001
]
[Cites]
Hum Genomics. 2004 Jan;1(2):134-40
[
15601541.001
]
[Cites]
Curr Opin Genet Dev. 2005 Feb;15(1):87-96
[
15661538.001
]
[Cites]
Clin Cancer Res. 2005 Jan 1;11(1):186-92
[
15671545.001
]
[Cites]
Clin Cancer Res. 2005 Apr 1;11(7):2597-605
[
15814639.001
]
[Cites]
Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804
[
16002322.001
]
[Cites]
Nature. 2005 Jul 28;436(7050):518-24
[
16049480.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62
[
16185662.001
]
[Cites]
Clin Cancer Res. 2006 Mar 1;12(5):1533-9
[
16533778.001
]
[ErratumIn]
BMC Cancer. 2011;11:488
(PMID = 17029629.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
[Other-IDs]
NLM/ PMC1615879
7.
Niinobu T, Nakagawa S, Itani Y, Nishikawa Y, Amano M, Higaki N, Hayashida H, Sakon M:
[Rectal stenosis due to Schnitzler metastasis following surgery for gastric cancer--a case successfully treated with TS-1 and CDDP combination chemotherapy].
Gan To Kagaku Ryoho
; 2005 Oct;32(11):1761-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The lesion was judged to be P1, SE, H0, N2 and
Stage
IV and the patient was managed on a regular schedule as an outpatient.
A fiber optic examination of the sigmoid
colon
detected an ulcerous lesion with a hemorrhage at the anterior rectal wall.
A biopsy revealed the lesion to be Group V poorly differentiated
adenocarcinoma
.
After 3 courses of this regimen, a fiber optic examination of the
colon
conducted in February 2005 no longer detected the rectal tumor, leaving only a cicatrix.
[MeSH-major]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Diseases / drug therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / secondary. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery
Genetic Alliance.
consumer health - Rectal Cancer
.
MedlinePlus Health Information.
consumer health - Rectal Disorders
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16315933.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
8.
den Dulk M, Marijnen CA, Putter H, Rutten HJ, Beets GL, Wiggers T, Nagtegaal ID, van de Velde CJ:
Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial.
Ann Surg
; 2007 Jul;246(1):83-90
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In a multivariate analysis, T-
stage
, N-
stage
, and tumor location were independent risk factors for CRM.
T-
stage
, N-
stage
, and CRM were risk factors for LR and age, T-
stage
, N-
stage
, CRM, and distance of the inferior tumor margin to the anal verge for OS.
CONCLUSION: Age, T-
stage
, N-
stage
, CRM, distance of the tumor to the anal verge, and tumor location were independent risk factors for adverse outcome in patients treated with an APR for low rectal cancer.
[MeSH-major]
Adenocarcinoma
/ surgery. Digestive System Surgical Procedures / methods. Postoperative Complications. Rectal Neoplasms / surgery
Genetic Alliance.
consumer health - Rectal Cancer
.
MedlinePlus Health Information.
consumer health - After Surgery
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 1999 Aug;17(8):2396
[
10561302.001
]
[Cites]
Ann Oncol. 2006 Aug;17(8):1239-48
[
16873440.001
]
[Cites]
Lancet. 2000 Jul 8;356(9224):93-6
[
10963244.001
]
[Cites]
J Clin Oncol. 2001 Apr 1;19(7):1976-84
[
11283130.001
]
[Cites]
N Engl J Med. 2001 Aug 30;345(9):638-46
[
11547717.001
]
[Cites]
Am J Surg Pathol. 2002 Mar;26(3):350-7
[
11859207.001
]
[Cites]
Dis Colon Rectum. 2002 Jul;45(7):857-66
[
12130870.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1311-20
[
12654443.001
]
[Cites]
Br J Surg. 2003 May;90(5):583-92
[
12734867.001
]
[Cites]
Colorectal Dis. 2003 Mar;5(2):180-4
[
12780910.001
]
[Cites]
Radiother Oncol. 2004 Jul;72(1):15-24
[
15236870.001
]
[Cites]
Br J Surg. 1982 Oct;69(10):613-6
[
6751457.001
]
[Cites]
Lancet. 1986 Nov 1;2(8514):996-9
[
2430152.001
]
[Cites]
Int J Colorectal Dis. 1988 Jun;3(2):127-31
[
3045231.001
]
[Cites]
Lancet. 1994 Sep 10;344(8924):707-11
[
7915774.001
]
[Cites]
Colorectal Dis. 2005 Jul;7(4):410-6
[
15932569.001
]
[Cites]
Ann Surg. 2005 Jul;242(1):74-82
[
15973104.001
]
[Cites]
J Clin Oncol. 2005 Aug 20;23(24):5620-7
[
16009958.001
]
[Cites]
Eur J Surg Oncol. 2005 Oct;31(8):845-53
[
15979269.001
]
[Cites]
J Clin Oncol. 2005 Dec 20;23(36):9257-64
[
16361623.001
]
[Cites]
Br J Surg. 2006 Jan;93(1):105-12
[
16302179.001
]
[Cites]
Dis Colon Rectum. 2005 Dec;48(12):2249-57
[
16400512.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):323-7
[
10661338.001
]
(PMID = 17592295.001).
[ISSN]
0003-4932
[Journal-full-title]
Annals of surgery
[ISO-abbreviation]
Ann. Surg.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC1899206
9.
Seo T, Tatsuguchi A, Shinji S, Yonezawa M, Mitsui K, Tanaka S, Fujimori S, Gudis K, Fukuda Y, Sakamoto C:
Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients.
Virchows Arch
; 2009 Jun;454(6):667-76
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The localization of each PGES and COX-2 protein was examined by immunohistochemistry in 155 surgical resections and correlated to clinicopathological factors and patient prognosis. mPGES-1 mRNA and protein levels were significantly higher in CRC than in paired normal tissues. mPGES-1 immunoreactivity localized in cancer cells in 43% of cases. mPGES-2 immunoreactivity was significantly more pronounced in cancer cells than in adjacent normal epithelium in 36% of cases. cPGES immunoreactivity was homogeneous in cancer cells and thus determined constitutive. mPGES-1 and mPGES-2 correlated with significantly worse prognosis in
stage I
-III patients.
[MeSH-major]
Adenocarcinoma
/ enzymology. Colorectal Neoplasms / enzymology. Intramolecular Oxidoreductases / metabolism. Microsomes / enzymology
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2005 Mar 17;352(11):1092-102
[
15713943.001
]
[Cites]
J Biol Chem. 2002 May 10;277(19):16355-64
[
11847219.001
]
[Cites]
Mol Carcinog. 2006 Jun;45(6):447-54
[
16688727.001
]
[Cites]
J Biochem Mol Biol. 2005 Nov 30;38(6):633-8
[
16336776.001
]
[Cites]
Cancer Res. 1998 Feb 1;58(3):409-12
[
9458081.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Mar 8;291(4):884-9
[
11866447.001
]
[Cites]
J Biol Chem. 2003 Sep 26;278(39):37937-47
[
12835322.001
]
[Cites]
J Immunol. 2001 Jul 1;167(1):469-74
[
11418684.001
]
[Cites]
Gut. 2006 Jan;55(1):54-61
[
16085694.001
]
[Cites]
Gut. 2006 Jan;55(1):115-22
[
16118353.001
]
[Cites]
N Engl J Med. 2006 Aug 31;355(9):885-95
[
16943401.001
]
[Cites]
N Engl J Med. 2007 May 24;356(21):2131-42
[
17522398.001
]
[Cites]
J Biol Chem. 2000 Oct 20;275(42):32783-92
[
10869354.001
]
[Cites]
Br J Pharmacol. 2004 Apr;141(7):1091-7
[
15023855.001
]
[Cites]
N Engl J Med. 2006 Aug 31;355(9):873-84
[
16943400.001
]
[Cites]
Nat Rev Cancer. 2006 Feb;6(2):130-40
[
16491072.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7220-5
[
10377395.001
]
[Cites]
Biochem Biophys Res Commun. 2008 Jul 18;372(1):249-53
[
18485889.001
]
[Cites]
Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):63-75
[
15000150.001
]
[Cites]
Hum Pathol. 2007 Dec;38(12 ):1826-35
[
17868774.001
]
[Cites]
Clin Cancer Res. 2005 Jul 1;11(13):4754-60
[
16000571.001
]
[Cites]
J Biol Chem. 2000 Oct 20;275(42):32775-82
[
10922363.001
]
[Cites]
Dis Colon Rectum. 2006 Aug;49(8):1184-92
[
16752205.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Jun 27;306(2):577-81
[
12804604.001
]
[Cites]
Cell. 1998 May 29;93(5):705-16
[
9630216.001
]
[Cites]
Lab Invest. 2005 Feb;85(2):225-36
[
15531909.001
]
[Cites]
Int J Cancer. 2003 Nov 20;107(4):551-6
[
14520691.001
]
[Cites]
Cancer Res. 2008 May 1;68(9):3251-9
[
18451151.001
]
[Cites]
J Biol Chem. 2003 May 23;278(21):19396-405
[
12626523.001
]
[Cites]
Gastroenterology. 2003 Aug;125(2):404-12
[
12891542.001
]
[Cites]
J Pathol. 2006 Feb;208(3):356-63
[
16353170.001
]
[Cites]
Clin Cancer Res. 2001 Dec;7(12 ):3971-6
[
11751489.001
]
[Cites]
J Clin Invest. 2006 May;116(5):1391-9
[
16614756.001
]
[Cites]
J Biol Chem. 2002 Aug 16;277(33):30253-63
[
12050152.001
]
[Cites]
Mol Cancer. 2006 Nov 16;5:62
[
17107625.001
]
[Cites]
Hum Pathol. 2004 Apr;35(4):488-95
[
15116331.001
]
(PMID = 19412621.001).
[ISSN]
1432-2307
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.99.3 / PTGES protein, human; EC 5.3.99.3 / PTGES2 protein, human; EC 5.3.99.3 / Prostaglandin-E Synthases
10.
Soumaoro LT, Uetake H, Takagi Y, Iida S, Higuchi T, Yasuno M, Enomoto M, Sugihara K:
Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis.
Dis Colon Rectum
; 2006 Mar;49(3):392-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Tissue samples of primary tumors and metastatic lymph nodes from 150 patients undergoing intentionally curative surgical resections for colorectal
adenocarcinoma
were immunohistochemically examined for vascular endothelial growth factor-C, cyclooxygenase-2, and CD34 expressions.
A significant correlation was found between the expression scores of vascular endothelial growth factor-C and cyclooxygenase-2 (P < 0.0001), and both also were correlated to microvessels density and several clinicopathologic parameters, including primary tumor size, lymph node metastasis, lymphatic invasion, and TNM
stage
.
[MeSH-major]
Adenocarcinoma
/ metabolism. Colorectal Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. Lymph Nodes / metabolism. Membrane Proteins / metabolism. Vascular Endothelial Growth Factor C / metabolism
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16474989.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD34; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor C; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
11.
Wang H, Safar B, Wexner SD, Denoya P, Berho M:
The clinical significance of fat clearance lymph node harvest for invasive rectal adenocarcinoma following neoadjuvant therapy.
Dis Colon Rectum
; 2009 Oct;52(10):1767-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The clinical significance of fat clearance lymph node harvest for invasive rectal
adenocarcinoma
following neoadjuvant therapy.
N1 and N2 stages were regarded as N+
stage
.
In the nonneoadjuvant group, there was no significant difference in the number of positive lymph nodes (0.5 +/- 0.2 vs. 1.0 +/- 0.3, P = 0.235), N
stage
(P = 0.265), or patients with N+
stage
(7/31 vs. 16/49, P = 0.332) between the two methods, even though the total lymph node harvest was significantly increased by use of the fat clearance method (9.6 +/- 1.3 vs. 27.6 +/- 2.5, P < 0.001).
In contrast, the total lymph node retrieval (5.2 +/- 0.6 vs. 20.4 +/- 1.2, P < 0.001), number of positive lymph nodes (0.4 +/- 0.2 vs. 1.2 +/- 0.3, P = 0.007), N
stage
(P = 0.005), and patients with N+
stage
(6/51 vs. 34/106, P = 0.006) were all increased by fat clearance in the neoadjuvant group.
Moreover, the number of patients with N+
stage
was stratified by T
stage
level (T0-T4) to eliminate the background bias, and the results were confirmed.
[MeSH-major]
Adenocarcinoma
/ pathology. Lymph Node Excision / methods. Rectal Neoplasms / pathology
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19966611.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
12.
Mansilla F, Birkenkamp-Demtroder K, Kruhøffer M, Sørensen FB, Andersen CL, Laiho P, Aaltonen LA, Verspaget HW, Orntoft TF:
Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups.
Br J Cancer
; 2007 Jun 18;96(12):1896-903
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Microarray analysis on pooled samples has previously identified ZDHHC9 (DHHC9) to be upregulated in
colon adenocarcinoma
compared to normal
colon
mucosa.
Immunohistochemical analysis was performed on 60
colon
adenocarcinomas, previously analysed on microarrays, as well as on tissue microarrays with 40
stage I
-IV tumours and 46 tumours from different organ sites.
In conclusion, DHHC9 is a gastrointestinal-related protein highly expressed in MSS
colon
tumours.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Med Chem. 1997 Sep 12;40(19):2971-90
[
9301658.001
]
[Cites]
Nature. 1997 Apr 10;386(6625):623-7
[
9121588.001
]
[Cites]
Cell. 1999 Jul 9;98(1):69-80
[
10412982.001
]
[Cites]
Neuron. 2004 Dec 16;44(6):987-96
[
15603741.001
]
[Cites]
Gut. 2005 Mar;54(3):374-84
[
15710986.001
]
[Cites]
Science. 2005 Mar 18;307(5716):1746-52
[
15705808.001
]
[Cites]
Br J Cancer. 2005 Jun 20;92(12):2240-8
[
15956967.001
]
[Cites]
J Biol Chem. 2005 Sep 2;280(35):31141-8
[
16000296.001
]
[Cites]
Clin Cancer Res. 2005 Dec 1;11(23):8332-40
[
16322293.001
]
[Cites]
Int J Cancer. 2006 Mar 1;118(5):1309-15
[
16152604.001
]
[Cites]
Cancer Res. 2006 Feb 15;66(4):1974-81
[
16488996.001
]
[Cites]
Carcinogenesis. 2006 Mar;27(3):419-28
[
16272173.001
]
[Cites]
J Mol Diagn. 2006 May;8(2):193-201
[
16645205.001
]
[Cites]
World J Gastroenterol. 2006 Aug 7;12(29):4636-9
[
16937431.001
]
[Cites]
Carcinogenesis. 2007 Jan;28(1):38-48
[
16774939.001
]
[Cites]
Mol Cell Biol. 2000 Apr;20(7):2475-87
[
10713171.001
]
[Cites]
Oncol Rep. 2001 Nov-Dec;8(6):1409-13
[
11605075.001
]
[Cites]
Cancer Res. 2002 Aug 1;62(15):4352-63
[
12154040.001
]
[Cites]
Sci STKE. 2002 Oct 1;2002(152):pe41
[
12359913.001
]
[Cites]
Cell. 2002 Oct 18;111(2):241-50
[
12408868.001
]
[Cites]
Gastroenterology. 2002 Dec;123(6):1804-11
[
12454837.001
]
[Cites]
Nat Genet. 2003 Jan;33(1):90-6
[
12469123.001
]
[Cites]
Bioinformatics. 2003 Jan 22;19(2):185-93
[
12538238.001
]
[Cites]
Nucleic Acids Res. 2003 Feb 15;31(4):e15
[
12582260.001
]
[Cites]
N Engl J Med. 2003 Jul 17;349(3):247-57
[
12867608.001
]
[Cites]
J Biol Chem. 2003 Dec 19;278(51):51957-67
[
14522980.001
]
[Cites]
Cancer Res. 2004 Aug 1;64(15):5245-50
[
15289330.001
]
[Cites]
Fam Cancer. 2004;3(2):85-91
[
15340258.001
]
[Cites]
Cell. 1990 Jun 1;61(5):759-67
[
2188735.001
]
[Cites]
J Biol Chem. 1996 May 10;271(19):11541-7
[
8626715.001
]
[Cites]
Biochem Pharmacol. 1998 Dec 1;56(11):1411-26
[
9827573.001
]
(PMID = 17519897.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Neoplasm; 0 / RNA, Neoplasm; EC 2.3.- / Acyltransferases; EC 2.3.1.- / ZDHHC9 protein, human
[Other-IDs]
NLM/ PMC2359975
13.
Lin JK, Shen MY, Lin TC, Lan YT, Wang HS, Yang SH, Li AF, Chang SC:
Distribution of a single nucleotide polymorphism of insulin-like growth factor-1 in colorectal cancer patients and its association with mucinous adenocarcinoma.
Int J Biol Markers
; 2010 Oct-Dec;25(4):195-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Distribution of a single nucleotide polymorphism of insulin-like growth factor-1 in colorectal cancer patients and its association with mucinous
adenocarcinoma
.
RESULTS: Young CRC patients had a higher frequency of advanced disease (58.7%) and mucinous
adenocarcinoma
(20%) than old CRC patients.
Other clinicopathological factors including tumor location, differentiation, lymphovascular invasion, and TNM
stage
were not associated with the AA genotype of IGF-1.
CONCLUSIONS: Older patients had a higher frequency of the AA genotype of IGF-1(-2995 C/A), while younger patients more often had advanced disease and mucinous
adenocarcinoma
.
[MeSH-major]
Adenocarcinoma
, Mucinous / genetics. Colorectal Neoplasms / genetics. Insulin-Like Growth Factor I / genetics. Polymorphism, Single Nucleotide
Genetic Alliance.
consumer health - Colorectal Cancer
.
Genetic Alliance.
consumer health - Colorectal cancer 1
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21161940.001).
[ISSN]
1724-6008
[Journal-full-title]
The International journal of biological markers
[ISO-abbreviation]
Int. J. Biol. Markers
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
67763-96-6 / Insulin-Like Growth Factor I
14.
Kawaguchi W, Itamochi H, Kigawa J, Kanamori Y, Oishi T, Shimada M, Sato S, Sato S, Terakawa N:
Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed müllerian tumor of the fallopian tube.
Int J Clin Oncol
; 2008 Oct;13(5):461-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Pathological examination determined International Federation of Gynecology and Obstetrics (FIGO)
stage
IIIc MMMT of the right fallopian tube.
Of note, multiple tumoral nodules were attached to the sigmoid
colon
.
The tumor attached to the sigmoid
colon
had shrunk by 60% after chemotherapy.
[MeSH-minor]
Adenocarcinoma
/ pathology. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Ovariectomy
Genetic Alliance.
consumer health - Malignant mixed Mullerian tumor
.
Hazardous Substances Data Bank.
TAXOL
.
Hazardous Substances Data Bank.
CARBOPLATIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Gynecol Oncol. 1992 Oct;47(1):114-24
[
1330846.001
]
[Cites]
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):101-5
[
16445618.001
]
[Cites]
Int J Gynecol Pathol. 1990;9(1):1-19
[
2152890.001
]
[Cites]
Gynecol Oncol. 2005 Apr;97(1):219-22
[
15790462.001
]
[Cites]
Arch Gynecol Obstet. 1996;258(1):47-53
[
8789433.001
]
[Cites]
Int J Gynecol Cancer. 2004 Jul-Aug;14(4):690-3
[
15304169.001
]
[Cites]
Cancer. 1993 Jan 1;71(1):187-92
[
8380115.001
]
[Cites]
Gynecol Oncol. 1984 Jul;18(3):278-92
[
6086467.001
]
[Cites]
Acta Obstet Gynecol Scand. 1994 Apr;73(4):352-4
[
8160547.001
]
[Cites]
Int J Gynecol Cancer. 1999 Jul;9(4):312-316
[
11240785.001
]
[Cites]
Obstet Gynecol. 1995 May;85(5 Pt 1):735-9
[
7724104.001
]
(PMID = 18946759.001).
[ISSN]
1341-9625
[Journal-full-title]
International journal of clinical oncology
[ISO-abbreviation]
Int. J. Clin. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
15.
Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI:
Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer.
Br J Cancer
; 2006 Oct 9;95(7):921-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In this study comparing normal
colon
to colorectal cancer by proteomics, hnRNP K was identified as being overexpressed in this type of cancer.
In normal
colon
hnRNP K was exclusively nuclear whereas in colorectal cancer the protein localised both in the cytoplasm and the nucleus.
There were significant increases in both nuclear (P=0.007) and cytoplasmic (P=0.001) expression of hnRNP K in Dukes C tumours compared with early
stage
tumours.
[MeSH-major]
Adenocarcinoma
/ metabolism. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Ribonucleoproteins / biosynthesis
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
EMBO J. 1994 Mar 15;13(6):1476-81
[
8137829.001
]
[Cites]
Br J Cancer. 2003 Oct 20;89(8):1493-501
[
14562022.001
]
[Cites]
J Histochem Cytochem. 1999 Nov;47(11):1457-64
[
10544218.001
]
[Cites]
Genetics. 2000 Dec;156(4):1765-76
[
11102372.001
]
[Cites]
Nat Cell Biol. 2001 Mar;3(3):325-30
[
11231586.001
]
[Cites]
J Biol Chem. 2001 Mar 30;276(13):9699-704
[
11121407.001
]
[Cites]
J Biol Chem. 2002 May 10;277(19):16614-23
[
11867641.001
]
[Cites]
Nucleic Acids Res. 2003 Mar 1;31(5):1502-13
[
12595559.001
]
[Cites]
Lung Cancer. 2003 Aug;41(2):131-43
[
12871776.001
]
[Cites]
Lung Cancer. 2003 Aug;41(2):179-86
[
12871781.001
]
[Cites]
Oncogene. 2003 Sep 11;22(39):8012-20
[
12970749.001
]
[Cites]
Biochim Biophys Acta. 2006 Apr;1765(2):85-100
[
16378690.001
]
[Cites]
Br J Cancer. 2004 May 17;90(10):1955-60
[
15138477.001
]
[Cites]
Cell. 2004 May 28;117(5):649-62
[
15163412.001
]
[Cites]
Bioessays. 2004 Jun;26(6):629-38
[
15170860.001
]
[Cites]
Proc Natl Acad Sci U S A. 1984 Dec;81(23):7471-5
[
6594697.001
]
[Cites]
J Biol Chem. 1993 Aug 25;268(24):18249-58
[
8349701.001
]
[Cites]
J Mol Biol. 1994 Feb 11;236(1):33-48
[
8107114.001
]
[Cites]
FEBS Lett. 1997 Feb 17;403(2):113-5
[
9042948.001
]
[Cites]
Mol Cell Biol. 1999 Nov;19(11):7846-56
[
10523673.001
]
[Cites]
J Pathol. 2005 Jan;205(1):74-81
[
15532096.001
]
[Cites]
J Cell Biochem. 2005 Aug 1;95(5):1042-56
[
15962305.001
]
[Cites]
Cell. 2005 Dec 16;123(6):1065-78
[
16360036.001
]
[CommentIn]
Br J Cancer. 2007 Aug 20;97(4):574-5; author reply 576
[
17667925.001
]
(PMID = 16953238.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Ribonucleoproteins; 146410-60-8 / HNRNPK protein, human
[Other-IDs]
NLM/ PMC2360539
16.
Horst D, Kriegl L, Engel J, Jung A, Kirchner T:
CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.
Eur J Cancer
; 2009 Jul;45(11):2034-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low
stage
colorectal cancer.
Nuclear beta-catenin and CD133 are linked with two hallmarks
of colon
cancer, wingless-type mouse mammary tumour virus integration site (WNT)-pathway dysregulation and
colon
cancer stem cells (Co-CSCs), respectively.
Herein, we investigated the expression of these markers on serial sections of 162
stage
IIA colonic adenocarcinomas.
Moreover, we show that their combined evaluation can identify
colon
cancer cases with vastly reduced survival (hazard ratio (HR) 13.4, 95% confidence interval (CI): 4.7-38.2) and a high risk of tumour progression (HR 6.8, 95%CI: 3.1-15.0).
In conclusion, the independence of these markers may on the one hand have implications for their presumed value to identify Co-CSCs; on the other hand it allows their combined analysis to become a powerful tool to identify high risk cases
of stage
IIA
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ metabolism. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Glycoproteins / analysis. Peptides / analysis. beta Catenin / analysis
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19403300.001).
[ISSN]
1879-0852
[Journal-full-title]
European journal of cancer (Oxford, England : 1990)
[ISO-abbreviation]
Eur. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides; 0 / beta Catenin
17.
Vorburger SA, Gloor B, Candinas D:
[Tumor surveillance after resection of colorectal cancer].
Ther Umsch
; 2008 Jun;65(6):329-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Because recurrent
adenocarcinoma of
the
colon
and rectum (CRC) can still be treated with acceptable 5-year survival rates, tumor surveillance plays an important role.
Only in cases where early
stage
CRC was been completely resected no schematic surveillance must take place.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - After Surgery
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18622956.001).
[ISSN]
0040-5930
[Journal-full-title]
Therapeutische Umschau. Revue thérapeutique
[ISO-abbreviation]
Ther Umsch
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
18.
Borie F, Tretarre B, Marchigiano E, Daurcs JP, Millat B:
Management and prognosis of colon cancer in patients with intestinal obstruction or peritonitis: a French population-based study.
Med Sci Monit
; 2005 Jun;11(6):CR266-273
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Management and prognosis
of colon
cancer in patients with intestinal obstruction or peritonitis: a French population-based study.
BACKGROUND: In spite of recent advances in our knowledge of tumor biology and therapy, the management and prognosis of patients with
colon
cancer (CC) revealed by intestinal obstruction or peritonitis (IOP) are not well defined.
The primary independent negative prognostic factor in multivariate analysis was the presence of nodal or distant metastases (Dukes'
stage
D, p=0.0001), followed by lack of chemotherapy (p=0.008), initial treatment in non-specialized hospitals (p=0.01), onset with IOP (p=0.02), low-volume surgeons (p=0.02).
[MeSH-major]
Adenocarcinoma
/ therapy. Colonic Neoplasms / therapy. Intestinal Obstruction / etiology. Peritonitis / etiology
MedlinePlus Health Information.
consumer health - Intestinal Obstruction
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15917717.001).
[ISSN]
1234-1010
[Journal-full-title]
Medical science monitor : international medical journal of experimental and clinical research
[ISO-abbreviation]
Med. Sci. Monit.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
Poland
19.
Reddy VB, Aslanian H, Suh N, Longo WE:
Asymptomatic ileal adenocarcinoma in the setting of undiagnosed Crohn's disease.
World J Gastroenterol
; 2008 Aug 7;14(29):4690-3
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Asymptomatic ileal
adenocarcinoma
in the setting of undiagnosed Crohn's disease.
Examination of the
colon
was normal.
The biopsy of the ileal mass was consistent with an
adenocarcinoma
arising from the terminal ileum.
Findings were consistent with ileal
adenocarcinoma
in the setting of Crohn's disease.
The pathology was
stage
1
adenocarcinoma
.
This is a unique case in that on a screening colonoscopy, a favorable ileal
adenocarcinoma
was discovered in the setting of asymptomatic, undiagnosed ileal Crohn's disease in a patient whose father had Crohn's disease diagnosed postmortem.
[MeSH-major]
Adenocarcinoma
/ diagnosis. Crohn Disease / diagnosis. Ileal Neoplasms / diagnosis
Genetic Alliance.
consumer health - Crohn Disease
.
MedlinePlus Health Information.
consumer health - Crohn's Disease
.
MedlinePlus Health Information.
consumer health - Intestinal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 1983 Mar 1;51(5):878-81
[
6821853.001
]
[Cites]
Cancer. 1984 Jan 1;53(1):23-5
[
6690001.001
]
[Cites]
J Clin Gastroenterol. 1984 Jun;6(3):217-24
[
6327804.001
]
[Cites]
World J Surg. 1985 Dec;9(6):914-20
[
4082613.001
]
[Cites]
Cancer. 1989 Jan 15;63(2):360-3
[
2910443.001
]
[Cites]
Surg Gynecol Obstet. 1991 Nov;173(5):343-9
[
1948581.001
]
[Cites]
Dig Dis Sci. 1992 Aug;37(8):1179-84
[
1499440.001
]
[Cites]
Gastroenterology. 1992 Nov;103(5):1444-51
[
1358741.001
]
[Cites]
J Gastroenterol Hepatol. 1999 Nov;14(11):1132-4
[
10574144.001
]
[Cites]
Clin Imaging. 1999 Sep-Oct;23(5):298-301
[
10665347.001
]
[Cites]
Cancer. 2001 Feb 15;91(4):854-62
[
11241255.001
]
[Cites]
Scand J Gastroenterol. 2001 Jun;36(6):641-6
[
11424324.001
]
[Cites]
Eur J Gastroenterol Hepatol. 2002 Jul;14(7):805-10
[
12169995.001
]
[Cites]
Dis Colon Rectum. 2002 Nov;45(11):1496-502
[
12432298.001
]
[Cites]
J Chemother. 2003 Oct;15(5):503-6
[
14598944.001
]
[Cites]
Australas Radiol. 2003 Dec;47(4):450-2
[
14641202.001
]
[Cites]
Endoscopy. 2003 Dec;35(12):1009-14
[
14648412.001
]
[Cites]
J Comput Assist Tomogr. 2004 Jan-Feb;28(1):106-16
[
14716243.001
]
[Cites]
Aliment Pharmacol Ther. 2004 Feb 1;19(3):287-93
[
14984375.001
]
[Cites]
Inflamm Bowel Dis. 2004 Jan;10(1):32-5
[
15058524.001
]
[Cites]
Dis Colon Rectum. 2004 May;47(5):778-81
[
15037927.001
]
[Cites]
Radiographics. 2004 May-Jun;24(3):689-702
[
15143222.001
]
[Cites]
Inflamm Bowel Dis. 2004 Feb;10 Suppl 1:S32-4
[
15168828.001
]
[Cites]
Clin Gastroenterol Hepatol. 2004 Jun;2(6):491-7
[
15181618.001
]
[Cites]
Cancer. 2004 Aug 1;101(3):518-26
[
15274064.001
]
[Cites]
World J Gastroenterol. 2004 Sep 1;10(17):2585-7
[
15300912.001
]
[Cites]
Gastroenterol Nurs. 2004 Jul-Aug;27(4):170-5
[
15326402.001
]
[Cites]
Lancet. 1973 Jan 6;1(7793):24-6
[
4118541.001
]
[Cites]
Gut. 1973 Feb;14(2):120-4
[
4696534.001
]
[Cites]
Am J Dig Dis. 1973 Dec;18(12):1095-8
[
4761532.001
]
[Cites]
Ann Surg. 1974 Aug;180(2):175-9
[
4843046.001
]
[Cites]
Cancer. 1976 Jun;37(6):2948-59
[
949714.001
]
[Cites]
Am J Surg. 1980 Sep;140(3):396-9
[
7425215.001
]
[Cites]
Gut. 1982 Mar;23(3):188-93
[
7040175.001
]
[Cites]
Dis Colon Rectum. 1993 Jul;36(7):654-61
[
8348849.001
]
[Cites]
Gastroenterology. 1993 Dec;105(6):1716-23
[
8253348.001
]
[Cites]
Med Clin North Am. 1994 Nov;78(6):1399-412
[
7967916.001
]
[Cites]
Gut. 1994 Nov;35(11):1507-8
[
7828962.001
]
[Cites]
Am J Gastroenterol. 1996 Mar;91(3):434-40
[
8633487.001
]
[Cites]
Dis Colon Rectum. 1996 Nov;39(11):1315-21
[
8918446.001
]
[Cites]
Am J Surg. 1997 Mar;173(3):237-9
[
9124635.001
]
[Cites]
J Comput Assist Tomogr. 1997 Nov-Dec;21(6):986-91
[
9386295.001
]
[Cites]
Am J Surg Pathol. 1998 Mar;22(3):275-84
[
9500769.001
]
[Cites]
Eur J Gastroenterol Hepatol. 1998 May;10(5):431-2
[
9619392.001
]
[Cites]
Surgery. 1956 Feb;39(2):347-51
[
13298987.001
]
[Cites]
Gastroenterology. 2006 Apr;130(4):1039-46
[
16618397.001
]
[Cites]
Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:1-5
[
12950413.001
]
(PMID = 18698685.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
China
[Other-IDs]
NLM/ PMC2738795
20.
Wille-Jørgensen P, Laurberg S, Påhlman L, Carriquiry L, Lundqvist N, Smedh K, Svanfeldt M, Bengtson J:
An interim analysis of recruitment to the COLOFOL trial.
Colorectal Dis
; 2009 Sep;11(7):756-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHOD: Prospective registration of all operated patients as well as inclusions (curative resection,
stage
II or III disease, <or= 75 years, clean
colon
and exclusions of the individual patients in eight participating departments.
[MeSH-major]
Adenocarcinoma
/ surgery. Colonic Neoplasms / surgery. Patient Selection. Rectal Neoplasms / surgery
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19708095.001).
[ISSN]
1463-1318
[Journal-full-title]
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
[ISO-abbreviation]
Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Randomized Controlled Trial
[Publication-country]
England
21.
Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M:
Are we undertreating rectal cancer in the elderly? An epidemiologic study.
Ann Surg
; 2007 Aug;246(2):215-21
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
SUMMARY BACKGROUND DATA: The incidence of rectal cancer increases with older age, and localized disease can be curatively treated with
stage
-appropriate radical surgery.
METHODS: Patients with localized rectal
adenocarcinoma
were identified in the Surveillance, Epidemiology, and End Results database (1991-2002).
Each half-decade increase in age > or =70 years was associated with a 37% increase in the relative risk (RR) for cancer-related mortality (RR = 1.37; 95% confidence interval [CI], 1.33-1.42); decreased receipt of cancer-directed surgery (odds ratio [OR] = 0.56; 95% CI, 0.36-0.63); more local excision and less radical surgery (OR = 0.76; 95% CI, 0.72-0.81); less radiotherapy (OR = 0.64; 95% CI, 0.61-0.67); and greater likelihood of N0 pathologic
stage
classification (OR = 1.10; 95% CI, 1.05-1.15) (P < 0.0001 for each factor).
[MeSH-major]
Adenocarcinoma
/ epidemiology. Rectal Neoplasms / epidemiology
Genetic Alliance.
consumer health - Rectal Cancer
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Surg. 2000 Mar;231(3):345-51
[
10714627.001
]
[Cites]
CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
[
16514137.001
]
[Cites]
Crit Rev Oncol Hematol. 2000 Sep;35(3):161-79
[
10960799.001
]
[Cites]
Lancet. 2000 Sep 16;356(9234):968-74
[
11041397.001
]
[Cites]
Dis Colon Rectum. 2000 Dec;43(12):1704-9
[
11156454.001
]
[Cites]
J Natl Cancer Inst. 2001 Jun 6;93(11):850-7
[
11390534.001
]
[Cites]
N Engl J Med. 2001 Oct 11;345(15):1091-7
[
11596588.001
]
[Cites]
Eur J Surg Oncol. 2002 Sep;28(6):661-6
[
12359205.001
]
[Cites]
Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30
[
12368681.001
]
[Cites]
Am J Surg. 2003 Jan;185(1):54-7
[
12531446.001
]
[Cites]
Crit Rev Oncol Hematol. 2003 Nov;48(2):159-63
[
14607379.001
]
[Cites]
Clin Colorectal Cancer. 2003 Nov;3(3):165-71
[
14706175.001
]
[Cites]
Strahlenther Onkol. 2004 Aug;180(8):478-87
[
15292968.001
]
[Cites]
Br J Surg. 2004 Oct;91(10):1345-51
[
15376202.001
]
[Cites]
JAMA. 1990 Sep 19;264(11):1444-50
[
2202842.001
]
[Cites]
Ann Surg Oncol. 2004 Nov;11(11):962-9
[
15525824.001
]
[Cites]
Surg Oncol. 2004 Dec;13(4):223-34
[
15615660.001
]
[Cites]
Br J Surg. 2005 May;92(5):615-23
[
15779071.001
]
[Cites]
J Clin Oncol. 2005 Jun 1;23(16):3802-10
[
15923574.001
]
[Cites]
J Natl Compr Canc Netw. 2005 Jul;3(4):492-508
[
16038640.001
]
[Cites]
Dis Colon Rectum. 2005 Sep;48(9):1755-63
[
15981072.001
]
[Cites]
Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4
[
10950004.001
]
(PMID = 17667499.001).
[ISSN]
0003-4932
[Journal-full-title]
Annals of surgery
[ISO-abbreviation]
Ann. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC1933551
22.
Childs AJ, Burke JJ 2nd, Perry MY, Check WE, Gallup DG:
Recurrent colorectal carcinoma detected by routine cervicovaginal papanicolaou smear testing.
J Low Genit Tract Dis
; 2005 Oct;9(4):236-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: We present a case of recurrent
colon
cancer detected by routine, annual Papanicolaou screening.
CASE: A 59-year-old African American woman who had been treated for T2N0M0 (
stage
II, Dukes A)
colon
cancer 2 years before to presentation had a Pap smear showing a high-grade squamous intraepithelial lesion with a normal cervical biopsy result.
Because of this discrepancy, a loop electrosurgical excision procedure and endocervical curettage were performed and showed atypical glandular cells suspicious for
adenocarcinoma
.
Subsequent colonoscopy showed recurrent
adenocarcinoma of
the
colon
.
The patient underwent an en-block total abdominal hysterectomy and anterior-perineal resection showing invasion of recurrent
colon
cancer into the uterus and cervix.
CONCLUSION: In patients with a history of extrauterine
adenocarcinoma
, abnormal Pap screening may indicate recurrent or metastatic carcinoma.
[MeSH-major]
Adenocarcinoma
/ diagnosis. Colorectal Neoplasms / diagnosis. Diagnostic Tests, Routine. Neoplasm Recurrence, Local / diagnosis. Papanicolaou Test. Uterine Neoplasms / diagnosis. Vaginal Smears
MedlinePlus Health Information.
consumer health - Cervical Cancer Screening
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Health Screening
.
MedlinePlus Health Information.
consumer health - Uterine Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16205196.001).
[ISSN]
1089-2591
[Journal-full-title]
Journal of lower genital tract disease
[ISO-abbreviation]
J Low Genit Tract Dis
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
23.
Sjo OH, Lunde OC, Nygaard K, Sandvik L, Nesbakken A:
Tumour location is a prognostic factor for survival in colonic cancer patients.
Colorectal Dis
; 2008 Jan;10(1):33-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: To evaluate survival and prognostic factors in a consecutive series
of colon
cancer patients from a defined city population in Norway.
METHOD: All patients with
adenocarcinoma of
the
colon
diagnosed between 1993 and 2000 were registered prospectively.
Tumour location in the transverse
colon
, splenic flexure and descending
colon
(OR = 1.8), emergency operation (OR = 1.7), TNM
stage
(OR = 1.8-2.9), blood transfusion of more than two units (OR = 1.8) and age (OR = 4.0-7.1) were independent negative prognostic factors.
CONCLUSION:
Colon
cancer located in the transverse and descending
colon
is associated with poor prognosis.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ surgery. Colectomy / methods. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17672872.001).
[ISSN]
1463-1318
[Journal-full-title]
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
[ISO-abbreviation]
Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
24.
Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG:
Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
J Clin Oncol
; 2005 Dec 1;23(34):8706-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Colon
cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
PATIENTS AND METHODS: We analyzed data from Intergroup trial 0089 of adjuvant chemotherapy for
stage
II and III patients with
colon
cancer, in which all patients received fluorouracil-based therapy.
Covariates included in the models were age, sex, tumor
stage
, grade, histology, number of positive LNs, number of LNs removed, and LNR.
[MeSH-major]
Adenocarcinoma
/ therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / therapy. Lymphatic Metastasis / pathology
Genetic Alliance.
consumer health - Metastatic cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16314630.001).
[ISSN]
0732-183X
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
25.
Morris M, Platell C, Fritschi L, Iacopetta B:
Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.
Br J Cancer
; 2007 Mar 12;96(5):701-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Failure to complete adjuvant chemotherapy is associated with adverse survival in
stage
III
colon
cancer patients.
Two recent North American studies have shown that completion of 5-fluorouracil (5FU)-based adjuvant chemotherapy is a major prognostic factor for the survival of elderly
stage
III
colon
cancer patients.
The study cohort comprised 851
stage
III
colon
cancer patients treated by surgery alone and 461 who initiated the Mayo chemotherapy regime.
The current and previous studies demonstrate the importance of completing adjuvant 5-FU-based chemotherapy for
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / drug therapy. Colonic Neoplasms / mortality
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2002 Sep 1;20(17):3605-16
[
12202661.001
]
[Cites]
J Clin Oncol. 2002 Mar 15;20(6):1491-8
[
11896096.001
]
[Cites]
J Clin Oncol. 2002 Oct 1;20(19):3992-8
[
12351596.001
]
[Cites]
Br J Cancer. 2003 May 19;88(10):1510-5
[
12771914.001
]
[Cites]
Br J Cancer. 2003 Jun 16;88(12):1859-65
[
12799627.001
]
[Cites]
J Clin Oncol. 2003 Aug 1;21(15):2896-903
[
12885807.001
]
[Cites]
Clin Cancer Res. 2003 Aug 1;9(8):2898-903
[
12912934.001
]
[Cites]
J Clin Oncol. 2003 Oct 15;21(20):3729-36
[
14551292.001
]
[Cites]
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5860-5
[
14676107.001
]
[Cites]
N Engl J Med. 2004 Jun 3;350(23):2343-51
[
15175436.001
]
[Cites]
Oncology (Williston Park). 2004 May;18(6):751-5; discussion 755-8
[
15214594.001
]
[Cites]
Eur J Cancer. 2004 Oct;40(15):2230-6
[
15454247.001
]
[Cites]
J Clin Oncol. 1988 Oct;6(10):1653-64
[
3049954.001
]
[Cites]
N Engl J Med. 1990 Feb 8;322(6):352-8
[
2300087.001
]
[Cites]
JAMA. 1990 Sep 19;264(11):1444-50
[
2202842.001
]
[Cites]
J Clin Oncol. 1992 Jul;10(7):1171-5
[
1607921.001
]
[Cites]
J Clin Oncol. 1993 Oct;11(10):1879-87
[
8410113.001
]
[Cites]
J Clin Oncol. 1994 Jun;12(6):1291-5
[
8201391.001
]
[Cites]
J Clin Oncol. 1997 Jan;15(1):246-50
[
8996149.001
]
[Cites]
J Clin Oncol. 1998 Nov;16(11):3537-41
[
9817272.001
]
[Cites]
Eur J Cancer. 1998 Nov;34(12):1871-5
[
10023308.001
]
[Cites]
Cancer. 2005 Mar 15;103(6):1165-71
[
15693031.001
]
[Cites]
J Clin Oncol. 2005 Mar 20;23(9):1819-25
[
15774775.001
]
[Cites]
N Engl J Med. 2005 Jun 30;352(26):2696-704
[
15987918.001
]
[Cites]
N Engl J Med. 2005 Jun 30;352(26):2746-8
[
15987925.001
]
[Cites]
JAMA. 2005 Dec 7;294(21):2703-11
[
16333005.001
]
[Cites]
Dig Surg. 2005;22(6):401-14
[
16479107.001
]
[Cites]
J Natl Cancer Inst. 2006 May 3;98(9):610-9
[
16670386.001
]
[Cites]
J Clin Oncol. 2006 May 20;24(15):2368-75
[
16618946.001
]
[Cites]
J Clin Oncol. 2007 Jan 1;25(1):102-9
[
17194911.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2412-8
[
10561304.001
]
[Cites]
Br J Cancer. 2001 Mar 2;84(5):600-3
[
11237378.001
]
[Cites]
Ann Intern Med. 2002 Mar 5;136(5):349-57
[
11874307.001
]
[Cites]
J Clin Oncol. 2002 Sep 1;20(17):3617-27
[
12202662.001
]
(PMID = 17299387.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
[Other-IDs]
NLM/ PMC2360063
26.
Qureshi AU, Iqbal M, Gondal KM:
Transhiatal esophageal surgery for malignancy--a 7-year experience at a tertiary care hospital.
J Coll Physicians Surg Pak
; 2009 Jul;19(7):413-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
All underwent transhiatal esophagectomy and gastric tube or
colon
was used as the conduit to restore continuity.
The TNM staging were
stage I
, IIa, IIb, III and IV in zero (0), 5 (11%), 10 (22%), 24 (57.8%) and 3 (7.1%) respectively.
The frequency of complications is lower as compared to transthoracic approach and the early
stage of
presentation can lead to high 5-year survival ratios.
[MeSH-major]
Adenocarcinoma
/ surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19576147.001).
[ISSN]
1022-386X
[Journal-full-title]
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
[ISO-abbreviation]
J Coll Physicians Surg Pak
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Pakistan
27.
Mukai M, Tanaka A, Tajima T, Fukasawa M, Yamagiwa T, Okada K, Sato K, Tobita K, Oida Y, Makuuchi H:
Two-port hand-assisted laparoscopic surgery for the 2-stage treatment of a complete bowel obstruction by left colon cancer: a case report.
Oncol Rep
; 2008 Apr;19(4):875-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Two-port hand-assisted laparoscopic surgery for the 2-
stage
treatment of a complete bowel obstruction by left
colon
cancer: a case report.
Since a bowel obstruction by left
colon
cancer was suspected due to a marked dilation of the transverse
colon
, she was referred to our hospital.
On admission, an enema disclosed a complete obstruction at the splenic flexure of the
colon
.
An emergency operation was performed, and a temporary loop colostomy was fashioned on the left side of the transverse
colon
within the range of resection for 2-
stage
radical surgery.
The histological diagnosis was Type 2 circumferential well-differentiated
adenocarcinoma
with local peritoneal dissemination.
Our experience suggests that 2-
stage
surgery combined with 2P-HALS is applicable even to a large obstructing left
colon
cancer.
MedlinePlus Health Information.
consumer health - Intestinal Obstruction
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18357370.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
28.
Sastre J, Maestro ML, Puente J, Veganzones S, Alfonso R, Rafael S, García-Saenz JA, Vidaurreta M, Martín M, Arroyo M, Sanz-Casla MT, Díaz-Rubio E:
Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.
Ann Oncol
; 2008 May;19(5):935-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Only
stage
correlated with positive CTCs (20.7% in
stage
II, 24.1% in
stage
III and 60.7% in
stage
IV, P = 0.005).
CONCLUSIONS: CTCs detection by CellSearch is a highly reproducible method that correlates with
stage
but not with other clinical and morphological variables in patients with colorectal cancer.
Colon
cancer tumor cells are detectable in all stages.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18212090.001).
[ISSN]
1569-8041
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; EC 1.1.1.27 / L-Lactate Dehydrogenase
29.
Yang R, Cheung MC, Zhuge Y, Armstrong C, Koniaris LG, Sola JE:
Primary solid tumors of the colon and rectum in the pediatric patient: a review of 270 cases.
J Surg Res
; 2010 Jun 15;161(2):209-16
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary solid tumors of the
colon
and rectum in the pediatric patient: a review of 270 cases.
OBJECTIVE: To study the outcomes of solid tumors of the
colon
and rectum in pediatric patients.
Tumors were identified in the right
colon
(45.9%), transverse
colon
(9.3%), left
colon
(20.4%), rectum (15.2%), and anal canal (1.1%).
The most common histology of these tumors was
adenocarcinoma
(35.6%), followed by carcinoid (34.1%).
Multivariate analysis of the cohort identified tumor
stage
(HR 8.39, P < 0.001 for distant disease), tumor type (signet ring HR 2.12, P = 0.025, and carcinoid HR = 0.14, P = 0.001), and surgical resection (no surgery HR 2.98, P = 0.010) as independent predictors of worse outcome.
CONCLUSION: In the pediatric population, solid tumors of the
colon
and rectum occur more frequently in the right side of the
colon
in teenagers.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Inc. All rights reserved.
(PMID = 19285688.001).
[ISSN]
1095-8673
[Journal-full-title]
The Journal of surgical research
[ISO-abbreviation]
J. Surg. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
30.
Endreseth BH, Romundstad P, Myrvold HE, Hestvik UE, Bjerkeset T, Wibe A, Norwegian Rectal Cancer Group:
Rectal cancer in the young patient.
Dis Colon Rectum
; 2006 Jul;49(7):993-1001
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: This prospective study from the Norwegian Rectal Cancer Project includes all 2,283 patients younger than aged 70 years with
adenocarcinoma of
the rectum from November 1993 to December 1999.
RESULTS: Patients younger than aged 40 years had significantly higher frequencies of poorly differentiated tumors (27 vs. 12-16 percent; P = 0.014), N2-
stage
(37 vs. 13-18 percent; P = 0.001), and distant metastases (38 vs. 19-24 percent; P = 0.019) compared with older patients.
CONCLUSIONS: Patients younger than aged 40 years had a more advanced
stage
at the time of diagnosis and poor prognosis compared with older patients.
[MeSH-major]
Adenocarcinoma
/ therapy. Rectal Neoplasms / therapy
Genetic Alliance.
consumer health - Rectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16741599.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
31.
Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Möller P:
Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
Gut
; 2005 May;54(5):661-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Impaired CD95 expression predisposes for recurrence in curatively resected
colon
carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
BACKGROUND: Loss of CD95 expression in tumour cells occurs frequently in
colon
carcinoma and may be associated with disease progression.
AIMS: We aimed at further exploring the functional role and prognostic significance of the CD95/CD95L death inducing system in
colon
carcinomas.
PATIENTS AND METHODS: CD95 and CD95L expression was examined by immunohistochemistry in 128 R0 resected UICC (International Union against Cancer)
stage
II/III
colon
carcinomas and correlated with disease free survival.
Tumour infiltrating lymphocytes (TIL) were the major source of CD95L in
colon
carcinomas.
Moreover, a high rate of CD95L+TIL correlated with prolonged disease free survival in patients with UICC
stage
II (p = 0.05) but not in those with
stage
III.
CONCLUSIONS: Loss of CD95 in tumour cells may be an independent prognostic factor in
colon
carcinomas.
The CD95L counterattack is not a relevant feature in
colon
carcinoma but CD95L+TIL may contribute to tumour control in the early stages of the disease, exerting a concurrent selection pressure in the direction of CD95 abrogation/resistance.
[MeSH-major]
Adenocarcinoma
/ immunology. Antigens, CD95 / metabolism. Biomarkers, Tumor / metabolism. Colonic Neoplasms / immunology. Membrane Glycoproteins / metabolism
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hum Pathol. 1999 Nov;30(11):1309-13
[
10571510.001
]
[Cites]
Cell Death Differ. 2001 Mar;8(3):273-8
[
11319610.001
]
[Cites]
J Immunol. 2000 May 15;164(10):5023-7
[
10799856.001
]
[Cites]
J Pathol. 2001 May;194(1):15-9
[
11329136.001
]
[Cites]
J Immunol. 2001 Aug 15;167(4):2068-73
[
11489989.001
]
[Cites]
Cancer Cell. 2002 Aug;2(2):139-48
[
12204534.001
]
[Cites]
J Immunol. 2003 Jun 15;170(12):5973-80
[
12794124.001
]
[Cites]
Gastroenterology. 2003 Sep;125(3):708-15
[
12949717.001
]
[Cites]
J Immunol. 2003 Oct 15;171(8):4164-74
[
14530339.001
]
[Cites]
Cancer. 1981 Mar 1;47(5):930-6
[
7226044.001
]
[Cites]
Cell. 1991 Jul 26;66(2):233-43
[
1713127.001
]
[Cites]
J Biol Chem. 1992 May 25;267(15):10709-15
[
1375228.001
]
[Cites]
Lab Invest. 1993 Oct;69(4):415-29
[
7693996.001
]
[Cites]
Int J Cancer. 1994 May 1;57(3):371-7
[
8168998.001
]
[Cites]
Int J Cancer. 1996 Sep 4;67(5):709-14
[
8782663.001
]
[Cites]
Science. 1996 Nov 22;274(5291):1363-6
[
8910274.001
]
[Cites]
J Exp Med. 1996 Sep 1;184(3):1075-82
[
9064324.001
]
[Cites]
J Exp Med. 1996 Sep 1;184(3):1149-54
[
9064331.001
]
[Cites]
Cell. 1997 Feb 7;88(3):355-65
[
9039262.001
]
[Cites]
Gastroenterology. 1997 Jul;113(1):160-7
[
9207274.001
]
[Cites]
Cancer Res. 1998 Feb 1;58(3):526-34
[
9458101.001
]
[Cites]
Cancer Res. 1998 Aug 15;58(16):3491-4
[
9721846.001
]
[Cites]
J Exp Med. 1998 Nov 2;188(9):1717-23
[
9802983.001
]
[Cites]
J Pathol. 1998 Nov;186(3):240-6
[
10211111.001
]
[Cites]
J Exp Med. 1999 Oct 4;190(7):1025-32
[
10510092.001
]
[Cites]
J Exp Med. 1999 Oct 4;190(7):1033-8
[
10510093.001
]
[Cites]
J Immunol. 2000 May 1;164(9):4941-54
[
10779805.001
]
(PMID = 15831912.001).
[ISSN]
0017-5749
[Journal-full-title]
Gut
[ISO-abbreviation]
Gut
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD95; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Ligands; 0 / Membrane Glycoproteins
[Other-IDs]
NLM/ PMC1774512
32.
Dahl O:
[Adjuvant chemotherapy for colon cancer].
Tidsskr Nor Laegeforen
; 2007 Nov 29;127(23):3094-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Adjuvant chemotherapy for
colon
cancer].
BACKGROUND: Radical resection is the main treatment for
adenocarcinoma of
the
colon
.
The background for adjuvant chemotherapy
of colon
cancer is presented.
RESULTS AND INTERPRETATION: Cure rates after curative resections
of colon
cancer (
stage
III) are improved by about 12% if patients are treated with adjuvant chemotherapy with oxaliplatin combined with 5-fluoruracil and folinat (or capecitabine) for 6 months.
Certain subgroups
of stage
II (Dukes'
stage
B) are also likely to benefit from adjuvant chemotherapy.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Colonic Neoplasms / drug therapy
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18049502.001).
[ISSN]
0807-7096
[Journal-full-title]
Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
[ISO-abbreviation]
Tidsskr. Nor. Laegeforen.
[Language]
nor
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Norway
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents
[Number-of-references]
35
33.
Chaleoykitti B:
Mucinous carcinoma of the colon and rectum in Phramongkutklao Hospital.
J Med Assoc Thai
; 2006 Jan;89(1):25-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mucinous carcinoma of the
colon
and rectum in Phramongkutklao Hospital.
OBJECTIVE: The objective of the present study was to compare the clinicopathological significance between mucinous carcinoma and nonmucinous
adenocarcinoma
.
MATERIAL AND METHOD: Patients with carcinoma of the
colon
and rectum who had the first operation in the Department of Surgery, Phramongkutklao Hospital between 1999 and 2004 were included in the present study.
There was no difference in sex distribution, location of tumors, depth of invasion, lymph node involvement, distant metastasis, TNM
stage
, lymphatic invasion, vascular invasion, perineural invasion, peritoneal seeding, curability, positive microscopic margin, and adhesion to the surrounding structure.
CONCLUSION: Colorectal mucinous carcinoma had no clinicopathological difference from nonmucinous
adenocarcinoma of colon
and rectum.
[MeSH-major]
Adenocarcinoma
/ pathology.
Adenocarcinoma
, Mucinous / pathology. Colonic Neoplasms / pathology. Rectal Neoplasms / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16583577.001).
[ISSN]
0125-2208
[Journal-full-title]
Journal of the Medical Association of Thailand = Chotmaihet thangphaet
[ISO-abbreviation]
J Med Assoc Thai
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Thailand
34.
Wang C, Zhou Z, Wang Z, Zheng Y, Zhao G, Yu Y, Cheng Z, Chen D, Liu W:
Patterns of neoplastic foci and lymph node micrometastasis within the mesorectum.
Langenbecks Arch Surg
; 2005 Aug;390(4):312-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
No significant difference in occurrence of micrometastasis was observed among tumors of different
stage
.
[MeSH-major]
Adenocarcinoma
/ pathology. Mesentery / pathology. Neoplasm Recurrence, Local / pathology. Rectal Neoplasms / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Surg. 1996 Jun;83(6):781-5
[
8696739.001
]
[Cites]
Br J Surg. 1997 May;84(5):652-6
[
9171754.001
]
[Cites]
Br J Surg. 1995 Aug;82(8):1031-3
[
7648142.001
]
[Cites]
J Clin Oncol. 1999 Sep;17(9):2896-900
[
10561368.001
]
[Cites]
Br J Surg. 1984 Jan;71(1):12-6
[
6689962.001
]
[Cites]
Am J Clin Pathol. 1996 Aug;106(2):209-16
[
8712176.001
]
[Cites]
J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44
[
1912440.001
]
[Cites]
Br J Surg. 1982 Oct;69(10):613-6
[
6751457.001
]
[Cites]
Lancet. 1990 May 5;335(8697):1055-9
[
1691810.001
]
[Cites]
Br J Surg. 2002 Mar;89(3):327-34
[
11872058.001
]
[Cites]
J Am Coll Surg. 1997 Jun;184(6):584-8
[
9179114.001
]
[Cites]
Lancet. 1986 Jun 28;1(8496):1479-82
[
2425199.001
]
[Cites]
Am J Surg Pathol. 2002 Mar;26(3):350-7
[
11859207.001
]
[Cites]
Cancer. 1995 Aug 1;76(3):388-92
[
8625118.001
]
[Cites]
Br J Hosp Med. 1992 Feb 19-Mar 3;47(4):247-8
[
1591538.001
]
[Cites]
Langenbecks Arch Surg. 1999 Apr;384(2):167-75
[
10328170.001
]
[Cites]
Ann Surg. 2002 Apr;235(4):449-57
[
11923599.001
]
[Cites]
Br J Surg. 1989 Nov;76(11):1165-7
[
2688803.001
]
[Cites]
Br J Surg. 1997 Nov;84(11):1546-50
[
9393276.001
]
[Cites]
Dis Colon Rectum. 1998 Aug;41(8):979-83
[
9715152.001
]
[Cites]
Lancet. 1994 Sep 10;344(8924):707-11
[
7915774.001
]
[Cites]
Dis Colon Rectum. 2003 Jun;46(6):779-85
[
12794580.001
]
[Cites]
Lancet. 1986 Nov 1;2(8514):996-9
[
2430152.001
]
(PMID = 16049726.001).
[ISSN]
1435-2443
[Journal-full-title]
Langenbeck's archives of surgery
[ISO-abbreviation]
Langenbecks Arch Surg
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
35.
Tsunoda A, Nakao K, Tsunoda Y, Watanabe M, Matsui N:
Health-related quality of life of colorectal cancer patients receiving oral UFT plus leucovorin compared with those with surgery alone.
Int J Clin Oncol
; 2010 Apr;15(2):153-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Adjuvant chemotherapy of oral uracil/ftorafur (UFT) plus leucovorin (LV) has been accepted as the standard of care in the treatment of patients with
stage
II and III carcinoma of the
colon
.
CONCLUSIONS: HRQOL in colorectal cancer patients with adjuvant chemotherapy with oral UFT plus LV deteriorated during this phase of treatment compared with those with surgery alone, despite the biased
stage of
tumor between the groups.
[MeSH-major]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colectomy. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / surgery. Quality of Life
Genetic Alliance.
consumer health - Colorectal Cancer
.
Genetic Alliance.
consumer health - Oral cancer
.
Genetic Alliance.
consumer health - Oral Health
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 2000 Mar 15;88(6):1294-303
[
10717609.001
]
[Cites]
Cancer. 1998 Jun 1;82(11):2135-44
[
9610692.001
]
[Cites]
J Clin Oncol. 2006 May 1;24(13):2059-64
[
16648506.001
]
[Cites]
Dis Colon Rectum. 2006 Nov;49(11):1663-72
[
17041749.001
]
[Cites]
J Clin Oncol. 2007 Feb 1;25(4):424-30
[
17264338.001
]
[Cites]
Eur J Cancer. 1998 May;34(6):810-5
[
9797690.001
]
[Cites]
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
[
8433390.001
]
[Cites]
J Clin Oncol. 2002 Sep 1;20(17):3605-16
[
12202661.001
]
[Cites]
J Clin Oncol. 1998 Jan;16(1):139-44
[
9440735.001
]
[Cites]
Qual Life Res. 2008 Mar;17(2):317-22
[
18095186.001
]
[Cites]
Br J Cancer. 2007 Apr 23;96(8):1170-7
[
17375049.001
]
[Cites]
Acta Oncol. 2007;46(1):77-82
[
17438708.001
]
[Cites]
J Clin Oncol. 2004 Sep 1;22(17):3466-74
[
15277535.001
]
[Cites]
J Clin Oncol. 2002 Sep 1;20(17):3617-27
[
12202662.001
]
[Cites]
Dis Colon Rectum. 1995 Apr;38(4):361-9
[
7720441.001
]
(PMID = 20191299.001).
[ISSN]
1437-7772
[Journal-full-title]
International journal of clinical oncology
[ISO-abbreviation]
Int. J. Clin. Oncol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin
36.
Nabi U, Nagi AH, Riaz S, Sami W:
Morphological evaluation of colorectal carcinoma with grading staging and histological types.
J Pak Med Assoc
; 2010 Dec;60(12):998-1001
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Haematoxylin and Eosin stained slides were examined to determine the histological type, grade and
stage of
CRC.
RESULTS: Among the 100 cases, 59 were non mucinous adenocarcinomas, of which 4 were in Dukes'
stage
A, 51 were in Dukes'
stage
B and 4 were in Dukes'
stage
C.
In thirty cases of mucinous carcinomas, 18 were in Dukes'
stage
B and 12 were in Dukes'
stage
C, of these 2 were of grade I, 20 were of grade II and 8 were of grade III.
All the 11 signet ring cell carcinomas were of grade III and in Dukes'
stage
C.
CONCLUSION: Mucin secreting and signet-ring cell adenocarcinomas
of colon
and rectum are high grade tumours and presented at an advanced
stage
.
[MeSH-major]
Adenocarcinoma
/ classification.
Adenocarcinoma
/ pathology. Colorectal Neoplasms / classification. Colorectal Neoplasms / pathology. Neoplasm Staging
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21381550.001).
[ISSN]
0030-9982
[Journal-full-title]
JPMA. The Journal of the Pakistan Medical Association
[ISO-abbreviation]
J Pak Med Assoc
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
Pakistan
37.
Veenhof AA, Bloemena E, Engel AF, van der Peet DL, Meijer OW, Cuesta MA:
The relationship of histological tumor regression grade (TRG) and two different time intervals to surgery following radiation therapy for locally advanced rectal cancer.
Int J Colorectal Dis
; 2009 Sep;24(9):1091-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A T3N0 preoperative tumor
stage
was found in 21 (75%) patients in the LI group and in 33 (85%) patients in the SI group (p = 0.36).
All tumors were histologically proven
adenocarcinoma
.
[MeSH-minor]
Adenocarcinoma
. Age Factors. Aged. Digestive System Surgical Procedures. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Time Factors. Treatment Outcome
Genetic Alliance.
consumer health - Rectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Colorectal Dis. 2007 May;22(5):507-13
[
17009009.001
]
[Cites]
Br J Surg. 1982 Oct;69(10):613-6
[
6751457.001
]
[Cites]
Ann Surg. 2007 Nov;246(5):693-701
[
17968156.001
]
[Cites]
Colorectal Dis. 2008 Jul;10(6):563-8
[
18070184.001
]
[Cites]
Br J Surg. 1995 Oct;82(10):1297-9
[
7489148.001
]
[Cites]
J Clin Oncol. 2001 Apr 1;19(7):1976-84
[
11283130.001
]
[Cites]
Cancer. 2002 Feb 15;94(4):1121-30
[
11920483.001
]
[Cites]
Int J Colorectal Dis. 2005 Sep;20(5):440-5
[
15856263.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):752-60
[
15936556.001
]
[Cites]
Hum Pathol. 2003 Jun;34(6):541-8
[
12827607.001
]
[Cites]
Dis Colon Rectum. 2004 Dec;47(12):2025-31
[
15657650.001
]
[Cites]
Colorectal Dis. 2002 May;4(3):177-183
[
12780612.001
]
[Cites]
Cancer Control. 2003 May-Jun;10(3):205-11
[
12794618.001
]
[Cites]
Cancer. 1994 Jun 1;73(11):2680-6
[
8194005.001
]
[Cites]
Ann Surg Oncol. 2008 Dec;15(12):3471-7
[
18846402.001
]
[Cites]
J Clin Oncol. 1999 Aug;17(8):2396
[
10561302.001
]
(PMID = 19415307.001).
[ISSN]
1432-1262
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
38.
Kent AJ, Woolf D, McCue J, Greenfield SM:
The use of symptoms to predict colorectal cancer site. Can we reduce the pressure on our endoscopy services?
Colorectal Dis
; 2010 Feb;12(2):114-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
C-reactive protein, albumin and carcinoembryonic antigen are not predictive of cancer site, Duke's
stage
or influenced by patient age or gender.
[MeSH-major]
Adenocarcinoma
/ pathology. Colonoscopy. Colorectal Neoplasms / pathology. Sigmoidoscopy
[MeSH-minor]
Anemia / diagnosis. Anemia / etiology.
Colon
, Ascending / pathology. Constipation / etiology. Diarrhea / etiology. Humans. Risk Factors
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colonoscopy
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Colorectal Dis. 2010 Aug;12(8):834-5
[
20456465.001
]
(PMID = 19207710.001).
[ISSN]
1463-1318
[Journal-full-title]
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
[ISO-abbreviation]
Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
39.
Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Adachi Y, Imai K, Shinomura Y:
Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer.
World J Gastroenterol
; 2009 Aug 21;15(31):3865-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
LNgamma2 expression was seen in 57% of patients with biliary tract cancer, and was associated with depth of invasion, histologic type, and advanced
stage
.
The invasive front dominant type was associated with histologic type and advanced
stage
.
Active MMP7 detected by casein zymography was correlated with depth of invasion and advanced
stage
.
[MeSH-minor]
Adenocarcinoma
/ genetics.
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ pathology. Aged. Animals. Cell Line, Tumor. Female. Humans. Male. Middle Aged. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cell. 1991 May 17;65(4):599-610
[
2032285.001
]
[Cites]
Pathol Int. 2004 Sep;54(9):688-92
[
15363037.001
]
[Cites]
Am J Pathol. 1994 Oct;145(4):782-91
[
7943170.001
]
[Cites]
FEBS Lett. 1995 Jul 24;368(3):556-8
[
7635220.001
]
[Cites]
Cancer Res. 1995 Sep 15;55(18):4132-9
[
7664291.001
]
[Cites]
Am J Pathol. 1995 Oct;147(4):1123-32
[
7573357.001
]
[Cites]
J Biochem. 1996 Dec;120(6):1196-202
[
9010770.001
]
[Cites]
Gastroenterology. 1997 Apr;112(4):1290-6
[
9098015.001
]
[Cites]
Science. 1997 Jul 11;277(5323):225-8
[
9211848.001
]
[Cites]
J Pathol. 1998 May;185(1):44-52
[
9713359.001
]
[Cites]
Cancer Res. 1999 Jul 15;59(14):3313-6
[
10416584.001
]
[Cites]
Am J Pathol. 1999 Oct;155(4):1033-8
[
10514384.001
]
[Cites]
Carcinogenesis. 2004 Dec;25(12):2353-60
[
15333466.001
]
[Cites]
Gastroenterology. 2005 Nov;129(5):1375-83
[
16285938.001
]
[Cites]
Oncogene. 2005 Nov 24;24(53):7946-52
[
16007117.001
]
[Cites]
Exp Biol Med (Maywood). 2006 Jan;231(1):20-7
[
16380641.001
]
[Cites]
Cancer Res. 2006 Dec 1;66(23):11228-37
[
17145868.001
]
[Cites]
Crit Rev Oncol Hematol. 2007 Jan;61(1):44-51
[
17164111.001
]
[Cites]
J Pathol. 2007 Apr;211(5):516-23
[
17318812.001
]
[Cites]
J Pathol. 2007 May;212(1):102-11
[
17370299.001
]
[Cites]
Cancer Lett. 2007 Aug 28;254(1):42-53
[
17374440.001
]
[Cites]
Curr Probl Surg. 2007 Jul;44(7):396-482
[
17693325.001
]
[Cites]
J Pathol. 2007 Oct;213(2):131-9
[
17724792.001
]
[Cites]
Cancer Res. 1999 Nov 1;59(21):5596-601
[
10554040.001
]
[Cites]
J Cell Biol. 2000 Feb 7;148(3):615-24
[
10662785.001
]
[Cites]
Am J Pathol. 2001 Mar;158(3):1129-35
[
11238061.001
]
[Cites]
Mol Carcinog. 2001 Feb;30(2):119-29
[
11241759.001
]
[Cites]
Clin Cancer Res. 2001 Apr;7(4):896-900
[
11309339.001
]
[Cites]
Int J Cancer. 2001 Sep 20;95(5):290-4
[
11494227.001
]
[Cites]
Cancer Res. 2001 Nov 15;61(22):8089-93
[
11719433.001
]
[Cites]
Semin Cancer Biol. 2002 Jun;12(3):197-207
[
12083850.001
]
[Cites]
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3684-91
[
14506159.001
]
[Cites]
Clin Chem. 2004 Mar;50(3):490-9
[
14726470.001
]
[Cites]
Dis Colon Rectum. 1993 Jul;36(7):627-35
[
8348847.001
]
(PMID = 19701966.001).
[ISSN]
2219-2840
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / Cell Adhesion Molecules; 0 / LAMC2 protein, human; 0 / Laminin; 0 / RNA, Small Interfering; 0 / kalinin; 170834-93-2 / laminin alpha 3; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
[Other-IDs]
NLM/ PMC2731248
40.
Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, Villalon-Gomez JM, Williams MA, Cress RD:
Understanding the burden of human papillomavirus-associated anal cancers in the US.
Cancer
; 2008 Nov 15;113(10 Suppl):2892-900
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The following anal cancer histologies were included in the analysis: squamous cell,
adenocarcinoma
, and small cell/neuroendocrine carcinomas.
The majority of SCC cases were diagnosed at the in situ or localized
stage
(58.1%).
API were more likely to be diagnosed with regional or distant
stage
disease than were other racial/ethnic groups (27.5% and 11.8%, respectively).
A higher proportion of API were diagnosed at regional/distant
stage
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10
[
10995805.001
]
[Cites]
Cancer. 2000 Mar 15;88(6):1464-9
[
10717631.001
]
[Cites]
Clin Infect Dis. 2002 Nov 1;35(9):1127-34
[
12384848.001
]
[Cites]
AIDS. 2003 Feb 14;17(3):311-20
[
12556684.001
]
[Cites]
Prev Med. 2003 May;36(5):555-60
[
12689800.001
]
[Cites]
Dis Colon Rectum. 2003 Nov;46(11):1517-23; discussion 1523-4; author reply 1524
[
14605572.001
]
[Cites]
Cancer Causes Control. 2003 Nov;14(9):837-46
[
14682441.001
]
[Cites]
Lancet Oncol. 2004 Mar;5(3):149-57
[
15003197.001
]
[Cites]
Cancer. 2004 Jul 15;101(2):270-80
[
15241823.001
]
[Cites]
Cancer. 2004 Jul 15;101(2):281-8
[
15241824.001
]
[Cites]
N Engl J Med. 1987 Oct 15;317(16):973-7
[
2821396.001
]
[Cites]
Gastroenterology. 1988 Jul;95(1):107-11
[
2836255.001
]
[Cites]
Am J Epidemiol. 1992 Jan 15;135(2):180-9
[
1311142.001
]
[Cites]
Am J Epidemiol. 1992 Jul 1;136(1):54-8
[
1329500.001
]
[Cites]
Am J Epidemiol. 1994 Apr 15;139(8):772-80
[
8178790.001
]
[Cites]
Am J Epidemiol. 1994 Jul 1;140(1):12-9
[
8017399.001
]
[Cites]
N Engl J Med. 1997 Nov 6;337(19):1350-8
[
9358129.001
]
[Cites]
Semin Cancer Biol. 1998 Aug;8(4):307-13
[
9870037.001
]
[Cites]
Cancer Res. 1999 Feb 1;59(3):753-7
[
9973228.001
]
[Cites]
JAMA. 1999 May 19;281(19):1822-9
[
10340370.001
]
[Cites]
Clin Infect Dis. 2006 Jul 15;43(2):223-33
[
16779751.001
]
[Cites]
MMWR Morb Mortal Wkly Rep. 2006 Oct 27;55(42):1145-8
[
17065979.001
]
[Cites]
Stat Methods Med Res. 2006 Dec;15(6):547-69
[
17260923.001
]
[Cites]
Lancet Oncol. 2007 Apr;8(4):311-6
[
17395104.001
]
[Cites]
Am J Surg Pathol. 2007 Jun;31(6):919-25
[
17527081.001
]
[Cites]
Clin Microbiol Rev. 2007 Jul;20(3):478-88, table of contents
[
17630336.001
]
[Cites]
Sex Transm Infect. 2007 Jul;83(4):257-66
[
17664359.001
]
[Cites]
Cancer Causes Control. 2007 Dec;18(10):1175-86
[
17805982.001
]
[Cites]
Cancer. 2008 Nov 15;113(10 Suppl):2841-54
[
18980203.001
]
[Cites]
Dermatol Ther. 2005 Jan-Feb;18(1):67-76
[
15842614.001
]
[Cites]
Dan Med Bull. 2002 Aug;49(3):194-209
[
12238281.001
]
(PMID = 18980293.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
ENG
[Grant]
None / None / / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCCDPHP CDC HHS / DP / U50 DP424071-04
[Publication-type]
Journal Article; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS104103; NLM/ PMC2729501
41.
Ryu HS, Park YL, Park SJ, Lee JH, Cho SB, Lee WS, Chung IJ, Kim KK, Lee KH, Kweon SS, Joo YE:
KITENIN is associated with tumor progression in human gastric cancer.
Anticancer Res
; 2010 Sep;30(9):3479-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: KAI1 COOH-terminal interacting tetraspanin (KITENIN) promotes tumor cell migration, invasion and metastasis in
colon
, bladder, head and neck cancer.
Expression of KITENIN was significantly associated with tumor size, Lauren classification, depth of invasion, lymph node metastasis, tumor
stage
and poor survival.
[MeSH-major]
Adenocarcinoma
/ pathology. Biomarkers, Tumor / analysis. Carrier Proteins / metabolism. Membrane Proteins / metabolism. Stomach Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20944126.001).
[ISSN]
1791-7530
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / Transcription Factor AP-1; 0 / VANGL1 protein, human
42.
Bellone G, Gramigni C, Vizio B, Mauri FA, Prati A, Solerio D, Dughera L, Ruffini E, Gasparri G, Camandona M:
Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa.
Int J Oncol
; 2010 Nov;37(5):1153-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the
colon
mucosa.
The simultaneous expression of Endoglin (CD105), transforming growth factor (TGF)-β1 and TGF-β receptor (R) II were quantified in surgical specimens comprising normal human
colon
, pre-malignant dysplastic tissue, in situ, and invasive
colon
cancer specimens, at mRNA and protein levels, respectively by real-time PCR and immunohistochemistry.
Serum concentrations of soluble Endoglin and TGF-β1 were evaluated. mRNA and CD105+-microvessel density (MVD) increased significantly in dysplastic
colon
and carcinoma versus normal tissues; values correlated respectively with dysplasia degree and Dukes' stages.
TGF-β1 RII was overexpressed in adenoma and carcinoma versus normal samples, but unrelated with dysplasia or Dukes'
stage
.
These findings suggest active angiogenesis occurs in many pre-malignant
colon
cases and supports more careful evaluation of different chemopreventive agents.
[MeSH-major]
Adenocarcinoma
/ metabolism. Antigens, CD / biosynthesis. Colonic Neoplasms / metabolism. Precancerous Conditions / metabolism. Protein-Serine-Threonine Kinases / biosynthesis. Receptors, Cell Surface / biosynthesis. Receptors, Transforming Growth Factor beta / biosynthesis. Transforming Growth Factor beta1 / biosynthesis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20878063.001).
[ISSN]
1791-2423
[Journal-full-title]
International journal of oncology
[ISO-abbreviation]
Int. J. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antigens, CD; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
43.
Kanellos I, Zacharakis E, Kanellos D, Pramateftakis MG, Tsahalis T, Altsitsiadis E, Betsis D:
Prognostic significance of CEA levels and detection of CEA mRNA in draining venous blood in patients with colorectal cancer.
J Surg Oncol
; 2006 Jul 1;94(1):3-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: From 1995 to 2000, 108 patients with
adenocarcinoma of
the
colon
or rectum, underwent curative surgery and enrolled in this prospective study.
The proportion of patients with portal CEA > or =5 ng/ml was greater in patients with higher
stage
than in patients with lower
stage
.
[MeSH-major]
Adenocarcinoma
/ diagnosis. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Carcinoembryonic Antigen / genetics. Colonic Neoplasms / diagnosis. Rectal Neoplasms / diagnosis
Genetic Alliance.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2006 Wiley-Liss, Inc.
(PMID = 16788936.001).
[ISSN]
0022-4790
[Journal-full-title]
Journal of surgical oncology
[ISO-abbreviation]
J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / RNA, Messenger
44.
Maggard MA, Yermilov I, Tomlinson JS, Ko CY:
Are 12 nodes needed to accurately stage T1 and T2 colon cancers?
Dig Dis Sci
; 2009 Mar;54(3):640-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Are 12 nodes needed to accurately
stage
T1 and T2
colon
cancers?
Evaluation of 12 lymph nodes has been mandated to prevent
colon
cancer understaging.
Given that the probability of node metastases is largely associated with T-
stage
, are <12 nodes substandard for T1 and T2 lesions?
In SEER, 61,237 patients undergoing
colon
cancer resection were identified.
For each T-
stage
, 5-year survival rates were compared for node-negative cancers by using stepwise node cut-point comparisons (4 nodes, <4, etc.).
In conclusion, the number of nodes to
stage
T1 and T2 lesions may be <12.
[MeSH-major]
Adenocarcinoma
/ pathology.
Colon
/ pathology. Colonic Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Neoplasm Staging / standards
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Dig Dis Sci. 2009 Apr;54(4):914-5; author reply 916
[
19003528.001
]
[Cites]
J Clin Oncol. 1999 Sep;17(9):2896-900
[
10561368.001
]
[Cites]
Colorectal Dis. 2008 Mar;10(3):231-8
[
18257848.001
]
[Cites]
Am J Clin Pathol. 1996 Aug;106(2):209-16
[
8712176.001
]
[Cites]
J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44
[
1912440.001
]
[Cites]
Cancer. 1998 Aug 15;83(4):666-72
[
9708929.001
]
[Cites]
J Clin Oncol. 1999 May;17(5):1349-55
[
10334518.001
]
[Cites]
J Surg Oncol. 2002 Oct;81(2):63-9
[
12355405.001
]
[Cites]
J Clin Oncol. 2001 Jan 1;19(1):157-63
[
11134208.001
]
[Cites]
Arch Pathol Lab Med. 2000 Jul;124(7):958-65
[
10888771.001
]
[Cites]
J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90
[
12504228.001
]
[Cites]
J Natl Cancer Inst. 2007 Mar 21;99(6):433-41
[
17374833.001
]
[Cites]
N Engl J Med. 1990 Feb 8;322(6):352-8
[
2300087.001
]
[Cites]
World J Surg. 2002 Mar;26(3):384-9
[
11865379.001
]
[Cites]
Ann Surg Oncol. 2003 Apr;10(3):213-8
[
12679304.001
]
[Cites]
Cancer. 1999 Jan 1;85(1):243-5
[
9922000.001
]
[Cites]
Bull Am Coll Surg. 2002 Jul;87(7):13-5
[
17387902.001
]
[Cites]
J Surg Oncol. 2008 Apr 1;97(5):383-7
[
18163435.001
]
[Cites]
Dis Colon Rectum. 2002 Feb;45(2):200-6
[
11852333.001
]
[Cites]
Cancer. 1998 Apr 15;82(8):1482-6
[
9554524.001
]
[Cites]
Cancer. 2000 Apr 1;88(7):1739-57
[
10738234.001
]
[Cites]
Virchows Arch. 2003 Aug;443(2):133-8
[
12844262.001
]
[Cites]
Arch Surg. 2005 Sep;140(9):881-6; discussion 886-7
[
16172297.001
]
[Cites]
Br J Surg. 1989 Nov;76(11):1165-7
[
2688803.001
]
[Cites]
J Natl Cancer Inst. 2001 Apr 18;93(8):583-96
[
11309435.001
]
[Cites]
Dis Colon Rectum. 1999 Feb;42(2):143-54; discussion 154-8
[
10211489.001
]
[Cites]
Scand J Gastroenterol. 2005 Jul;40(7):858-61
[
16109663.001
]
(PMID = 18612817.001).
[ISSN]
1573-2568
[Journal-full-title]
Digestive diseases and sciences
[ISO-abbreviation]
Dig. Dis. Sci.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
45.
Shotar AM:
P53 and heat shock protein 70 expressions in colorectal adenocarcinoma.
Saudi Med J
; 2005 Oct;26(10):1602-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
P53 and heat shock protein 70 expressions in colorectal
adenocarcinoma
.
OBJECTIVE: To examine the localization and over expression of heat shock protein 70 (HSP70) and p53 in patients with colorectal cancer and compared it with control tissue (including normal
colon
tissue).
METHODS: This was a retrospective study of 60 patients with colorectal
adenocarcinoma
at the Jordan University of Science and Technology (JUST), Irbid, Jordan from 1997 to 2000.
Immuno-histochemistry showed that over expression of HSP70 had no statistically significant difference with any of the different prognostic factors assessed, mainly the grade and the
stage
.
Control tissue (normal
colon
) was negative, p53, cell-cycle-related oncogene product, was strongly over expressed in the nuclei of the cancer cells of the cancer tissue.
We found no significant difference in terms of size, patient age, lymph node state, and
stage
.
[MeSH-major]
Adenocarcinoma
/ pathology. Biomarkers, Tumor / analysis. Colorectal Neoplasms / pathology. HSP70 Heat-Shock Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16228064.001).
[ISSN]
0379-5284
[Journal-full-title]
Saudi medical journal
[ISO-abbreviation]
Saudi Med J
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Saudi Arabia
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / HSP70 Heat-Shock Proteins; 0 / Tumor Suppressor Protein p53
46.
Nishiyama N, Yamamoto S, Matsuoka N, Fujimoto H, Moriya Y:
Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending colon carcinoma and left ureteral carcinoma: report of a case.
Surg Today
; 2009;39(8):728-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Simultaneous laparoscopic descending colectomy and nephroureterectomy for descending
colon
carcinoma and left ureteral carcinoma: report of a case.
To our knowledge, there is no case report of the synchronous resection
of colon
and ureteral carcinomas by laparoscopy, because of the rareness of this combination and the technical difficulties involved.
We report a case of simultaneous descending
colon
and left ureteral carcinomas, both of which were judged to be relatively early
stage
carcinoma, which we resected successfully laparoscopically.
[MeSH-minor]
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ surgery. Aged. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Colonoscopy. Humans. Laparoscopy. Male. Urography
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4
[
17893502.001
]
[Cites]
Surg Today. 2007;37(11):1004-8
[
17952536.001
]
[Cites]
Am J Clin Oncol. 2000 Aug;23(4):364-70
[
10955865.001
]
[Cites]
Lancet. 2004 Apr 10;363(9416):1187-92
[
15081650.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2007 Aug;17 (4):283-6
[
17710049.001
]
[Cites]
J Clin Oncol. 2007 Jul 20;25(21):3061-8
[
17634484.001
]
[Cites]
Dis Colon Rectum. 2006 Oct;49(10 Suppl):S30-6
[
17106813.001
]
[Cites]
J Laparoendosc Adv Surg Tech A. 2004 Jun;14(3):179-81
[
15245672.001
]
[Cites]
Lancet. 2002 Jun 29;359(9325):2224-9
[
12103285.001
]
[Cites]
J Urol. 2005 Apr;173(4):1102-7
[
15758710.001
]
[Cites]
Can J Surg. 2007 Feb;50(1):48-57
[
17391617.001
]
[Cites]
Int J Colorectal Dis. 2006 Jan;21(1):92-3
[
15668786.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2003 Dec;13(6):382-6
[
14712100.001
]
[Cites]
J Laparoendosc Adv Surg Tech A. 2006 Jun;16(3):297-300
[
16796445.001
]
[Cites]
Urology. 2001 Jan;57(1):133-7
[
11164158.001
]
(PMID = 19639445.001).
[ISSN]
1436-2813
[Journal-full-title]
Surgery today
[ISO-abbreviation]
Surg. Today
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
47.
Schiessel R, Novi G, Holzer B, Rosen HR, Renner K, Hölbling N, Feil W, Urban M:
Technique and long-term results of intersphincteric resection for low rectal cancer.
Dis Colon Rectum
; 2005 Oct;48(10):1858-65; discussion 1865-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Cancers were staged according to the Dukes classification (
Stage
A in 41 percent,
Stage
B in 28 percent, and
Stage
C in 31 percent; median distance from the anal margin, 3 (range, 1-5) cm).
[MeSH-major]
Adenocarcinoma
/ surgery. Adenoma, Villous / surgery. Anal Canal / surgery. Carcinoid Tumor / surgery. Colectomy / methods. Rectal Neoplasms / surgery
Genetic Alliance.
consumer health - Rectal Cancer
.
MedlinePlus Health Information.
consumer health - Carcinoid Tumors
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16086223.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
48.
Euanorasetr C, Lertsithichai P:
Prognostic significance of peritoneal washing cytology in Thai patients with gastric adenocarcinoma undergoing curative D2 gastrectomy.
Gastric Cancer
; 2007;10(1):18-23
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic significance of peritoneal washing cytology in Thai patients with gastric
adenocarcinoma
undergoing curative D2 gastrectomy.
BACKGROUND: The aim of the present study was to determine the prognostic significance of peritoneal washing cytology (PWC) among Thai patients with gastric
adenocarcinoma
.
METHODS: Medical charts of 97 patients with gastric
adenocarcinoma
who underwent curative D2 gastrectomy between October 1995 and September 2005 were reviewed.
Factors significantly associated with positive PWC included tumor location, macroscopic findings, histology, depth of tumor invasion, nodal involvement, TNM
stage
, and angiolymphatic invasion.
CONCLUSION: Gastric
adenocarcinoma
with positive PWC should be considered
stage
IV disease.
PWC should be included in the staging of gastric
adenocarcinoma
.
[MeSH-major]
Adenocarcinoma
/ pathology. Peritoneal Neoplasms / pathology. Peritoneum / cytology. Stomach Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Am Coll Surg. 2006 Feb;202(2):231-6
[
16427547.001
]
[Cites]
Gastric Cancer. 2001;4(1):27-33
[
11706624.001
]
[Cites]
Surg Gynecol Obstet. 1961 Apr;112:469-74
[
13772295.001
]
[Cites]
J Surg Oncol. 1998 Oct;69(2):71-5
[
9808508.001
]
[Cites]
World J Gastroenterol. 2005 Dec 14;11(46):7374-7
[
16437646.001
]
[Cites]
J Gastrointest Surg. 2006 Feb;10(2):170-6, discussion 176-7
[
16455447.001
]
[Cites]
Surg Today. 1999;29(2):111-5
[
10030734.001
]
[Cites]
Am J Surg. 1999 Sep;178(3):256-62
[
10527450.001
]
[Cites]
J Am Coll Surg. 1997 Jun;184(6):611-7
[
9179118.001
]
[Cites]
Ann Surg Oncol. 2005 May;12(5):347-53
[
15915368.001
]
[Cites]
Hepatogastroenterology. 2001 Nov-Dec;48(42):1776-82
[
11813623.001
]
[Cites]
Surg Today. 2005;35(11):919-24
[
16249844.001
]
[Cites]
Dis Colon Rectum. 2000 Jan;43(1):92-100
[
10813130.001
]
[Cites]
Cancer. 1991 Jul 1;68(1):44-7
[
2049751.001
]
[Cites]
Gastric Cancer. 1999 May;2(1):1-7
[
11957063.001
]
[Cites]
Br J Surg. 1990 Apr;77(4):436-9
[
2340396.001
]
[Cites]
Surg Oncol. 1992 Oct;1(5):341-6
[
1341269.001
]
[Cites]
Ann Surg. 1998 Mar;227(3):372-9
[
9527060.001
]
[Cites]
Acta Cytol. 1978 Jul-Aug;22(4):225-9
[
281825.001
]
[Cites]
Semin Surg Oncol. 1999 Sep;17(2):103-7
[
10449681.001
]
[Cites]
Gastric Cancer. 1998 Dec;1(1):10-24
[
11957040.001
]
[Cites]
Br J Cancer. 1999 Feb;79(3-4):520-4
[
10027323.001
]
[Cites]
World J Surg. 2005 Sep;29(9):1131-4
[
16086213.001
]
[Cites]
Cancer. 1979 Oct;44(4):1476-80
[
498022.001
]
[Cites]
Gastric Cancer. 2005;8(4):228-37
[
16328597.001
]
[Cites]
Lancet. 1992 Mar 14;339(8794):629-31
[
1347336.001
]
[Cites]
Ann Surg Oncol. 2005 May;12(5):339-41
[
15843872.001
]
[Cites]
J Surg Oncol. 1999 Oct;72(2):60-4; discussion 64-5
[
10518099.001
]
[Cites]
Int J Oncol. 2003 Nov;23(5):1419-23
[
14532985.001
]
[Cites]
J Surg Oncol. 1995 Aug;59(4):226-9
[
7630168.001
]
[Cites]
Br J Surg. 1996 May;83(5):672-4
[
8689216.001
]
[Cites]
Ann Surg Oncol. 1998 Jul-Aug;5(5):411-5
[
9718170.001
]
[Cites]
World J Surg. 1995 Jan-Feb;19(1):133-7; discussion 137
[
7740800.001
]
[Cites]
World J Surg. 1995 May-Jun;19(3):450-4; discussion 455
[
7639005.001
]
[Cites]
Acta Cytol. 1990 May-Jun;34(3):437-42
[
2160771.001
]
[Cites]
Int J Cancer. 1998 Aug 21;79(4):429-33
[
9699538.001
]
(PMID = 17334713.001).
[ISSN]
1436-3291
[Journal-full-title]
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
[ISO-abbreviation]
Gastric Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
49.
Hashino S, Kobayashi S, Takahata M, Onozawa M, Nakagawa M, Kawamura T, Fujisawa F, Izumiyama K, Kahata K, Kondo T, Asaka M:
Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer.
Int J Clin Oncol
; 2008 Apr;13(2):176-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced
colon
cancer.
A 27-year-old man with advanced
colon
cancer that was resistant to conventional chemoradiotherapies was treated with reduced-intensity allogeneic peripheral blood stem cell transplantation (PBSCT).
The antitumor effect observed in this patient was insufficient for the patient to achieve complete remission, because the disease was at an already widespread and treatment-resistant
stage
.
He finally died of hepatic failure due to extensive liver GVHD 65 months after the diagnosis of the advanced
colon
cancer and 29 months after the allogeneic PBSCT.
Prospective studies are necessary to achieve better clinical results in patients with advanced
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ therapy. Colonic Neoplasms / therapy. Graft vs Host Disease / etiology. Hematopoietic Stem Cell Transplantation
Genetic Alliance.
consumer health - Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 1997 Feb;15(2):863-4
[
9053517.001
]
[Cites]
Bone Marrow Transplant. 2004 Jan;33(2):255-6; author reply 257-8
[
14676774.001
]
[Cites]
J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16
[
10655437.001
]
[Cites]
Transplantation. 2004 Dec 27;78(12):1740-6
[
15614146.001
]
[Cites]
Blood. 1995 Sep 1;86(5):2041-50
[
7655033.001
]
[Cites]
Blood. 1999 Aug 15;94(4):1201-8
[
10438707.001
]
[Cites]
N Engl J Med. 2004 Jun 3;350(23 ):2335-42
[
15175435.001
]
[Cites]
Bone Marrow Transplant. 2003 Feb;31(4):253-61
[
12621459.001
]
[Cites]
Lancet Oncol. 2001 May;2(5):290-7
[
11905784.001
]
[Cites]
Blood. 2002 Jun 1;99(11):4234-6
[
12010834.001
]
[Cites]
Blood. 1990 Feb 1;75(3):555-62
[
2297567.001
]
[Cites]
Blood. 2006 May 1;107(9):3795-803
[
16403911.001
]
[Cites]
N Engl J Med. 2000 Sep 14;343(11):750-8
[
10984562.001
]
[Cites]
N Engl J Med. 2004 Jul 22;351(4):337-45
[
15269313.001
]
[Cites]
N Engl J Med. 2000 Sep 28;343 (13):905-14
[
11006366.001
]
[Cites]
Blood. 1998 Dec 1;92(11):4072-9
[
9834212.001
]
[Cites]
Bone Marrow Transplant. 2001 Dec;28(12):1161-6
[
11803361.001
]
[Cites]
J Clin Oncol. 2004 Apr 1;22(7):1201-8
[
14993230.001
]
(PMID = 18463966.001).
[ISSN]
1341-9625
[Journal-full-title]
International journal of clinical oncology
[ISO-abbreviation]
Int. J. Clin. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
50.
Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N:
Is there a difference in survival between right- versus left-sided colon cancers?
Ann Surg Oncol
; 2008 Sep;15(9):2388-94
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Is there a difference in survival between right- versus left-sided
colon
cancers?
BACKGROUND: The incidence of right-sided
colon
cancers has been increasing in recent years.
In this study, we have compared the survival of right-and left-sided
colon
cancers in a longitudinal population-based database.
METHODS: A retrospective survival analysis was performed using the Surveillance, Epidemiology, and End Results Program (SEER) database between 1988 and 2003 on subjects who underwent surgical resection for the a primary diagnosis of pathologically confirmed invasive
colon adenocarcinoma
.
Cox proportional hazard regression analysis was used to assess long-term survival outcomes comparing right-sided (cecum to transverse
colon
, excluding appendix) versus left-sided (splenic flexure to sigmoid, excluding rectum)
colon
cancers.
RESULTS: A total of 77,978 subjects were identified with
adenocarcinoma of
the
colon
.
By Cox proportional hazard regression analysis, controlling for statistically significant confounders, including age, sex, race, marital status, tumor
stage
, tumor size, histologic grade, number of lymph nodes examined, and year of diagnosis, right-sided
colon
cancers were associated with a 5% increased mortality risk compared with left-sided
colon
cancers (hazard ratio, 1.04; 95% confidence interval, 1.02-1.07).
CONCLUSION: On the basis of analysis of information from the SEER database, we found that right-sided
colon
cancers have a worse prognosis than left-sided
colon
cancers.
The reason for this remains unclear but may be due to biological and/or environmental factors and may have particular bearing, given the rising incidence of right-sided
colon
cancers.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Dig Dis. 1997 Jul-Oct;15(4-5):302-11
[
9359018.001
]
[Cites]
Cancer. 1995 Dec 1;76(11):2343-50
[
8635041.001
]
[Cites]
Cancer. 1993 Jul 1;72(1):46-50
[
8508429.001
]
[Cites]
Dis Colon Rectum. 1991 Jan;34(1):56-9
[
1991421.001
]
[Cites]
Langenbecks Arch Chir. 1987;371(3):193-200
[
2446097.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):755-62
[
12917207.001
]
[Cites]
Int J Cancer. 2002 Oct 10;101(5):403-8
[
12216066.001
]
[Cites]
J Clin Oncol. 2005 Jan 20;23(3):609-18
[
15659508.001
]
[Cites]
Gut. 2005 Mar;54(3):374-84
[
15710986.001
]
[Cites]
Br J Surg. 1998 Feb;85(2):246-8
[
9501827.001
]
[Cites]
Clin Cancer Res. 2007 Jul 1;13(13):3831-9
[
17606714.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
J Surg Oncol. 2004 Dec 15;88(4):261-6
[
15565587.001
]
(PMID = 18622647.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
ENG
[Grant]
United States / NIDDK NIH HHS / DK / DK007713-13; United States / NIDDK NIH HHS / DK / T32 DK007713; United States / NIDDK NIH HHS / DK / T32 DK007713-13; United States / NIDDK NIH HHS / DK / T32DK007713
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS280426; NLM/ PMC3072702
51.
Chin CC, Yeh CY, Huang WS, Wang JY:
Clinical outcome of intersphincteric resection for ultra-low rectal cancer.
World J Gastroenterol
; 2006 Jan 28;12(4):640-3
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: From 1995 to 1998, patients with a non-fixed rectal
adenocarcinoma
(tumor
stage
T2) preserving the lower margin at 1-3 cm above the dentate line without distant metastasis was enrolled (period I).
CONCLUSION: As to ultra-low rectal cancer, intersphincteric resection could provide acceptable local control and cancer-related survival with no permanent stoma in early-staged tumor (tumor
stage
T2); moreover, preoperative concurrent chemoradiotherapy would make ISR feasible with surgical curative intent in more advanced tumors (tumor stages T3-4).
Genetic Alliance.
consumer health - Rectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Dis Colon Rectum. 2000 Jun;43(6):843-50
[
10859087.001
]
[Cites]
Ann Surg. 2005 Mar;241(3):465-9
[
15729069.001
]
[Cites]
Ann Surg. 2001 Nov;234(5):633-40
[
11685026.001
]
[Cites]
Chir Ital. 2001 Nov-Dec;53(6):765-72
[
11824051.001
]
[Cites]
Br J Surg. 2002 Sep;89(9):1108-17
[
12190675.001
]
[Cites]
Colorectal Dis. 2003 Jan;5(1):33-7
[
12780924.001
]
[Cites]
Tumori. 2003 Mar-Apr;89(2):152-6
[
12841662.001
]
[Cites]
Colorectal Dis. 2003 Sep;5(5):454-7
[
12925080.001
]
[Cites]
Dis Colon Rectum. 2004 Apr;47(4):459-66
[
14978613.001
]
[Cites]
Dis Colon Rectum. 2004 Jun;47(6):832-8
[
15108027.001
]
[Cites]
J Clin Oncol. 2004 Jun 15;22(12):2404-9
[
15197202.001
]
[Cites]
Int Surg. 1983 Jan-Mar;68(1):7-11
[
6853088.001
]
[Cites]
Br J Surg. 1986 Feb;73(2):136-8
[
3947904.001
]
[Cites]
Br J Surg. 1986 Feb;73(2):139-41
[
3947905.001
]
[Cites]
Br J Surg. 1994 Sep;81(9):1376-8
[
7953423.001
]
[Cites]
Dis Colon Rectum. 1996 Sep;39(9):986-91
[
8797646.001
]
[Cites]
Dis Colon Rectum. 1998 Jun;41(6):740-6
[
9645742.001
]
[Cites]
Dis Colon Rectum. 1999 Sep;42(9):1168-75
[
10496557.001
]
[Cites]
Br J Surg. 2004 Nov;91(11):1506-12
[
15455363.001
]
[Cites]
Hepatogastroenterology. 2004 Nov-Dec;51(60):1703-7
[
15532809.001
]
[Cites]
World J Gastroenterol. 2005 Jan 21;11(3):319-22
[
15637735.001
]
[Cites]
Ann Chir. 2000 Sep;125(7):618-24
[
11051690.001
]
(PMID = 16489683.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China
[Other-IDs]
NLM/ PMC4066102
52.
Anderin C, Martling A, Hellborg H, Holm T:
A population-based study on outcome in relation to the type of resection in low rectal cancer.
Dis Colon Rectum
; 2010 May;53(5):753-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In multivariate analysis, local pelvic control was significantly associated with neoadjuvant radiotherapy and complete tumor resection, and survival was significantly associated with neoadjuvant radiotherapy, lower tumor
stage
, female gender, younger age, and complete tumor resection.
[MeSH-major]
Adenocarcinoma
/ surgery. Colorectal Surgery / methods. Outcome and Process Assessment (Health Care). Rectal Neoplasms / surgery
Genetic Alliance.
consumer health - Rectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20389209.001).
[ISSN]
1530-0358
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
53.
Lang K, Lines LM, Lee DW, Korn JR, Earle CC, Menzin J:
Trends in healthcare utilization among older Americans with colorectal cancer: a retrospective database analysis.
BMC Health Serv Res
; 2009;9:227
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Cohorts included patients aged 66+ newly diagnosed with
adenocarcinoma of
the
colon
(n = 52,371) or rectum (n = 18,619) between 1992 and 2002 and matched patients from the general Medicare population, followed until death or December 31, 2005.
Resource use, including the percentage that used each type of resource, number of hospitalizations, and number of hospital and skilled nursing facility days, was evaluated by
stage
and subsite.
Hospice use rates in the last year of life were calculated by year of service,
stage
, and subsite for CRC patients who died of CRC.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Public Health. 2000 May;90(5):695-8
[
10800415.001
]
[Cites]
Clin Gastroenterol Hepatol. 2009 Feb;7(2):198-204
[
18849013.001
]
[Cites]
Med Care. 2002 Aug;40(8 Suppl):IV-104-17
[
12187175.001
]
[Cites]
J Clin Oncol. 2003 Feb 15;21(4):728-35
[
12586813.001
]
[Cites]
JAMA. 2003 May 7;289(17):2238-45
[
12734135.001
]
[Cites]
Am J Med. 2003 Jul;115(1):47-53
[
12867234.001
]
[Cites]
J Palliat Med. 2003 Oct;6(5):757-68
[
14622455.001
]
[Cites]
J Clin Oncol. 2004 Jan 15;22(2):315-21
[
14722041.001
]
[Cites]
Med Care. 2004 Feb;42(2):116-22
[
14734948.001
]
[Cites]
Health Serv Res. 2004 Aug;39(4 Pt 1):969-83
[
15230937.001
]
[Cites]
J Clin Epidemiol. 1992 Jun;45(6):613-9
[
1607900.001
]
[Cites]
Med Care. 1993 Aug;31(8):732-48
[
8336512.001
]
[Cites]
Palliat Med. 2005 Mar;19(2):160-2
[
15810757.001
]
[Cites]
J Clin Epidemiol. 2005 Apr;58(4):323-37
[
15862718.001
]
[Cites]
J Pain Symptom Manage. 2007 Mar;33(3):238-46
[
17349493.001
]
[Cites]
J Womens Health (Larchmt). 2007 Mar;16(2):214-27
[
17388738.001
]
[Cites]
Int J Cancer. 2007 Aug 15;121(4):871-7
[
17417782.001
]
[Cites]
Soc Sci Med. 2007 Oct;65(7):1466-78
[
17600605.001
]
[Cites]
Health Econ. 2008 Aug;17(8):947-59
[
17910108.001
]
[Cites]
Med Care. 2002 Aug;40(8 Suppl):IV-3-18
[
12187163.001
]
(PMID = 20003294.001).
[ISSN]
1472-6963
[Journal-full-title]
BMC health services research
[ISO-abbreviation]
BMC Health Serv Res
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Other-IDs]
NLM/ PMC2797788
54.
Kim SS, Ahn CH, Kang MR, Kim YR, Kim HS, Yoo NJ, Lee SH:
Expression of CARD6, an NF-kappaB activator, in gastric, colorectal and oesophageal cancers.
Pathology
; 2010 Jan;42(1):50-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
By contrast, corresponding normal epithelial cells of oesophagus (0%), stomach (8.0%) and
colon
(5.0%) displayed lower frequencies of CARD6 immunostaining.
The CARD6 expression was evident from an early TNM
stage
(
stage I
).
[MeSH-minor]
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Count. Female. Fluorescent Antibody Technique, Direct. Humans. Male. Middle Aged. Signal Transduction. Tissue Array Analysis
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20025480.001).
[ISSN]
1465-3931
[Journal-full-title]
Pathology
[ISO-abbreviation]
Pathology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CARD Signaling Adaptor Proteins; 0 / CARD6 protein, human; 0 / NF-kappa B
55.
Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J:
SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
J Biol Chem
; 2009 Jul 3;284(27):18210-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
SirT1 is an inhibitor of proliferation and tumor formation in
colon
cancer.
Immunohistochemical staining revealed high level SirT1 in normal
colon
mucosa and benign adenomas.
SirT1 overexpression was observed in approximately 25%
of stage
I/II/III colorectal adenocarcinomas but rarely found in advanced
stage
IV tumors.
These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment
of colon
cancer.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 2000 Feb 17;403(6771):795-800
[
10693811.001
]
[Cites]
Science. 2000 Sep 22;289(5487):2126-8
[
11000115.001
]
[Cites]
Nature. 2001 Mar 8;410(6825):227-30
[
11242085.001
]
[Cites]
Cell. 2001 Oct 19;107(2):137-48
[
11672522.001
]
[Cites]
Cell. 2001 Oct 19;107(2):149-59
[
11672523.001
]
[Cites]
Nature. 2003 Sep 11;425(6954):191-6
[
12939617.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9
[
12960381.001
]
[Cites]
Cell. 2004 Feb 20;116(4):551-63
[
14980222.001
]
[Cites]
EMBO J. 2004 Jun 16;23(12):2369-80
[
15152190.001
]
[Cites]
Science. 2004 Jul 16;305(5682):390-2
[
15205477.001
]
[Cites]
Science. 1990 Jan 19;247(4940):322-4
[
2296722.001
]
[Cites]
Cancer Res. 1994 Nov 15;54(22):5947-52
[
7954427.001
]
[Cites]
Nature. 2005 Mar 3;434(7029):113-8
[
15744310.001
]
[Cites]
Cell Metab. 2005 Jul;2(1):67-76
[
16054100.001
]
[Cites]
Cell Metab. 2005 Aug;2(2):105-17
[
16098828.001
]
[Cites]
Cell. 2005 Nov 4;123(3):437-48
[
16269335.001
]
[Cites]
Cancer Res. 2005 Nov 15;65(22):10457-63
[
16288037.001
]
[Cites]
Mol Cell Biol. 2006 Jan;26(1):28-38
[
16354677.001
]
[Cites]
Oncogene. 2006 Jan 12;25(2):176-85
[
16170353.001
]
[Cites]
PLoS Biol. 2006 Feb;4(2):e31
[
16366736.001
]
[Cites]
Cancer Res. 2006 Apr 15;66(8):4368-77
[
16618762.001
]
[Cites]
Nat Cell Biol. 2006 Sep;8(9):1025-31
[
16892051.001
]
[Cites]
Mol Cell Biol. 2006 Nov;26(21):8122-35
[
16923962.001
]
[Cites]
Nature. 2006 Nov 16;444(7117):337-42
[
17086191.001
]
[Cites]
Cell. 2006 Dec 15;127(6):1109-22
[
17112576.001
]
[Cites]
Mol Cell. 2007 Feb 23;25(4):543-57
[
17317627.001
]
[Cites]
Arch Dermatol Res. 2007 May;299(2):103-6
[
17180656.001
]
[Cites]
Mol Cell. 2007 Jul 6;27(1):149-62
[
17612497.001
]
[Cites]
Cancer Res. 2007 Jul 15;67(14):6612-8
[
17638871.001
]
[Cites]
Oncogene. 2007 Aug 13;26(37):5489-504
[
17694089.001
]
[Cites]
Biochem J. 2007 Nov 1;407(3):451-60
[
17620057.001
]
[Cites]
Biotechnol J. 2007 Nov;2(11):1360-8
[
17806102.001
]
[Cites]
Nature. 2007 Nov 29;450(7170):712-6
[
18046409.001
]
[Cites]
Mol Biol Cell. 2008 Mar;19(3):1210-9
[
18184747.001
]
[Cites]
PLoS One. 2008;3(4):e2020
[
18414679.001
]
[Cites]
Cancer Cell. 2008 Oct 7;14(4):312-23
[
18835033.001
]
(PMID = 19433578.001).
[ISSN]
1083-351X
[Journal-full-title]
The Journal of biological chemistry
[ISO-abbreviation]
J. Biol. Chem.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
[Other-IDs]
NLM/ PMC2709385
56.
Mammen JM, James LE, Molloy M, Williams A, Wray CJ, Sussman JJ:
The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry.
Am J Surg
; 2007 Sep;194(3):349-54
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The relationship of lymph node dissection and
colon
cancer survival in the Veterans Affairs Central Cancer Registry.
BACKGROUND: The extent of lymphadenectomy in
colon
cancer may impact potential to cure and accuracy of staging.
METHODS: The Veterans Affairs Central Cancer Registry database was queried for TNM
stage I
-III
colon adenocarcinoma
patients and yielded 5,823 individuals.
RESULTS: The overall survival (OS) in
stage
II patients was greater with the higher number of lymph node (LN) examined.
For
stage
II patients, the 5-year OS was 34%, 43%, 47%, and 55% for the lowest to highest quartiles (P = .007).
For
stage
III patients, the 5-year OS was 31%, 27%, 38%, and 53% for the lowest to highest quartiles (not significant overall).
CONCLUSIONS: More extensive lymphadenectomy is associated with improved OS in
stage
II
colon
cancer patients.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ surgery. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Lymph Node Excision
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17693281.001).
[ISSN]
1879-1883
[Journal-full-title]
American journal of surgery
[ISO-abbreviation]
Am. J. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
57.
Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, Gui SY, Wu Q, Wang Y:
Correlation between expression and differentiation of endocan in colorectal cancer.
World J Gastroenterol
; 2008 Jul 28;14(28):4562-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: The expression of endocan was higher in normal
colon
and rectum tissue samples than in cancerous tissue samples (mRNA = 92.6%, protein = 36%), and was lower in colorectal cancer tissue samples (mRNA = 70.4%, protein = 36.1%).
No correlation was found between staining intensity and clinical parameters such as sex, age, tumor size and TNM
stage
.
[MeSH-major]
Adenocarcinoma
/ metabolism. Colorectal Neoplasms / metabolism. Neoplasm Proteins / metabolism. Proteoglycans / metabolism
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology.
Colon
/ metabolism.
Colon
/ pathology. Down-Regulation. Female. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Middle Aged. RNA, Messenger / metabolism. Rectum / metabolism. Rectum / pathology. Young Adult
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2000 Nov 1;96(9):3139-46
[
11049995.001
]
[Cites]
Dis Aquat Organ. 2007 May 9;75(3):183-90
[
17629112.001
]
[Cites]
Eur J Biochem. 2001 Aug;268(16):4423-9
[
11502202.001
]
[Cites]
Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66
[
11602373.001
]
[Cites]
Br J Cancer. 2001 Nov 30;85(11):1713-21
[
11742493.001
]
[Cites]
J Biol Chem. 2001 Dec 21;276(51):48341-9
[
11590178.001
]
[Cites]
Nature. 2002 Jan 31;415(6871):530-6
[
11823860.001
]
[Cites]
Microvasc Res. 2002 Mar;63(2):159-71
[
11866539.001
]
[Cites]
Semin Cancer Biol. 2002 Jun;12(3):173-86
[
12083848.001
]
[Cites]
Oncogene. 2002 Jul 18;21(31):4765-77
[
12101415.001
]
[Cites]
Cancer Res. 2004 Feb 1;64(3):844-56
[
14871811.001
]
[Cites]
Lancet Oncol. 2004 May;5(5):292-302
[
15120666.001
]
[Cites]
BMC Cancer. 2003 Nov 27;3:31
[
14641932.001
]
[Cites]
Am J Respir Crit Care Med. 2004 Jul 15;170(2):167-74
[
15087295.001
]
[Cites]
Cancer. 1974 May;33(5):1480-4
[
4823490.001
]
[Cites]
J Biol Chem. 1996 Aug 23;271(34):20458-64
[
8702785.001
]
[Cites]
Cancer. 1997 Nov 1;80(9):1803-4
[
9351551.001
]
[Cites]
J Histochem Cytochem. 1998 Mar;46(3):397-403
[
9487122.001
]
[Cites]
J Biol Chem. 1998 Oct 23;273(43):28116-21
[
9774430.001
]
[Cites]
Matrix Biol. 2004 Oct;23(6):341-52
[
15533755.001
]
[Cites]
Nature. 2004 Nov 18;432(7015):332-7
[
15549095.001
]
[Cites]
Oncogene. 2005 Feb 3;24(6):1104-10
[
15690056.001
]
[Cites]
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
[
15761078.001
]
[Cites]
Biochim Biophys Acta. 2006 Jan;1765(1):25-37
[
16168566.001
]
[Cites]
Crit Care Med. 2006 Feb;34(2):532-7
[
16424738.001
]
[Cites]
Proteomics. 2006 Feb;6(3):767-74
[
16400680.001
]
[Cites]
Microvasc Res. 2006 Nov;72(3):136-45
[
16956626.001
]
[Cites]
J Clin Invest. 2001 Aug;108(3):349-55
[
11489925.001
]
(PMID = 18680240.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / ESM1 protein, human; 0 / Neoplasm Proteins; 0 / Proteoglycans; 0 / RNA, Messenger
[Other-IDs]
NLM/ PMC2731287
58.
Mielko J, Polkowski WP, Skomra DG, Stanisławek AJ, Kurylcio AM, Korobowicz EM:
Prognostic value of p27 kip1 expression in adenocarcinoma of the pancreatic head region.
HPB (Oxford)
; 2006;8(3):216-22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic value of p27 kip1 expression in
adenocarcinoma of
the pancreatic head region.
BACKGROUND: p27(kip1) is a tumour suppressor gene, functioning as a cyclin-dependent kinase inhibitor, and an independent prognostic factor in breast,
colon
, and prostate adenocarcinomas.
Conflicting data are reported for
adenocarcinoma of
the pancreas.
The aim of this study was to establish the prognostic value of p27(kip1) expression in
adenocarcinoma of
the pancreatic head region.
There were no significant correlations between p27(kip1) index and
stage
or lymph node involvement.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Surg. 2004 May;91(5):586-94
[
15122610.001
]
[Cites]
Pancreas. 2004 Apr;28(3):231-4
[
15084962.001
]
[Cites]
Ann Surg Oncol. 2004 Nov;11(11):955-61
[
15525823.001
]
[Cites]
Br J Surg. 1995 Jan;82(1):111-5
[
7881926.001
]
[Cites]
Mol Cell. 1998 Mar;1(4):553-63
[
9660939.001
]
[Cites]
Ann Surg. 1996 Feb;223(2):147-53
[
8597508.001
]
[Cites]
Anticancer Res. 1995 Sep-Oct;15(5B):2181-6
[
8572621.001
]
[Cites]
Pancreas. 1999 Jan;18(1):104-10
[
9888666.001
]
[Cites]
Cancer. 1996 Feb 1;77(3):459-66
[
8630952.001
]
[Cites]
Anticancer Res. 1995 Nov-Dec;15(6B):2659-68
[
8669843.001
]
[Cites]
Nat Med. 1996 Nov;2(11):1204-10
[
8898746.001
]
[Cites]
Int J Pancreatol. 1996 Dec;20(3):155-61
[
9013275.001
]
[Cites]
J Immunother. 1997 Jan;20(1):70-8
[
9101416.001
]
[Cites]
Hepatogastroenterology. 1997 Sep-Oct;44(17):1463-8
[
9356873.001
]
[Cites]
Cancer Res. 1997 Dec 15;57(24):5441-5
[
9407946.001
]
[Cites]
Ann Surg. 1998 Jun;227(6):821-31
[
9637545.001
]
[Cites]
Am J Pathol. 1999 Feb;154(2):313-23
[
10027389.001
]
[Cites]
Cancer. 1999 Mar 15;85(6):1250-60
[
10189129.001
]
[Cites]
Eur J Surg. 1999 Apr;165(4):292-306
[
10365829.001
]
[Cites]
Br J Cancer. 1999 Aug;80(11):1830-7
[
10468306.001
]
[Cites]
Gastroenterology. 1999 Dec;117(6):1464-84
[
10579989.001
]
[Cites]
Am Surg. 1999 Dec;65(12):1143-9
[
10597062.001
]
[Cites]
Oncology. 2000;58(1):45-51
[
10644940.001
]
[Cites]
J Cell Physiol. 2000 Apr;183(1):10-7
[
10699961.001
]
[Cites]
J Pathol. 2000 Jun;191(2):154-61
[
10861575.001
]
[Cites]
J Surg Oncol. 2000 May;74(1):36-40
[
10861607.001
]
[Cites]
Clin Cancer Res. 2000 Jul;6(7):2726-34
[
10914717.001
]
[Cites]
Pancreas. 2000 Oct;21(3):226-30
[
11039465.001
]
[Cites]
Int J Cancer. 2000 Nov 20;89(6):469-74
[
11102889.001
]
[Cites]
Int J Oncol. 2001 Oct;19(4):709-15
[
11562745.001
]
[Cites]
Lancet. 2001 Nov 10;358(9293):1576-85
[
11716884.001
]
[Cites]
J Hepatobiliary Pancreat Surg. 2002;9(1):1-11
[
12021893.001
]
[Cites]
Clin Cancer Res. 2002 Jun;8(6):1808-15
[
12060621.001
]
[Cites]
Cancer. 2003 Apr 1;97(7):1591-600
[
12655514.001
]
[Cites]
Hum Pathol. 2003 Apr;34(4):385-90
[
12733121.001
]
[Cites]
Hepatobiliary Pancreat Dis Int. 2003 Feb;2(1):142-6
[
14607668.001
]
[Cites]
Am J Clin Pathol. 2003 Nov;120(5):685-90
[
14608893.001
]
[Cites]
Oncology. 2003;65(4):371-7
[
14707458.001
]
[Cites]
Oncol Rep. 2004 Feb;11(2):277-84
[
14719054.001
]
[Cites]
Korean J Intern Med. 2004 Mar;19(1):10-4
[
15053037.001
]
[Cites]
Pathol Int. 2004 Sep;54(9):675-81
[
15363035.001
]
(PMID = 18333280.001).
[ISSN]
1365-182X
[Journal-full-title]
HPB : the official journal of the International Hepato Pancreato Biliary Association
[ISO-abbreviation]
HPB (Oxford)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2131676
59.
Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS, Ogino S:
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Mod Pathol
; 2009 Jul;22(7):922-32
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
SIRT1 was not significantly related with age, sex, tumor location,
stage
, signet ring cells, cyclooxygenase-2 (COX-2), LINE-1 hypomethylation, KRAS, BRAF, BMI, PIK3CA, HDAC, p53, beta-catenin, COX-2, or patient prognosis.
In conclusion, SIRT1 expression is associated with CIMP-high MSI-high
colon
cancer, suggesting involvement of SIRT1 in gene silencing in this unique tumor subtype.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
PLoS One. 2008;3(4):e2020
[
18414679.001
]
[Cites]
Int J Cancer. 2008 Jun 15;122(12):2767-73
[
18366060.001
]
[Cites]
Neoplasia. 2008 Jun;10(6):534-41
[
18516290.001
]
[Cites]
Cancer Lett. 2008 Sep 18;268(2):177-86
[
18471961.001
]
[Cites]
PLoS One. 2008;3(11):e3698
[
19002263.001
]
[Cites]
Mod Pathol. 2008 Dec;21(12):1533-41
[
18849918.001
]
[Cites]
J Natl Cancer Inst. 2008 Dec 3;100(23):1734-8
[
19033568.001
]
[Cites]
J Clin Oncol. 2008 Dec 10;26(35):5713-20
[
18955444.001
]
[Cites]
Mod Pathol. 2008 Nov;21(11):1403-12
[
18587323.001
]
[Cites]
Gut. 2009 Jan;58(1):90-6
[
18832519.001
]
[Cites]
Mod Pathol. 2009 Jan;22(1):151-60
[
19011600.001
]
[Cites]
Science. 2004 Jul 16;305(5682):390-2
[
15205477.001
]
[Cites]
Stat Med. 1989 May;8(5):551-61
[
2657958.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6
[
10411935.001
]
[Cites]
Science. 2004 Dec 17;306(5704):2105-8
[
15604409.001
]
[Cites]
Cell. 2005 Feb 25;120(4):473-82
[
15734680.001
]
[Cites]
Nat Rev Cancer. 2005 May;5(5):388-96
[
15864280.001
]
[Cites]
J Mol Diagn. 2005 Aug;7(3):413-21
[
16049314.001
]
[Cites]
Gastroenterology. 2005 Sep;129(3):837-45
[
16143123.001
]
[Cites]
Gastroenterology. 2005 Sep;129(3):1121-4
[
16143149.001
]
[Cites]
Cell. 2005 Nov 4;123(3):437-48
[
16269335.001
]
[Cites]
Mod Pathol. 2006 Jan;19(1):59-68
[
16118624.001
]
[Cites]
PLoS Genet. 2006 Mar;2(3):e40
[
16596166.001
]
[Cites]
Nat Genet. 2006 May;38(5):566-9
[
16642021.001
]
[Cites]
J Mol Diagn. 2006 May;8(2):209-17
[
16645207.001
]
[Cites]
PLoS Genet. 2005 Dec;1(6):e77
[
16362078.001
]
[Cites]
Gut. 2006 Jul;55(7):1000-6
[
16407376.001
]
[Cites]
Nat Genet. 2006 Jul;38(7):787-93
[
16804544.001
]
[Cites]
J Mol Diagn. 2006 Nov;8(5):582-8
[
17065427.001
]
[Cites]
Mod Pathol. 2007 Jan;20(1):15-22
[
17086168.001
]
[Cites]
Mod Pathol. 2007 Mar;20(3):375-83
[
17277760.001
]
[Cites]
Nucleic Acids Res. 2000 Apr 15;28(8):E32
[
10734209.001
]
[Cites]
Genes Dev. 2000 May 1;14(9):1021-6
[
10809662.001
]
[Cites]
Nature. 2000 Nov 9;408(6809):255-62
[
11089983.001
]
[Cites]
Cell. 2001 Oct 19;107(2):137-48
[
11672522.001
]
[Cites]
Cell. 2001 Oct 19;107(2):149-59
[
11672523.001
]
[Cites]
EMBO J. 2002 May 15;21(10):2383-96
[
12006491.001
]
[Cites]
Nat Genet. 2002 Nov;32(3):378-83
[
12379856.001
]
[Cites]
Nat Genet. 2002 Nov;32(3):370-7
[
12410229.001
]
[Cites]
Cancer Res. 2002 Nov 1;62(21):6011-4
[
12414620.001
]
[Cites]
Nucleic Acids Res. 2004;32(3):e38
[
14973332.001
]
[Cites]
Cell. 2004 Feb 20;116(4):551-63
[
14980222.001
]
[Cites]
Mod Pathol. 2007 Mar;20(3):331-8
[
17277767.001
]
[Cites]
Nat Rev Genet. 2007 Apr;8(4):286-98
[
17339880.001
]
[Cites]
Biochem J. 2007 May 15;404(1):1-13
[
17447894.001
]
[Cites]
Cancer J. 2007 Jan-Feb;13(1):49-55
[
17464246.001
]
[Cites]
N Engl J Med. 2007 May 24;356(21):2131-42
[
17522398.001
]
[Cites]
J Mol Diagn. 2007 Jul;9(3):305-14
[
17591929.001
]
[Cites]
Neoplasia. 2007 Jul;9(7):569-77
[
17710160.001
]
[Cites]
Gut. 2007 Nov;56(11):1498-500
[
17938428.001
]
[Cites]
Mod Pathol. 2007 Nov;20(11):1183-90
[
17873897.001
]
[Cites]
Nat Rev Genet. 2007 Nov;8(11):829-33
[
17909537.001
]
[Cites]
Nat Rev Genet. 2007 Nov;8(11):835-44
[
17909538.001
]
[Cites]
Biotechnol J. 2007 Nov;2(11):1360-8
[
17806102.001
]
[Cites]
J Mol Diagn. 2008 Jan;10(1):13-27
[
18165277.001
]
[Cites]
Carcinogenesis. 2008 Feb;29(2):434-9
[
18048385.001
]
[Cites]
Epigenetics. 2008 Jan-Feb;3(1):28-37
[
18326939.001
]
[Cites]
Mod Pathol. 2008 May;21 Suppl 2:S23-30
[
18437170.001
]
(PMID = 19430421.001).
[ISSN]
1530-0285
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / K07 CA122826-02; United States / NCI NIH HHS / CA / P01 CA087969; United States / NCI NIH HHS / CA / P01 CA055075; United States / NCI NIH HHS / CA / CA122826-02; United States / NCI NIH HHS / CA / K07 CA122826; United States / NCI NIH HHS / CA / CA055075-15; United States / NCI NIH HHS / CA / P50 CA127003-02; United States / NCI NIH HHS / CA / P01 CA87969; United States / NCI NIH HHS / CA / P01 CA55075; United States / NCI NIH HHS / CA / P01 CA087969-09; United States / NCI NIH HHS / CA / P50 CA127003; United States / NCI NIH HHS / CA / P01 CA055075-15
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA, Neoplasm; EC 2.3.1.85 / Fatty Acid Synthases; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins
[Other-IDs]
NLM/ NIHMS100427; NLM/ PMC2704253
60.
Wietfeldt ED, Thiele J:
Malignancies of the anal margin and perianal skin.
Clin Colon Rectal Surg
; 2009 May;22(2):127-35
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial
adenocarcinoma
), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.
Wide local excision is the mainstay of treatment for early
stage
tumors as it preserves continence and obtains adequate local control.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Dis Colon Rectum. 2008 Dec;51(12):1842-5
[
18584248.001
]
[Cites]
J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7
[
17637368.001
]
[Cites]
Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2
[
17430376.001
]
[Cites]
Br J Dermatol. 2007 Jan;156(1):11-21
[
17199561.001
]
[Cites]
Dermatol Surg. 2001 Jun;27(6):587-90
[
11442599.001
]
[Cites]
Dis Colon Rectum. 1997 Oct;40(10):1187-94
[
9336114.001
]
[Cites]
Br J Dermatol. 1995 Jun;132(6):970-2
[
7662577.001
]
[Cites]
Dis Colon Rectum. 2003 May;46(5):612-6
[
12792436.001
]
[Cites]
Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1
[
15540295.001
]
(PMID = 20436838.001).
[ISSN]
1530-9681
[Journal-full-title]
Clinics in colon and rectal surgery
[ISO-abbreviation]
Clin Colon Rectal Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2780245
[Keywords]
NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
61.
Messalli EM, Scaffa C, Mainini G, Rotondi M, Pecori E, Cobellis L:
Third stage ovarian carcinoma--case report: the necessity of a multidisciplinary approach to treatment.
Eur J Gynaecol Oncol
; 2006;27(3):291-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Third
stage
ovarian carcinoma--case report: the necessity of a multidisciplinary approach to treatment.
Excellent cytoreduction with peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy (Figure 2), bilateral pelvic lymphadenectomy, total omentectomy, removal of nodules from the mesentery, the
colon
and three nodules in the abdominal wall thickness was executed.
The histological report was G3, angioinvasive bilateral ovarian endometrioid
adenocarcinoma
.
It is concluded that the complexity of similar cases always requires a multidisciplinary approach as in our case, involving an oncologist, hematologist, surgeon, gynaecologist, radiologist, anaesthesiologist, and nursing staff in the management of third
stage
ovarian cancer patients to obtain the best treatment thus guaranteeing a higher survival rate and better quality of life.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16800262.001).
[ISSN]
0392-2936
[Journal-full-title]
European journal of gynaecological oncology
[ISO-abbreviation]
Eur. J. Gynaecol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Italy
62.
Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L:
Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome.
Clin Colorectal Cancer
; 2009 Oct;8(4):215-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Human immunodeficiency virus-associated
adenocarcinoma of
the
colon
: clinicopathologic findings and outcome.
BACKGROUND: Patients infected with Human immunodeficiency virus (HIV) living longer with antiretroviral therapy (ART) are more likely to develop non-AIDS-defining cancers such as
adenocarcinoma of
the
colon
.
There have been limited case reports regarding HIV-associated
colon adenocarcinoma
.
The aim of this study was to characterize the clinicopathologic findings and outcome in a series of HIV-infected patients diagnosed and treated for
colon adenocarcinoma
.
PATIENTS AND METHODS: A retrospective study involving HIV-related
colon adenocarcinoma
was performed.
Most carcinomas (57%) involved the right
colon
, were largely TNM
stage
4 cancers (47%), and, when present, metastases were mainly to the liver.
Immunosuppression (AIDS diagnosis and/or CD4+ < 500 cells/mm3) did not appear to correlate with tumor grade,
stage
, or an adverse outcome.
CONCLUSION: These data show that HIV-infected patients with
adenocarcinoma of
the
colon
tend to be young men with a high incidence of right-sided involvement.
Additional research is needed to determine if screening HIV-infected individuals for
colon
cancer should include younger patients and involve the entire
colon
.
[MeSH-major]
Adenocarcinoma
/ complications. Colonic Neoplasms / complications. HIV Infections / complications
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - HIV/AIDS in Women
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19822512.001).
[ISSN]
1533-0028
[Journal-full-title]
Clinical colorectal cancer
[ISO-abbreviation]
Clin Colorectal Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
63.
Johnston MH:
Technology insight: ablative techniques for Barrett's esophagus--current and emerging trends.
Nat Clin Pract Gastroenterol Hepatol
; 2005 Jul;2(7):323-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
These techniques have been developed primarily to treat the precursors of esophageal
adenocarcinoma
: dysplasia in Barrett's esophagus and early esophageal cancer.
Although high-grade dysplasia and early
stage
cancer can be treated with esophagectomy, the inherent morbidity and mortality of esophageal
adenocarcinoma
and the morbidities, difficulties, costs and limitations of the current technology mean that there has been a significant increase in interest and research regarding alternative treatments such as ablative techniques.
At this
stage
it is not clear which of the numerous endoscopic ablative techniques available-photodynamic therapy, laser therapy, multipolar electrocoagulation, argon plasma coagulation, endoscopic mucosal resection, radiofrequency ablation or cryotherapy-will emerge as superior.
[MeSH-major]
Adenocarcinoma
/ prevention & control. Barrett Esophagus / therapy. Esophageal Neoplasms / prevention & control
Genetic Alliance.
consumer health - Barrett's Esophagus
.
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16265286.001).
[ISSN]
1743-4378
[Journal-full-title]
Nature clinical practice. Gastroenterology & hepatology
[ISO-abbreviation]
Nat Clin Pract Gastroenterol Hepatol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
48
64.
Cellini C, Hunt SR, Fleshman JW, Birnbaum EH, Bierhals AJ, Mutch MG:
Stage IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?
World J Surg
; 2010 May;34(5):1102-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Stage
IV rectal cancer with liver metastases: is there a benefit to resection of the primary tumor?
BACKGROUND: Resection of primary and liver lesions is the optimal management
of Stage
IV rectal cancer with liver metastases.
We compared survival outcomes in patients with
Stage
IV rectal cancer with liver metastases undergoing staged or synchronous resection with those undergoing primary rectal resection only or no resection at all.
[MeSH-major]
Adenocarcinoma
/ surgery. Liver Neoplasms / surgery. Rectal Neoplasms / surgery
Genetic Alliance.
consumer health - Liver cancer
.
Genetic Alliance.
consumer health - Rectal Cancer
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Colorectal Dis. 2007 Jun;9(5):430-7
[
17504340.001
]
[Cites]
Arch Surg. 2000 May;135(5):530-4; discussion 534-5
[
10807276.001
]
[Cites]
J Am Coll Surg. 2003 Aug;197(2):233-41; discussion 241-2
[
12892803.001
]
[Cites]
Br J Surg. 2001 Oct;88(10 ):1352-6
[
11578291.001
]
[Cites]
N Engl J Med. 2004 Jun 3;350(23 ):2335-42
[
15175435.001
]
[Cites]
Ann Surg Oncol. 2002 Dec;9(10):954-60
[
12464586.001
]
[Cites]
Int J Colorectal Dis. 2007 Oct;22(10):1269-76
[
17318552.001
]
[Cites]
Ann Surg. 2008 Oct;248(4):592-8
[
18936572.001
]
[Cites]
Cancer. 2002 Dec 1;95(11):2283-92
[
12436433.001
]
[Cites]
J Surg Oncol. 2006 Jun 1;93(7):523-8
[
16705728.001
]
[Cites]
J Clin Oncol. 2008 Dec 20;26(36):5910-7
[
19018087.001
]
[Cites]
Ann Surg Oncol. 2009 Jan;16(1):35-41
[
18987915.001
]
[Cites]
Dis Colon Rectum. 1988 Nov;31(11):842-7
[
2460299.001
]
[Cites]
J Am Coll Surg. 2003 May;196(5):722-8
[
12742204.001
]
[Cites]
Ann Surg Oncol. 2005 Aug;12(8):637-45
[
15965730.001
]
[Cites]
J Clin Oncol. 2009 Jul 10;27(20):3379-84
[
19487380.001
]
[Cites]
Int J Colorectal Dis. 2008 Jun;23(6):559-68
[
18330581.001
]
[Cites]
Gastroenterol Clin Biol. 2004 May;28(5):434-7
[
15243315.001
]
[Cites]
Oncologist. 1999;4(3):197-208
[
10394588.001
]
[Cites]
Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7
[
10560850.001
]
[Cites]
Dis Colon Rectum. 1981 Jul-Aug;24(5):355-60
[
6167412.001
]
[Cites]
ANZ J Surg. 2004 Apr;74(4):229-32
[
15043733.001
]
[Cites]
J Clin Oncol. 2004 Jan 1;22(1):23-30
[
14665611.001
]
[Cites]
J Clin Oncol. 2004 Apr 1;22(7):1209-14
[
15051767.001
]
[Cites]
Ann Surg. 1996 Oct;224(4):509-20; discussion 520-2
[
8857855.001
]
[Cites]
Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8
[
15383792.001
]
[Cites]
Ann Oncol. 2008 Nov;19(11):1829-35
[
18662955.001
]
(PMID = 20177683.001).
[ISSN]
1432-2323
[Journal-full-title]
World journal of surgery
[ISO-abbreviation]
World J Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
65.
Iannello S, Milazzo P, Bordonaro F, Belfiore F:
Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid--two case reports and literature review.
MedGenMed
; 2006;8(4):60
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A fortuitous observation was made by the first author of this study who, at age 54, developed an erythematous and painful postsurgical abdominal keloid scar after undergoing left colectomy for
colon adenocarcinoma
.
During the posttraumatic or postoperative
stage
, it is useful to achieve the best possible aesthetic results and to decrease the risk of a disfiguring keloid scar, thereby avoiding revision surgery; to this purpose, an early treatment with a low dose of enalapril is a possible solution, even if further confirmatory observations are needed.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Arch Otolaryngol Head Neck Surg. 2001 Sep;127(9):1145
[
11556871.001
]
[Cites]
Can J Cardiol. 2000 May;16(5):617-25
[
10833541.001
]
[Cites]
J Dermatol Sci. 2002 May;29(1):26-34
[
12007718.001
]
[Cites]
Plast Reconstr Surg. 2002 Aug;110(2):560-71
[
12142678.001
]
[Cites]
Plast Reconstr Surg. 2003 Feb;111(2):535-43; discussion 544-6
[
12560674.001
]
[Cites]
Plast Reconstr Surg. 2003 Feb;111(2):547-53; discussion 554-5
[
12560675.001
]
[Cites]
Plast Reconstr Surg. 2003 May;111(6):1853-9
[
12711944.001
]
[Cites]
J Craniofac Surg. 2003 Sep;14(5):654-7
[
14501323.001
]
[Cites]
Am J Physiol Lung Cell Mol Physiol. 2004 Jan;286(1):L156-64
[
12754187.001
]
[Cites]
Curr Gene Ther. 2004 Mar;4(1):123-36
[
15032619.001
]
[Cites]
Wound Repair Regen. 2004 Mar-Apr;12(2):169-74
[
15086768.001
]
[Cites]
J Am Acad Dermatol. 2004 Jun;50(6):850-3
[
15153883.001
]
[Cites]
BMJ. 2004 Jun 5;328(7452):1329-30
[
15178589.001
]
[Cites]
Br J Radiol. 1990 May;63(749):349-54
[
2198982.001
]
[Cites]
J Am Coll Cardiol. 1992 Mar 1;19(3):713-21
[
1538033.001
]
[Cites]
Aust N Z J Med. 1992 Oct;22(5 Suppl):601-6
[
1449447.001
]
[Cites]
J Dermatol Surg Oncol. 1993 Aug;19(8):738-46
[
8349914.001
]
[Cites]
Cardiovasc Res. 2000 May;46(2):250-6
[
10773228.001
]
[Cites]
J Mol Cell Cardiol. 1997 Aug;29(8):2001-12
[
9281434.001
]
[Cites]
Ann Plast Surg. 1997 Oct;39(4):418-32
[
9339286.001
]
[Cites]
J Am Coll Cardiol. 1998 Aug;32(2):552-3
[
9708494.001
]
[Cites]
Plast Reconstr Surg. 1998 Nov;102(6):1954-61
[
9810991.001
]
[Cites]
Am J Physiol. 1998 Nov;275(5 Pt 1):L1013-7
[
9815121.001
]
[Cites]
Hum Pathol. 1998 Nov;29(11):1273-8
[
9824106.001
]
[Cites]
Br J Radiol. 1999 Dec;72(864):1222-4
[
10703484.001
]
[Cites]
J Lab Clin Med. 1993 Oct;122(4):395-403
[
8228553.001
]
[Cites]
Int J Radiat Biol. 2000 Apr;76(4):523-32
[
10815633.001
]
[Cites]
Proc Soc Exp Biol Med. 1994 Jan;205(1):80-4
[
8115354.001
]
[Cites]
Rev Prat. 1994 Sep 1;44(13):1763-8
[
7939260.001
]
[Cites]
Int J Oral Maxillofac Surg. 1994 Aug;23(4):232-6
[
7798696.001
]
[Cites]
Circulation. 1995 Feb 1;91(3):802-12
[
7828309.001
]
[Cites]
Cardiovasc Drugs Ther. 1997 Apr;11(2):177-85
[
9140694.001
]
[Cites]
Surg Clin North Am. 1997 Jun;77(3):701-30
[
9194888.001
]
[Cites]
J Mol Cell Cardiol. 1997 May;29(5):1375-86
[
9201623.001
]
[Cites]
Eur J Dermatol. 1998 Dec;8(8):591-5
[
9889433.001
]
[Cites]
Ann Plast Surg. 1999 Aug;43(2):179-84
[
10454326.001
]
[Cites]
Plast Reconstr Surg. 1999 Sep;104(3):694-8
[
10456520.001
]
[Cites]
Plast Reconstr Surg. 1999 Oct;104(5):1435-58
[
10513931.001
]
[Cites]
Am J Physiol Heart Circ Physiol. 2005 Jul;289(1):H108-13
[
15722410.001
]
[Cites]
Plast Reconstr Surg. 2005 Aug;116(2):675
[
16079716.001
]
[Cites]
J Histochem Cytochem. 2005 Oct;53(10):1245-56
[
15956033.001
]
[Cites]
Plast Reconstr Surg. 2005 Oct;116(5):1387-90; discussion 1391-2
[
16217483.001
]
[Cites]
Plast Reconstr Surg. 2005 Dec;116(7):150e-157e
[
16327593.001
]
[Cites]
Plast Reconstr Surg. 2006 Jan;117(1):247-52
[
16404275.001
]
[Cites]
Plast Reconstr Surg. 2006 Jan;117(1):286-300
[
16404281.001
]
[Cites]
Plast Reconstr Surg. 2006 Apr 15;117(5):1645-6
[
16641743.001
]
[Cites]
Plast Reconstr Surg. 2001 Oct;108(5):1218-24
[
11604622.001
]
(PMID = 17415337.001).
[ISSN]
1531-0132
[Journal-full-title]
MedGenMed : Medscape general medicine
[ISO-abbreviation]
MedGenMed
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Angiotensin-Converting Enzyme Inhibitors; 69PN84IO1A / Enalapril
[Number-of-references]
48
[Other-IDs]
NLM/ PMC1868346
66.
Hecht JL, Dolinski BM, Gardner HA, Violette SM, Weinreb PH:
Overexpression of the alphavbeta6 integrin in endometrial cancer.
Appl Immunohistochem Mol Morphol
; 2008 Dec;16(6):543-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The alpha(v)beta(6) integrin (alphavbeta6) has been shown to be up-regulated in
adenocarcinoma of
the breast,
colon
, stomach, and ovary, generally reflecting a more aggressive phenotype.
We analyzed alphavbeta6 expression in the tissue from primary endometrial carcinomas (endometrioid type) using a mouse monoclonal antibody against human alphavbeta6, and correlated the findings with grade,
stage
, and nodal involvement.
Genetic Alliance.
consumer health - Endometrial cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18698261.001).
[ISSN]
1533-4058
[Journal-full-title]
Applied immunohistochemistry & molecular morphology : AIMM
[ISO-abbreviation]
Appl. Immunohistochem. Mol. Morphol.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Integrin alphaV; 0 / Integrin beta Chains; 0 / integrin beta6
67.
Paduch R, Kandefer-Szerszeń M, Piersiak T:
The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs.
Oncol Res
; 2010;18(9):419-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The importance of release of proinflammatory cytokines, ROS, and NO in different stages
of colon
carcinoma growth and metastasis after treatment with cytotoxic drugs.
We analyzed the levels of reactive oxygen species (ROS), nitric oxide (NO), and cachexia-mediated cytokines (IL-1beta, IL-6, TNF-alpha) in cocultures of human
colon
carcinoma spheroids prepared with cells derived from tumors of different grades with human normal
colon
epithelial and myofibroblast cells and normal endothelial cells.
The results indicated that adhesion
of colon
carcinoma spheroids to
colon
epithelium and myofibroblast monolayers induced O2- anion production but decreased NO levels compared to the sum of the radicals released by monocultures of the two types of cells.
Coculture
of colon
carcinoma spheroids with endothelium was an exception to this rule, as only HT29 cells decreased NO production.
However, the levels of released ROS and NO were dependent on the
stage of colon
carcinoma that the cells were derived from.
In conclusion, cytotoxic drugs may, dependent on the
stage of
tumor growth or the type of chemotherapy regimen administered, significantly influence the proinflammatory cytokine network and local ROS and NO levels.
On the other hand, high level of NO seems to facilitate tumor cell interactions with the endothelium and metastasis as NO production was the highest in a monoculture of HUVEC and remained at high levels in cocultures
of colon
cancer cells with HUVEC.
Among the proinflammatory cytokines, only IL-6 seems to significantly influence
colon
carcinoma development and metastasis.
[MeSH-minor]
Adenocarcinoma
/ drug therapy.
Adenocarcinoma
/ metabolism.
Adenocarcinoma
/ pathology. Camptothecin / administration & dosage. Coculture Techniques.
Colon
/ drug effects.
Colon
/ metabolism.
Colon
/ pathology. Endothelium, Vascular / drug effects. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Enzyme-Linked Immunosorbent Assay. Fibroblasts / drug effects. Fibroblasts / metabolism. Fibroblasts / pathology. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Neoplasm Metastasis
Hazardous Substances Data Bank.
NITRIC OXIDE
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20524400.001).
[ISSN]
0965-0407
[Journal-full-title]
Oncology research
[ISO-abbreviation]
Oncol. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Cytokines; 0 / Reactive Oxygen Species; 31C4KY9ESH / Nitric Oxide; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
68.
Arfa N, Hamdani I, Gharbi L, Ben Abid S, Ghariani B, Mannai S, Mestiri H, Khalfallah MT, Mzabi SR:
[Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases].
Ann Chir
; 2006 Feb;131(2):104-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Survival and prognostic factors of colorectal
adenocarcinoma
: analytic multifactor review of 150 cases].
[Transliterated title]
Survie et facteurs pronostiques
des
adénocarcinomes colorectaux: étude analytique uni- et multifactorielle
de
150 cas.
This study attempts to observe the survival of colorectal
adenocarcinoma
and to find prognostic factors and other variables potentially associated with outcome of colorectal
adenocarcinoma
.
MATERIAL AND METHODS: It's a retrospective study based on 150 patients with colorectal
adenocarcinoma
from 1990 to 2002.
84 patients had
colon adenocarcinoma
and 66 patients had rectal
adenocarcinoma
.
In histological exam the
adenocarcinoma
was well differenced in 69 cases (46%), and undifferentiated in 17 cases (18, 3%).
There were 6 patients (4%) Dukes
stage I
TNM, 61
stage
II (40, 7%), 51
stage
III TNM (34%) and 32 patients
stage
IV TNM (34%).
All patients had surgical curative resection associated with adjuvant chemotherapy in 60 cases
of colon adenocarcinoma
and preoperative radiotherapy in 33 cases of rectal
adenocarcinoma
.
In addition to the clinical factors, we found of significant prognostic value undifferentiated
adenocarcinoma
and an elevated value of serum carcinoembryonic antigen>5 ng/ml.
[MeSH-major]
Adenocarcinoma
/ mortality. Colorectal Neoplasms / mortality
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16443189.001).
[ISSN]
0003-3944
[Journal-full-title]
Annales de chirurgie
[ISO-abbreviation]
Ann Chir
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
69.
Chin CC, Wang JY, Yeh CY, Kuo YH, Huang WS, Yeh CH:
Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in stage III colon cancer.
Int J Colorectal Dis
; 2009 Nov;24(11):1297-302
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metastatic lymph node ratio is a more precise predictor of prognosis than number of lymph node metastases in
stage
III
colon
cancer.
OBJECTIVE: The objective of this study is to assess the value of metastatic lymph node ratio (LNR) in predicting disease-free survival (DFS) in patients with
stage
III
adenocarcinoma of
the
colon
.
MATERIALS AND METHODS: From 1995 to 2003 inclusively, a total of 624 patients featuring
stage
III
adenocarcinoma of
the
colon
underwent curative resection.
In T3/4LNR1 patients (n = 411), there was no difference in survival between those with N1
stage
and those with N2
stage
.
Cox proportional hazards regression analysis revealed that N
stage
(number of positive lymph nodes) was not a significant factor when LNR was taken into consideration.
CONCLUSIONS: LNR is a more precise predictor of 5-year DFS than number of positive lymph nodes (N
stage
) in patients with
stage
III
colon
cancer.
Genetic Alliance.
consumer health - Metastatic cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Clin Oncol. 2004 Jun;27(3):304-6
[
15170153.001
]
[Cites]
J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90
[
12504228.001
]
[Cites]
Ann Surg Oncol. 2002 Jan-Feb;9(1):27-34
[
11829427.001
]
[Cites]
Eur J Cancer. 2005 Jan;41(2):272-9
[
15661553.001
]
[Cites]
J Natl Cancer Inst. 2007 Mar 21;99(6):433-41
[
17374833.001
]
[Cites]
Ann Surg. 2002 Oct;236(4):416-21; discussion 421
[
12368669.001
]
[Cites]
Gut. 2006 Nov;55(11):1681
[
17047131.001
]
[Cites]
Ann Surg Oncol. 2007 May;14(5):1712-7
[
17253102.001
]
[Cites]
Eur J Surg Oncol. 2005 Feb;31(1):59-66
[
15642427.001
]
[Cites]
Breast Cancer Res. 2004;6(6):R680-8
[
15535850.001
]
[Cites]
Am J Surg. 2007 Dec;194(6):827-31; discussion 831-2
[
18005779.001
]
[Cites]
Eur J Surg Oncol. 2008 Jul;34(7):771-5
[
18079086.001
]
[Cites]
J Clin Oncol. 2005 Dec 1;23(34):8706-12
[
16314630.001
]
[Cites]
Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71
[
12513963.001
]
[Cites]
Ann Surg Oncol. 2008 Jun;15(6):1600-8
[
18327530.001
]
[Cites]
Ann Surg. 2002 Apr;235(4):458-63
[
11923600.001
]
[Cites]
Am J Surg Pathol. 2002 Feb;26(2):179-89
[
11812939.001
]
[Cites]
Am Surg. 2004 Mar;70(3):235-40; discussion 240
[
15055847.001
]
[Cites]
J Natl Cancer Inst. 2001 Apr 18;93(8):583-96
[
11309435.001
]
[Cites]
Cancer. 1967 Nov;20(11):1976-85
[
6061631.001
]
[Cites]
J Natl Cancer Inst. 2005 Feb 2;97(3):219-25
[
15687365.001
]
(PMID = 19479270.001).
[ISSN]
1432-1262
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
70.
Baccari P, Bisagni P, Crippa S, Sampietro R, Staudacher C:
Operative and long-term results after one-stage surgery for obstructing colonic cancer.
Hepatogastroenterology
; 2006 Sep-Oct;53(71):698-701
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Operative and long-term results after one-
stage
surgery for obstructing colonic cancer.
BACKGROUND/AIMS: To analyze retrospectively the operative results and five-year survival after single-
stage
resection and primary anastomosis for right- or left-sided colonic malignant obstruction.
METHODOLOGY: From 1994 to 2002, 83 patients with acute obstruction due to primary cancer underwent a one-
stage
procedure, 36 (43.3%) for cancer of the right and 47 (56.7%) of the left
colon
.
CONCLUSIONS: One-
stage
resection and primary anastomosis can be applied to the majority of patients with malignant colonic obstruction and it allows achieving excellent operative results.
[MeSH-major]
Adenocarcinoma
/ drug therapy. Colectomy. Colonic Neoplasms / drug therapy. Intestinal Obstruction / surgery
MedlinePlus Health Information.
consumer health - Intestinal Obstruction
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17086871.001).
[ISSN]
0172-6390
[Journal-full-title]
Hepato-gastroenterology
[ISO-abbreviation]
Hepatogastroenterology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Greece
71.
Brosens RP, Oomen JL, Glas AS, van Bochove A, Cuesta MA, Engel AF:
POSSUM predicts decreased overall survival in curative resection for colorectal cancer.
Dis Colon Rectum
; 2006 Jun;49(6):825-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Risk factors for overall survival were advanced
stage of
disease, poor tumor differentiation, mucinous
adenocarcinoma
, older than age 70 years, and poor condition of the patient at time of operation.
[MeSH-major]
Adenocarcinoma
/ mortality.
Adenocarcinoma
/ surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / surgery. Severity of Illness Index
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16550320.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
72.
Tsuneoka M, Teye K, Arima N, Soejima M, Otera H, Ohashi K, Koga Y, Fujita H, Shirouzu K, Kimura H, Koda Y:
A novel Myc-target gene, mimitin, that is involved in cell proliferation of esophageal squamous cell carcinoma.
J Biol Chem
; 2005 May 20;280(20):19977-85
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Whereas specific inhibition of mimitin expression did not affect cell proliferation in human cervical carcinoma,
colon adenocarcinoma
, and hepatocarcinoma cell lines, it did suppress cell proliferation in human glioblastoma, esophageal squamous cell carcinoma (ESCC), and embryonic lung fibroblastic cells, with the greatest suppression efficiency in ESCC cells.
The expression level of Mimitin was found to be correlated with that of c-Myc and cell proliferation, but not with the histopathological grade,
stage of
cancer, or age of patients.
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
SciCrunch.
HGNC: Data: Gene Annotation
.
SciCrunch.
OMIM: Data: Gene Annotation
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15774466.001).
[ISSN]
0021-9258
[Journal-full-title]
The Journal of biological chemistry
[ISO-abbreviation]
J. Biol. Chem.
[Language]
eng
[Databank-accession-numbers]
GENBANK/ AB183433/ AB183434/ AB183435
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA, Complementary; 0 / DNA, Neoplasm; 0 / MYC protein, human; 0 / Mitochondrial Proteins; 0 / Molecular Chaperones; 0 / NDUFAF2 protein, human; 0 / Proto-Oncogene Proteins c-myc
73.
Ogata H, Sekikawa A, Yamagishi H, Ichikawa K, Tomita S, Imura J, Ito Y, Fujita M, Tsubaki M, Kato H, Fujimori T, Fukui H:
GROα promotes invasion of colorectal cancer cells.
Oncol Rep
; 2010 Dec;24(6):1479-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We examined the expression of GROα and its pathophysiological significance in human CRCs and investigated whether GROα promotes the invasive potential
of colon
cancer cells.
The mRNA expression of GROα and its receptor CXCR2 was examined in ten
colon
cancer cell lines using RT-PCR.
GROα expression was significantly associated with tumor size, tumor
stage
, depth of invasion, LN metastasis and patient survival (P=0.021, P<0.0001, P=0.0033, P<0.0001, P=0.039, respectively).
Expression of CXCR2 mRNA was detectable in all ten
colon
cancer cell lines examined, whereas expression of GROα mRNA was detectable in six.
[MeSH-major]
Adenocarcinoma
/ pathology. Chemokine CXCL1 / physiology. Colorectal Neoplasms / pathology
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21042742.001).
[ISSN]
1791-2431
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CXCL1 protein, human; 0 / Chemokine CXCL1
74.
Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS:
Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma.
Histopathology
; 2010 Jan;56(2):229-39
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinicopathological significance of nuclear PTEN expression in colorectal
adenocarcinoma
.
On univariate survival analysis, patients with PTEN-
adenocarcinoma
revealed a poor overall and disease-free survival (P = 0.030 and P = 0.046, respectively).
On multivariate analysis, a significant difference was observed in patients with
stage
II cancer that was not observed in other stages.
CONCLUSIONS: Nuclear PTEN expression gradually decrease during the normal-adenoma-
adenocarcinoma
-metastasis sequence, which suggests an important role for PTEN in carcinogenesis.
Moreover, loss of nuclear PTEN expression was a marker of poor clinical outcome in patients with
stage
II colorectal cancer.
[MeSH-major]
Adenocarcinoma
/ metabolism. Adenomatous Polyps / metabolism. Cell Nucleus / metabolism.
Colon
/ metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Lymph Nodes / metabolism. PTEN Phosphohydrolase / metabolism. Rectum / metabolism
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20102402.001).
[ISSN]
1365-2559
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase
75.
Preis M, Korc M:
Kinase signaling pathways as targets for intervention in pancreatic cancer.
Cancer Biol Ther
; 2010 May 15;9(10):754-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Pancreatic ductal
adenocarcinoma
(PDAC) is the fourth leading cause of cancer related mortality in the United States.
The prognosis of patients with PDAC is extremely poor with a median survival of 6 months, in part due to the advanced
stage
at the time of diagnosis and early metastatic spread.
The relatively recent introduction of novel therapies targeting tyrosine kinase and serine/threonine kinase pathways have yielded dramatic results in certain hematological malignancies, and have resulted in significant advances in our ability to treat patients with melanoma, breast, lung and
colon
cancer, thereby leading to improved survival and quality of life.
Genetic Alliance.
consumer health - Pancreatic cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20234186.001).
[ISSN]
1555-8576
[Journal-full-title]
Cancer biology & therapy
[ISO-abbreviation]
Cancer Biol. Ther.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA-R37-75059
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Hedgehog Proteins; EC 2.7.- / Phosphotransferases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
76.
Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB:
Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.
Cancer Biol Ther
; 2009 Sep;8(17):1671-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Mirk/Dyrk1B is a serine/threonine kinase that has been found to be upregulated in solid tumors and mediates cell survival in
colon
cancer, pancreatic ductal
adenocarcinoma
and rhabdomyosarcomas.
Using automated quantitative determination of the Mirk protein in tumor specimens of patients with early-
stage
lung cancer, overexpression of Mirk was found in nearly 90% of tumor specimens in both the cytoplasm and nucleus.
Genetic Alliance.
consumer health - Lung Cancer
.
Genetic Alliance.
consumer health - Non-small cell lung cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2000 Jul 1;60(13):3631-7
[
10910078.001
]
[Cites]
J Hematol Oncol. 2009;2:2
[
19159467.001
]
[Cites]
Mol Cell. 2000 Dec;6(6):1389-99
[
11163212.001
]
[Cites]
Science. 2001 Apr 27;292(5517):727-30
[
11326099.001
]
[Cites]
Cancer Res. 2001 May 15;61(10):3986-97
[
11358816.001
]
[Cites]
Nat Med. 2002 Nov;8(11):1323-7
[
12389040.001
]
[Cites]
Oncogene. 2003 Jul 3;22(27):4150-65
[
12833138.001
]
[Cites]
J Biol Chem. 2003 Oct 17;278(42):41347-54
[
12902328.001
]
[Cites]
J Biol Chem. 2004 May 21;279(21):22498-504
[
15010468.001
]
[Cites]
Clin Lung Cancer. 2004 Sep;6(2):113-22
[
15476597.001
]
[Cites]
J Biol Chem. 1998 Oct 2;273(40):25893-902
[
9748265.001
]
[Cites]
Biochem Biophys Res Commun. 1999 Jan 19;254(2):474-9
[
9918863.001
]
[Cites]
Prog Nucleic Acid Res Mol Biol. 1999;62:1-17
[
9932450.001
]
[Cites]
Nat Biotechnol. 2005 Jan;23(1):94-101
[
15592455.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93
[
15731348.001
]
[Cites]
Nat Cell Biol. 2005 Jun;7(6):591-600
[
15864305.001
]
[Cites]
Clin Cancer Res. 2005 Dec 1;11(23):8288-94
[
16322287.001
]
[Cites]
Cancer Res. 2006 Mar 15;66(6):3162-8
[
16540667.001
]
[Cites]
Cancer Res. 2006 Apr 15;66(8):4149-58
[
16618736.001
]
[Cites]
Cancer Res. 2006 May 15;66(10):5143-50
[
16707437.001
]
[Cites]
Cancer Res. 2006 Jun 1;66(11):5542-8
[
16740687.001
]
[Cites]
Cell Biochem Biophys. 2006;45(3):303-15
[
16845176.001
]
[Cites]
N Engl J Med. 2007 Feb 22;356(8):800-8
[
17314339.001
]
[Cites]
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4637-40
[
17671156.001
]
[Cites]
J Cell Biochem. 2007 Oct 1;102(2):274-9
[
17583556.001
]
[Cites]
Mol Cancer Ther. 2007 Oct;6(10):2652-63
[
17913856.001
]
[Cites]
Cell. 2007 Dec 14;131(6):1190-203
[
18083107.001
]
[Cites]
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
[
18287387.001
]
[Cites]
J Immunol Methods. 2001 Jan 1;247(1-2):141-51
[
11150545.001
]
(PMID = 19633423.001).
[ISSN]
1555-8576
[Journal-full-title]
Cancer biology & therapy
[ISO-abbreviation]
Cancer Biol. Ther.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA121182; United States / NCI NIH HHS / CA / 1R01 CA121182-01A1
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / BAK1 protein, human; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / bcl-2 Homologous Antagonist-Killer Protein; EC 2.7.1.- / Dyrk kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
[Other-IDs]
NLM/ NIHMS521373; NLM/ PMC3839311
77.
Csejtei A, Tibold A, Varga Z, Koltai K, Ember A, Orsos Z, Feher G, Horvath OP, Ember I, Kiss I:
GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer.
Anticancer Res
; 2008 May-Jun;28(3B):1917-22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The influence of two allelic polymorphisms of GSTM1 and GSTT1, and that of p53 gene codon 72 on
colon
cancer was investigated.
A significant association was found in Dukes' B
stage
patients between the GSTM1 and p53 gene variants and survival.
CONCLUSION: The significance of the investigated polymorphisms in prognosis is dependent on the tumor
stage
.
[MeSH-major]
Adenocarcinoma
/ genetics. Colorectal Neoplasms / genetics. Glutathione Transferase / genetics. Tumor Suppressor Protein p53 / genetics
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18630481.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
78.
Lan YT, Lin JK, Li AF, Lin TC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC:
Metachronous colorectal cancer: necessity of post-operative colonoscopic surveillance.
Int J Colorectal Dis
; 2005 Mar;20(2):121-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In total, 3,846 cases
of adenocarcinoma
of the
colon
and rectum, which received curative resection during this period, were found.
The age, gender of the patients, the location, pathological characteristics of the metachronous tumors, occurrence of associated adenomas, the number of lesions, and the tumor
stage
were analyzed and compared with the control group.
[MeSH-major]
Adenocarcinoma
/ surgery. Colonoscopy. Colorectal Neoplasms / surgery. Neoplasms, Second Primary / surgery
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colonoscopy
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Dis Colon Rectum. 1982 Sep;25(6):569-74
[
7117062.001
]
[Cites]
Dis Colon Rectum. 1993 Apr;36(4):388-93
[
8458267.001
]
[Cites]
Cancer. 1974 Jun;33(6):1630-4
[
4834157.001
]
[Cites]
Cancer. 1984 Nov 1;54(9):1870-4
[
6478423.001
]
[Cites]
Ann Intern Med. 2002 Feb 19;136(4):261-9
[
11848723.001
]
[Cites]
Dis Colon Rectum. 1997 May;40(5):603-8
[
9152192.001
]
[Cites]
Br J Surg. 1990 May;77(5):502-5
[
2354331.001
]
[Cites]
Br J Surg. 1998 Jul;85(7):897-901
[
9692559.001
]
[Cites]
Cancer Detect Prev. 1993;17(3):417-24
[
8402729.001
]
[Cites]
Dis Colon Rectum. 2000 Aug;43(8):1093-9
[
10950007.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1312
[
10561194.001
]
(PMID = 15349739.001).
[ISSN]
0179-1958
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
79.
Baron S, Vangheluwe P, Sepúlveda MR, Wuytack F, Raeymaekers L, Vanoevelen J:
The secretory pathway Ca(2+)-ATPase 1 is associated with cholesterol-rich microdomains of human colon adenocarcinoma cells.
Biochim Biophys Acta
; 2010 Aug;1798(8):1512-21
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The secretory pathway Ca(2+)-ATPase 1 is associated with cholesterol-rich microdomains of human
colon adenocarcinoma
cells.
Within this pathway, the membranes of the Golgi complex represent a transition
stage
between the cholesterol-poor membranes of the endoplasmic reticulum (ER) and the cholesterol-rich plasma membrane.
[MeSH-major]
Adenocarcinoma
/ metabolism. Calcium-Transporting ATPases / chemistry. Calcium-Transporting ATPases / metabolism. Cholesterol / chemistry. Cholesterol / metabolism. Colonic Neoplasms / metabolism. Membrane Microdomains / chemistry. Membrane Microdomains / metabolism
MedlinePlus Health Information.
consumer health - Cholesterol
.
Hazardous Substances Data Bank.
CHOLESTEROL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier B.V. All rights reserved.
(PMID = 20363212.001).
[ISSN]
0006-3002
[Journal-full-title]
Biochimica et biophysica acta
[ISO-abbreviation]
Biochim. Biophys. Acta
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / DNA Primers; 0 / Recombinant Fusion Proteins; 97C5T2UQ7J / Cholesterol; EC 3.6.3.8 / ATP2A2 protein, human; EC 3.6.3.8 / ATP2C1 protein, human; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases
80.
Kiran RP, Tripodi G, Frederick W, Dudrick SJ:
Adenosquamous carcinoma of the colon: a rare tumor.
Am Surg
; 2006 Aug;72(8):754-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adenosquamous carcinoma of the
colon
: a rare tumor.
Adenosquamous carcinoma of the
colon
is rare.
Survival for more advanced stages of disease is lower than for patients with
adenocarcinoma
at a corresponding
stage
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16913323.001).
[ISSN]
0003-1348
[Journal-full-title]
The American surgeon
[ISO-abbreviation]
Am Surg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
81.
Miyazaki K, Satoh H, Sekizawa K:
Metastasis to appendix from lung adenocarcinoma.
Int J Gastrointest Cancer
; 2005;36(1):59-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metastasis to appendix from lung
adenocarcinoma
.
We previously read with interest the case report by Filik et al. (International Journal of Gastrointestinal Cancer, 2003;34:55-58) on appendicular metastases from pancreatic
adenocarcinoma
.
His past medical history included a pneumonectomy of the left lung for locally advanced lung
adenocarcinoma
9 mo previously.
TNM
stage of
the original lung cancer was T2N2M0.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Int J Gastrointest Cancer. 2003;34(1):55-8
[
15235136.001
]
[Cites]
Pathol Int. 1996 Mar;46(3):216-20
[
10846573.001
]
[Cites]
Int J Gastrointest Cancer. 2003;34(1):55-8
[
15235136.001
]
[Cites]
Dis Colon Rectum. 1970 Jul-Aug;13(4):336-40
[
5459822.001
]
(PMID = 16227637.001).
[ISSN]
1537-3649
[Journal-full-title]
International journal of gastrointestinal cancer
[ISO-abbreviation]
Int J Gastrointest Cancer
[Language]
eng
[Publication-type]
Case Reports; Comment; Journal Article
[Publication-country]
United States
82.
Ahn CH, Jeong EG, Lee JW, Kim MS, Kim SH, Kim SS, Yoo NJ, Lee SH:
Expression of beclin-1, an autophagy-related protein, in gastric and colorectal cancers.
APMIS
; 2007 Dec;115(12):1344-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In contrast, normal mucosal cells of both stomach and
colon
showed no or very weak expression of beclin-1.
There was no significant association of beclin-1 expression with clinocopathologic characteristics, including invasion, metastasis and
stage
.
[MeSH-major]
Adenocarcinoma
/ metabolism. Apoptosis Regulatory Proteins / biosynthesis. Colorectal Neoplasms / metabolism. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18184403.001).
[ISSN]
0903-4641
[Journal-full-title]
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
[ISO-abbreviation]
APMIS
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Apoptosis Regulatory Proteins; 0 / BECN1 protein, human; 0 / Membrane Proteins
83.
Ebisui C, Ohkubo K, Akitake H, Ohtsuka M, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Fujimoto T:
[A case of ovarian metastasis from colon cancer successfully treated with multidisciplinary therapy].
Gan To Kagaku Ryoho
; 2010 Nov;37(12):2542-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A case of ovarian metastasis from
colon
cancer successfully treated with multidisciplinary therapy].
An 80-year-old female patient was undergone sigmoidectomy with D2 lymph node dissection for type 2 sigmoid
colon
cancer in February 2007.
A post operative pathological finding of cancer was SS, N0, P0, H0, M0 (
Stage
II), curative A.
In May 2008, total hysterectomy, bilateral oophorectomy, and partial omentectomy were performed and its pathological finding was metastatic ovarian tumor originating from
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ pathology. Krukenberg Tumor / secondary. Krukenberg Tumor / therapy. Ovarian Neoplasms / secondary. Ovarian Neoplasms / therapy. Sigmoid Neoplasms / pathology
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21224633.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 1-UFT protocol
84.
You YN, Baxter NN, Stewart A, Nelson H:
Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database.
Ann Surg
; 2007 May;245(5):726-33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Is the increasing rate of local excision for
stage I
rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database.
SUMMARY BACKGROUND DATA: Despite the lack of level I/level II evidence supporting its oncologic adequacy, LE is performed for
stage I
rectal cancer.
METHODS: Surgical therapy for 35,179 patients with
stage I
rectal cancer diagnosed in 1989 to 2003 was examined over time, utilizing the National Cancer Database.
Genetic Alliance.
consumer health - Rectal Cancer
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Surg. 2000 Mar;231(3):345-51
[
10714627.001
]
[Cites]
Dis Colon Rectum. 2002 Jul;45(7):875-9
[
12130873.001
]
[Cites]
J Natl Cancer Inst. 2001 Apr 18;93(8):583-96
[
11309435.001
]
[Cites]
Cancer. 2001 Aug 15;92(4):896-902
[
11550163.001
]
[Cites]
Dis Colon Rectum. 2001 Sep;44(9):1345-61
[
11584215.001
]
[Cites]
Dis Colon Rectum. 2002 Feb;45(2):200-6
[
11852333.001
]
[Cites]
Pathol Oncol Res. 2002;8(1):7-17
[
11994757.001
]
[Cites]
Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30
[
12368681.001
]
[Cites]
Surg Clin North Am. 2002 Oct;82(5):983-93
[
12507204.001
]
[Cites]
Br J Surg. 1985 Sep;72 Suppl:S54-6
[
4041764.001
]
[Cites]
Dis Colon Rectum. 1986 Jun;29(6):374-7
[
3709314.001
]
[Cites]
Dis Colon Rectum. 1992 Feb;35(2):131-6
[
1735314.001
]
[Cites]
Ann Surg. 1994 Nov;220(5):676-82
[
7979617.001
]
[Cites]
Br J Surg. 1996 Jul;83(7):964-8
[
8813788.001
]
[Cites]
World J Surg. 1997 Sep;21(7):706-14
[
9276701.001
]
[Cites]
Am J Surg. 1998 May;175(5):360-3
[
9600277.001
]
[Cites]
Semin Surg Oncol. 1998 Sep;15(2):101-13
[
9730416.001
]
[Cites]
Cancer. 1998 Dec 1;83(11):2408-18
[
9840542.001
]
[Cites]
Br J Surg. 1999 Jan;86(1):17-28
[
10027354.001
]
[Cites]
Ann Surg. 1999 Jul;230(1):49-54
[
10400036.001
]
[Cites]
Dis Colon Rectum. 1999 Jul;42(7):881-5
[
10411434.001
]
[Cites]
Arch Surg. 1999 Aug;134(8):863-7; discussion 867-8
[
10443810.001
]
[Cites]
J Clin Oncol. 1999 Jan;17(1):312-8
[
10458248.001
]
[Cites]
Dis Colon Rectum. 2004 Nov;47(11):1773-9
[
15622568.001
]
[Cites]
Dis Colon Rectum. 2005 Mar;48(3):429-37
[
15747069.001
]
[Cites]
Dis Colon Rectum. 2005 Jul;48(7):1380-8
[
15906120.001
]
[Cites]
J Clin Oncol. 2005 Aug 1;23(22):4905-12
[
16051945.001
]
[Cites]
J Clin Oncol. 2005 Sep 1;23(25):6199-206
[
16135487.001
]
[Cites]
Ann Surg. 2005 Oct;242(4):472-7; discussion 477-9
[
16192807.001
]
[Cites]
JAMA. 2005 Nov 23;294(20):2587-93
[
16304072.001
]
[Cites]
Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4
[
10950004.001
]
(PMID = 17457165.001).
[ISSN]
0003-4932
[Journal-full-title]
Annals of surgery
[ISO-abbreviation]
Ann. Surg.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / T32 CA101695; United States / NCI NIH HHS / CA / U10 CA076001; United States / NCI NIH HHS / CA / T32 CA 101695; United States / NCI NIH HHS / CA / U01 CA 76001
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC1877081
86.
Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lièvre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P, Piard F:
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
Int J Cancer
; 2008 May 15;122(10):2255-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series
of colon
cancers.
We evaluated the clinicopathological features and the prognosis of patients with activated-network
colon
cancers in a population-based study.
A total of 586
colon
adenocarcinomas were evaluated using sequencing for mutations of KRAS and PI3KCA, and allelic discrimination for mutation of BRAF.
These results remained significant in a multivariate analysis adjusted for sex, age, location,
stage
and microsatellite instability (HR = 1.48; CI CI(95%) = [1.07-2.04]).
Our study is the first report to underline the potential role of RAS-MAPK, PI (3)K network mutations on survival in
colon
cancers.
[MeSH-major]
Adenocarcinoma
/ genetics. Colonic Neoplasms / genetics. Mitogen-Activated Protein Kinases / genetics. Mutation / genetics. Phosphatidylinositol 3-Kinases / genetics. Proto-Oncogene Proteins / genetics. ras Proteins / genetics
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 Wiley-Liss, Inc.
(PMID = 18224685.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.6.5.2 / ras Proteins
87.
García-Oria Serrano MJ, Armengol Carrasco M, Ortiz R, Codina Cazador A:
[The impact of obesity on the histopathological characteristics of colorectal tumours. An observational study].
Cir Esp
; 2010 Jan;87(1):33-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
Impacto
de
la obesidad en las características anatomopatológicas
de
los tumores colorrectales. Estudio observacional.
Patients subjected to curative elective colorectal cancer surgery at Hospital Josep Trueta
de
Girona (Spain), from 1990 to 2001.
RESULTS: A total of 369 patients with colorectal cancer were included into the study, 213 (57.7%) with
colon
cancer, and 156 (42.3%) with rectal cancer.
For
colon
cancer patients, when the BMI was higher than 25 kg/m(2), the tumour grade was worst (P=0.011), and when BMI was above 30 kg/m(2) there were more lymph node metastasis.
For rectal tumours, the higher the BMI, the more lymph node metastasis (P=0.041), and higher tumour
stage
(P=0.023).
In the case
of colon
cancer they also have worst tumour grades, and in the case of rectal cancer, a more advanced tumour
stage
.
[MeSH-major]
Adenocarcinoma
/ complications.
Adenocarcinoma
/ pathology. Colorectal Neoplasms / complications. Colorectal Neoplasms / pathology. Obesity / complications
Genetic Alliance.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Obesity
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 AEC. Published by Elsevier Espana. All rights reserved.
(PMID = 19914612.001).
[ISSN]
0009-739X
[Journal-full-title]
Cirugía española
[ISO-abbreviation]
Cir Esp
[Language]
spa
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Spain
88.
Zwahlen D, Jezioranski J, Chan P, Haider MA, Cho YB, Yeung I, Levin W, Manchul L, Fyles A, Milosevic M:
Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix.
Int J Radiat Oncol Biol Phys
; 2009 Jul 15;74(4):1157-64
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS AND MATERIALS: A total of 20 patients with International Federation of Gynecology and Obstetrics
Stage
IB-IV cervical cancer had an MRI-compatible intrauterine BT applicator inserted after external beam radiotherapy.
[MeSH-minor]
Adenocarcinoma
, Clear Cell / pathology.
Adenocarcinoma
, Clear Cell / radiotherapy. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy.
Colon
, Sigmoid / anatomy & histology. Feasibility Studies. Female. Humans. Middle Aged. Radiation Injuries / prevention & control. Radiotherapy Dosage. Rectum / anatomy & histology. Tumor Burden. Urinary Bladder / anatomy & histology
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19101097.001).
[ISSN]
1879-355X
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
89.
Korkolis DP, Plataniotis GD, Gondikakis E, Xinopoulos D, Koulaxouzidis GV, Katsilieris J, Vassilopoulos PP:
Short-term preoperative radiotherapy is a safe approach for treatment of locally advanced rectal cancer.
Int J Colorectal Dis
; 2006 Jan;21(1):1-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We therefore evaluated early postoperative complications in patients treated with neoadjuvant radiotherapy for locally advanced rectal
adenocarcinoma
.
Both groups were homogeneous regarding age, gender and preoperative
stage of
the disease.
[MeSH-major]
Adenocarcinoma
/ pathology.
Adenocarcinoma
/ radiotherapy. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / radiotherapy
Genetic Alliance.
consumer health - Rectal Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 1996 Dec 14;348(9042):1605-10
[
8961989.001
]
[Cites]
Am J Surg. 2000 Feb;179(2):92-6
[
10773140.001
]
[Cites]
Pathol Oncol Res. 2002;8(1):7-17
[
11994757.001
]
[Cites]
Strahlenther Onkol. 2001 Apr;177(4):173-81
[
11370551.001
]
[Cites]
Br J Surg. 1993 Oct;80(10):1333-6
[
8242317.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1076-81
[
12419434.001
]
[Cites]
N Engl J Med. 1997 Apr 3;336(14 ):980-7
[
9091798.001
]
[Cites]
N Engl J Med. 2001 Aug 30;345(9):638-46
[
11547717.001
]
[Cites]
World J Surg. 1999 May;23(5):463-7; discussion 467-8
[
10085394.001
]
[Cites]
Eur J Cancer. 1994;30A(11):1602-6
[
7530469.001
]
[Cites]
Lancet. 2000 Jul 8;356(9224):93-6
[
10963244.001
]
[Cites]
N Engl J Med. 1997 Apr 3;336(14):1016-7
[
9077384.001
]
[Cites]
Int J Colorectal Dis. 2000 Feb;15(1):1-8
[
10766085.001
]
[Cites]
J Clin Oncol. 2002 Feb 1;20(3):817-25
[
11821466.001
]
[Cites]
Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51
[
9593234.001
]
[Cites]
Eur J Cancer. 1995 Jul-Aug;31A(7-8):1189-92
[
7577019.001
]
[Cites]
Eur J Surg Oncol. 1998 Dec;24(6):528-35
[
9870729.001
]
[Cites]
Ann Med. 1997 Apr;29(2):127-33
[
9187227.001
]
[Cites]
Cancer. 1995 May 1;75(9):2269-75
[
7712435.001
]
[Cites]
Dis Colon Rectum. 1993 Jun;36(6):564-72
[
8500374.001
]
[Cites]
Int J Colorectal Dis. 2003 Nov;18(6):495-9
[
14517686.001
]
[Cites]
Br J Surg. 1994 Aug;81(8):1224-6
[
7953369.001
]
[Cites]
Ann Surg Oncol. 1996 Sep;3(5):423-30
[
8876883.001
]
[Cites]
Dis Colon Rectum. 1999 Oct;42(10):1276-83; discussion 1283-4
[
10528764.001
]
[Cites]
Dis Colon Rectum. 1999 Feb;42(2):167-73
[
10211491.001
]
[Cites]
Br J Surg. 1998 Apr;85(4):526-9
[
9607540.001
]
(PMID = 15947936.001).
[ISSN]
0179-1958
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
90.
Yamaguchi S, Tatsumi T, Takehara T, Sakamori R, Uemura A, Mizushima T, Ohkawa K, Storkus WJ, Hayashi N:
Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
Cancer
; 2007 Oct 1;110(7):1469-77
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunotherapy of murine
colon
cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
BACKGROUND: Further optimization of dendritic cell (DC)-based vaccines is required clinically against advanced
stage
cancer.
Given the broad range of expression levels observed in the recently defined tumor antigen EphA2 in a diverse types of cancers, especially in advanced
stage
or metastatic cancers, the authors evaluated the effectiveness of vaccination using DCs pulsed with EphA2-derived peptides (Eph-DCs) in a murine
colon
cancer model.
Immunized mice were challenged subcutaneously with EphA2-positive murine colorectal
adenocarcinoma
(MC38) mouse
colon
tumors or with EphA2-negative BL6 melanoma tumors.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17685394.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cancer Vaccines; 82115-62-6 / Interferon-gamma; EC 2.7.10.1 / Receptor, EphA2
91.
Kim JY, Lim SJ, Park K, Lee CM, Kim J:
Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Gynecol Oncol
; 2005 May;97(2):337-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Chemotherapeutic agents targeting COX-2 and c-erbB-2 are used to treat
colon
and breast cancers.
COX-2 protein expression correlated with histology (P < 0.005) and
stage
(P < 0.05), but was not associated with patient survival.
[MeSH-minor]
Adenocarcinoma
/ enzymology.
Adenocarcinoma
/ pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Cyclooxygenase 2. Female. Humans. Immunohistochemistry. Membrane Proteins. Microarray Analysis. Middle Aged
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15863127.001).
[ISSN]
0090-8258
[Journal-full-title]
Gynecologic oncology
[ISO-abbreviation]
Gynecol. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 2.7.10.1 / Receptor, ErbB-2
92.
Read TE, Fleshman JW, Caushaj PF:
Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy.
Dis Colon Rectum
; 2005 Jan;48(1):80-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sentinel lymph node mapping for
adenocarcinoma of
the
colon
does not improve staging accuracy.
PURPOSE: This study was designed to: determine the efficacy of sentinel lymph node mapping in patients with intraperitoneal
colon
cancer; and create an algorithm to predict potential survival benefit by using best-case estimates in favor of sentinel node mapping and lymph node ultraprocessing techniques.
METHODS: Forty-one patients with intraperitoneal
colon
cancer undergoing colectomy with curative intent were studied prospectively.
After mobilization of the
colon
and mesentery, 1 to 2 ml of isosulfan blue dye was injected subserosally around the tumor.
Stage of
disease in the remaining 38 patients was: I, n = 10 (26 percent); II, n = 15 (39 percent); III, n = 11 (29 percent); IV, n = 2 (5 percent).
To create a survival benefit algorithm, we assumed the following: combined fraction
of Stage
I and II disease (0.5); fraction understaged by bivalving and hematoxylin and eosin staining that would have occult positive nodes by more sophisticated analysis (0.15); fraction of occult positive nodes detected by sentinel node mapping (0.9); and survival benefit from chemotherapy (0.33).
CONCLUSIONS: Sentinel node mapping with isosulfan blue dye and routine processing of retrieved nodes does not improve staging accuracy in patients with intraperitoneal
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ pathology. Algorithms. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15690662.001).
[ISSN]
0012-3706
[Journal-full-title]
Diseases of the colon and rectum
[ISO-abbreviation]
Dis. Colon Rectum
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
93.
Commane DM, Shortt CT, Silvi S, Cresci A, Hughes RM, Rowland IR:
Effects of fermentation products of pro- and prebiotics on trans-epithelial electrical resistance in an in vitro model of the colon.
Nutr Cancer
; 2005;51(1):102-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effects of fermentation products of pro- and prebiotics on trans-epithelial electrical resistance in an in vitro model of the
colon
.
Evidence from in vivo and in vitro studies suggests that the consumption of pro- and prebiotics may inhibit
colon
carcinogenesis; however, the mechanisms involved have, thus far, proved elusive.
There are some indications from animal studies that the effects are being exerted during the promotion
stage of
carcinogenesis.
One feature of the promotion
stage of
colorectal cancer is the disruption of tight junctions, leading to a loss of integrity across the intestinal barrier.
We have used the Caco-2 human
adenocarcinoma
cell line as a model for the intestinal epithelia.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15749636.001).
[ISSN]
0163-5581
[Journal-full-title]
Nutrition and cancer
[ISO-abbreviation]
Nutr Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Anticarcinogenic Agents; 0 / Oligosaccharides
94.
Ouellette JR, Harboe-Schmidt JE, Luthringer D, Brackert S, Silberman AW:
Colorectal cancer metastasis presenting as a testicular mass: case report and review of the literature.
Am Surg
; 2007 Jan;73(1):79-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This case describes a 51-year-old white man who presented with an enlarged right testicle 9 months after undergoing a right hemicolectomy for a
stage
IIIC
colon adenocarcinoma
.
[MeSH-major]
Adenocarcinoma
/ secondary. Colorectal Neoplasms / pathology. Testicular Neoplasms / secondary
Genetic Alliance.
consumer health - Colorectal Cancer
.
Genetic Alliance.
consumer health - Testicular cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Testicular Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17249463.001).
[ISSN]
0003-1348
[Journal-full-title]
The American surgeon
[ISO-abbreviation]
Am Surg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
95.
Woznick AR, Braddock AL, Dulai M, Seymour ML, Callahan RE, Welsh RJ, Chmielewski GW, Zelenock GB, Shanley CJ:
Lysyl oxidase expression in bronchogenic carcinoma.
Am J Surg
; 2005 Mar;189(3):297-301
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Recent studies have documented differential lysyl oxidase expression in the stromal reaction to
colon
, breast, prostate, and lung cancer.
The present study was undertaken to test the hypothesis that lysyl oxidase mRNA and protein expression decrease with advancing tumor
stage
in patients with bronchogenic carcinoma.
RESULTS: Real-time polymerase chain reaction studies documented a 3.4-fold graded decrease in lysyl oxidase mRNA levels as tumors progressed from
stage I
to IV.
[MeSH-major]
Adenocarcinoma
/ enzymology. Carcinoma, Bronchogenic / enzymology. Lung Neoplasms / enzymology. Protein-Lysine 6-Oxidase / metabolism
MedlinePlus Health Information.
consumer health - Lung Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15792754.001).
[ISSN]
0002-9610
[Journal-full-title]
American journal of surgery
[ISO-abbreviation]
Am. J. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Messenger; EC 1.4.3.13 / Protein-Lysine 6-Oxidase
96.
Kuester D, Dalicho S, Mönkemüller K, Benedix F, Lippert H, Guenther T, Roessner A, Meyer F:
Synchronous multifocal colorectal carcinoma in a patient with delayed diagnosis of ulcerative pancolitis.
Pathol Res Pract
; 2008;204(12):905-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In the resection specimen, four clinically unsuspected, partly mucinous adenocarcinomas accompanied by several foci of low- and high-grade dysplasia were found in the left
colon
and rectum.
At the time of colectomy, advanced tumor
stage
was diagnosed and classified as pT3c(4) pN1(2/120) M0 V1 R0, UICC
stage
IIIB, G2.
[MeSH-major]
Adenocarcinoma
/ pathology. Colitis, Ulcerative / complications. Colitis, Ulcerative / pathology. Colorectal Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Ulcerative Colitis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Zentralbl Chir. 2015 Dec;140(6):624-6
[
25076166.001
]
(PMID = 18842350.001).
[ISSN]
0344-0338
[Journal-full-title]
Pathology, research and practice
[ISO-abbreviation]
Pathol. Res. Pract.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
97.
Wang W, Li YF, Sun XW, Chen G, Zhan YQ, Huang CY, Wan DS, Pan ZZ, Zhou ZW:
Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients.
Chin J Cancer
; 2010 Aug;29(8):761-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the
stage
-II
colon
cancer patients.
In this study we detected the frequency of loss of heterozygosity (LOH) at chromosome 18q and investigated the relationship between LOH and clinicopathologic features and its prognostic value for patients with
stage
II
colon
cancer.
METHODS: A total of 106 samples of tumor tissues and corresponding normal mucosa from patients with sporadic
stage
-II
colon
cancer were included in this study.
Multivariate analysis for association between LOH and prognosis in
colon
cancer patients was performed with Cox proportional hazards regression model.
LOH was more frequent on the left-side, poorly-differentiated
adenocarcinoma
, and nonmucinous
colon
cancers.
The occurrence of 18q-LOH is an independent poor prognostic factor for the patients with
stage
-II
colon
cancer.
[MeSH-major]
Adenocarcinoma
/ genetics. Chromosomes, Human, Pair 18 / genetics. Colonic Neoplasms / genetics. Loss of Heterozygosity
[MeSH-minor]
Adenocarcinoma
, Mucinous / genetics.
Adenocarcinoma
, Mucinous / pathology.
Adenocarcinoma
, Mucinous / surgery.
Adenocarcinoma
, Papillary / genetics.
Adenocarcinoma
, Papillary / pathology.
Adenocarcinoma
, Papillary / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Grading. Neoplasm Staging. Proportional Hazards Models. Survival Rate. Young Adult
Genetic Alliance.
consumer health - Chromosome 18q-
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20663324.001).
[ISSN]
1000-467X
[Journal-full-title]
Chinese journal of cancer
[ISO-abbreviation]
Chin J Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China
98.
Doviner V, Maly B, Kaplan V, Gingis-Velitski S, Ilan N, Vlodavsky I, Sherman Y:
Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence.
Mod Pathol
; 2006 Jun;19(6):878-88
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Spatial and temporal heparanase expression in
colon
mucosa throughout the adenoma-carcinoma sequence.
Here, we employed anti-heparanase 733 polyclonal antibody that preferentially recognizes the 50 kDa active heparanase subunit over the 65 kDa proenzyme, as well as anti-heparanase 92.4 monoclonal antibody that recognizes both the latent and the active enzyme, to follow heparanase expression, processing and localization throughout the adenoma-carcinoma transition of the
colon
epithelium.
Interestingly, although reactivity with antibody 733 was markedly reduced in severe dysplasia and in colorectal carcinoma, response to antibody 92.4 exhibited the opposite trend and staining intensities increased in parallel with tumor
stage
, the highest being in carcinoma cells.
Involvement of latent heparanase (detected by 92.4, but not by 733 antibody) in tumor progression was suggested by activation of the Akt/PKB signal transduction pathway upon heparanase overexpression or exogenous addition to HT29 human
colon
carcinoma cells.
These results suggest that heparanase expression is induced during
colon
carcinogenesis, and that its processing, conformation and localization are tightly regulated during the course
of colon
adenoma-carcinoma progression.
[MeSH-major]
Adenocarcinoma
/ enzymology.
Colon
/ enzymology. Colorectal Neoplasms / enzymology. Glucuronidase / metabolism. Intestinal Mucosa / enzymology
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address: